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T-CELL TREATMENTS FOR SOLID AND HEMATOLOGICAL TUMORS
Publication No. ____________
Drew Caldwell Deniger, M.S.
Supervisory Professor: Laurence Cooper, M.D., Ph.D.

Cell-based therapies have demonstrated potency and efficacy as cancer
treatment modalities. T cells can be dichotomized by their T cell receptor (TCR)
complexes where αβ T cells (95% of T cells) and γδ T cells (<5% of T cells) express
α/β and γ/δ TCR heterodimers, respectively. γδ T cells have inherent anti-tumor
immunity, but their use in the clinic is hampered by a lack of clinically-relevant
expansion protocols. In contrast, αβ T cells do not have predictable anti-tumor
immunity so they can be re-directed to specific molecules on the tumor surface through
introduction of tumor-specific molecules such as chimeric antigen receptors (CARs) for
reproducible tumor killing. CARs are constructed with the extracellular specificity of a
monoclonal antibody to a tumor antigen, e.g. CD19 or receptor tyrosine kinase-like
orphan receptor-1 (ROR1), fused to intracellular T cell signaling domains (CD3ζ,
CD28, CD137). A comparative study was done between αβ T cells re-directed with
ROR1-specific CARs signaling through CD3ζ and either CD28 (ROR1RCD28) or
CD137 (ROR1RCD137) in the first specific aim of this dissertation. CAR+ T cells
proliferated to clinically significant numbers and ROR1+ tumor cells were effectively
targeted and killed by both ROR1-specific CAR+ T cell populations, although
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ROR1RCD137 were superior to ROR1RCD28 in clearance of leukemia xenografts in
vivo. The second specific aim focused on generating bi-specific CD19-specific CAR+ γδ
T cells with polyclonal TCRγδ repertoire on CD19+ artificial antigen presenting cells
(aAPC). Enhanced cytolysis of CD19+ leukemia was observed by CAR+ γδ T cells
compared to CARneg γδ T cells, and leukemia xenografts were significantly reduced
compared to control mice in vivo. The third specific aim looked at the broad anti-tumor
effects of polyclonal γδ T cells expanded on aAPC without CAR+ T cells, where Vδ1,
Vδ2, and Vδ3 populations had naïve, effector memory, and central memory phenotypes
and effector function strength in the following order: Vδ2>Vδ3>Vδ1. Polyclonal γδ T
cells eliminated ovarian cancer xenografts in vivo and increased survival compared to
control mice. Thus, translating these methodologies to clinical trials will provide cancer
patients novel, safe, and effective options for their treatment.
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CHAPTER I
INTRODUCTION

I.A. Cancer
Cancer is caused by the uncontrolled and abnormal growth of cells that leads to disease
and remains the second most common cause of death in the United States of America
behind heart disease.(1) It is more prevalent in women than men where the median time
at diagnosis is in their 60’s and 70’s, respectively.(2) Overall, the median age at
diagnosis is 66 years old for all cancer types and more than 1.5 million people are
estimated to have been diagnosed with cancer in 2012, according to the most current
statistics from the National Cancer Institute (NCI) Surveillance Epidemiology and End
Results (SEER; http://seer.cancer.gov/statistics). Of these diagnoses, >200,000 are
represented from each of the three most common cancers: prostate, breast, and lung.
The other groups of cancers, therefore, affect roughly 900,000 people per year in the
United States, and some of the diagnoses carry dismal chances for survival. For
example, roughly 22,000 women are expected to have a new diagnosis of ovarian
cancer in 2013 where only 44% of them are expected to survive 5 years, and over
186,000 women are currently estimated to have a history of ovarian cancer in the
United States. Similarly, greater than 48,000 new leukemia diagnoses, with 5-year
overall survival rate of 56% are predicted for 2013, and more than 287,000 people in
the United States have leukemia at present. Cancers can either arise from either (i) the
hematopoietic compartment, i.e. bone marrow, blood, and lymphatic system, giving rise
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to hematological tumors or (ii) tissues outside of the hematological systems that are
generically termed solid tumors. Despite the many treatments that exist for cancer,
novel therapies are desperately needed to decrease the mortality and morbidity of this
disease.

I.A.1. Hematological Tumors
Hematological cancers are delineated by their hematopoietic differentiation status and
the tissue from which the tumor arises. In regards to leukemia, the different types are
separated first by either myeloid or lymphoid lineages and then into acute or chronic
stages. Thus, they are classified as (i) acute myeloid leukemia (AML), (ii) chronic
myeloid leukemia (CML), (iii) acute lymphoblastic leukemia (ALL), or (iv) chronic
lymphocytic leukemia.(3) Immunotherapy targeting tumor associated antigens (TAA),
e.g. CD19 or Receptor tyrosine kinase-like orphan receptor-1 (ROR1), have potential to
lead to tumor regressions and, in some cases when targeting CD19, complete responses
have been observed in the clinic.(4-7) The main focus of this dissertation is on
developing immunotherapies for the lymphoid subsets of leukemia.

I.A.1.a. B-cell Acute Lymphoblastic Leukemia
The most common pediatric malignancy known is ALL but also affects many adults.(810) The median age at ALL diagnosis in 2012 was estimated to be 13 years old.(2) For
B-cell ALL (B-ALL), tumors typically arise from the pro-B cell stage and retain
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primitive characteristics without undergoing further differentiation.(11) A common
subtype of B-ALL halted in normal B cell development is t(1;19) ALL, where the
translocation results in an E2A-PBX1 fusion protein that functions in promoting
developmental arrest and oncogenic transformation simultaneously.(12) Therapies are
being actively sought after for treatment of this B-ALL group by targeting unique or
dysregulated proteins resulting from aberrant E2A-PBX1 gene regulation.(13)
Cytogenetics and flow cytometric staining of the tumor cell surface molecules are two
key tools in the diagnosis of B-ALL, which has clinical presentation consistent of
common ailments, i.e. fever, bleeding, pain, fatigue, and lethargy, but is commonly first
detected due to high white blood cell counts (WBC).(14, 15) Aggressive treatment,
including chemotherapy, radiation therapy, and hematopoietic stem cell transplantation
(HSCT), has dramatically improved overall survival, but long-term health problems
frequently arise following therapy particularly amongst children.(16, 17) More
specifically, children in remission commonly develop secondary malignancies later in
life, and most commonly develop AML.(18) Unfortunately, few effective treatments
exist for AML. Incomplete eradication of the primary tumor can result in minimal
residual disease (MRD) of the primary tumor and is also a common cause of
malignancies later in life that are usually resistant to conventional therapies.(16, 19)
Thus, it is of paramount importance that safe and effective therapies are developed for
B-ALL patients in order to fully remove their primary tumor, reduce risk the for
development of secondary tumors, and improve their expected quality of life as adults.
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I.A.1.b. T-cell Acute Lymphoblastic Leukemia
T-cell ALL (T-ALL) accounts for less than 25% of ALL cases and has a dismal
prognosis relative to B-ALL.(20) The differentiation stage of T-ALL has importance as
more immature T cells are correlated to more aggressive disease.(14, 21) Diagnosis and
treatment are, in general, similar to those for B-ALL, although one unique and common
clinical manifestation of T-ALL is a large mediastinal mass causing shortness of
breath.(20, 22) Prognostic indicators for T-ALL response to therapy are widely sought
after but are not yet predictive of response. However, particular emphasis on NOTCH
mutations and chromosomal translocations has generated much enthusiasm for being
able to stratify patients into potential responders and non-responders.(23, 24) As with
B-ALL, MRD is a primary concern as it contributes to relapse in many cases and can be
diagnosed by amplification of specific TCR alleles.(25) Currently, no adoptive T cell
therapies directly targeting their neoplastic T cell counterparts exist for T-ALL.
Therefore, development of T cells capable of fratricide may improve the outcomes for
T-ALL patients in dire need of therapeutic intervention.

I.A.1.c. Chronic Lymphocytic Leukemia
In contrast to ALL, CLL occurs much later in life and is not as aggressive as ALL.(26)
CLL often arises from activated or memory B cells and progresses slowly but is deadly
nonetheless with a 5-year median survival.(27) Furthermore, a CLL profile with (i)
alterations in chromosomes 11 or 17, (ii) unmutated immunoglobulin heavy chain
(IgVH) genes, (iii) expression of zeta-chain associated protein kinase-70 (ZAP70), (iv)
4
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expression of CD38, (v) rapid doubling time of tumor lymphocytes, or (vi) increased
serum β2-microglobulin, soluble CD23, and thymidine kinase activity have been
correlated with a more aggressive disease status and markedly decreased median
survival.(28) CLL is generally asymptomatic and high WBC commonly results in early
diagnosis that is later corroborated with cytogenetics and flow cytometry. Most current
therapies are not curative and often require palliative care, but some strategies, e.g.
chemotherapy, antibody therapy, and stem cell transplant, can extend survival up to
multiple years.(29) T cell immunotherapy is an actively pursued therapy for CLL due to
the many targetable TAA, e.g. CD19, CD20, CD23, CD52, and CD40, and monoclonal
antibody therapies directed at these TAA have resulted in objective clinical responses in
CLL treatments.(30) Furthermore, mAbs can be also adapted to T cell therapies in the
form of chimeric antigen receptors (CARs) by linking a single chain antibody specific
for the TAA to T cell intracellular activation domains.(31) Indeed, several clinical trials
with CAR-based T cell therapies targeting CD19 have generated complete responses in
both B-ALL and B-CLL (discussed further in Chapter I.D.3.).(4-7, 32) Because CLL
can be sensitive to immunotherapy, it is a prime disease target for T cell treatments.

I.A.2. Solid Tumors
There are many different types of solid tumors but this dissertation will focus on
generating T cell therapies for two model cancers with hopes of future applications to
other solid tumors. Ovarian and pancreatic cancers were chosen because of (i) their poor
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prognostic outcome, (ii) lack of efficacious T cell immunotherapies, and (iii) favorable
responses targeting these tumors in initial pre-clinical tests.

I.A.2.a. Ovarian Cancer
Ovarian cancer (OvCa) is commonly referred to as “the most common gynecological
malignancy.”(33) The median age at diagnosis is 63 years old, and most patients are
diagnosed in late stage (III or IV) which has a 5-year overall survival rate of 27%.(3436) OvCa typically arises from the ovary, fallopian tube, or peritoneal cavity, and is
unique in that traditional metastasis is not common outside of the intraperitoneal
cavity.(37) Growth within the intraperitoneal cavity can grossly impact the ability of
surrounding organs to function properly and, in some case, can be sites for local
metastases. The most useful prognostic indicator for OvCa is CA125, also known as
mucin 16 (MUC16), which is shed into the bloodstream and is predictive of progressive
OvCa disease status.(38) Standard of care for women facing OvCa treatment is surgical
resection and aggressive chemotherapy.(39, 40) Many immunotherapy approaches have
been tried with few objective clinical responses.(41-44) Even though OvCa appears to
have sensitivity to immunomodulation, a cell-based therapy that results in objective
clinical responses has yet to be developed. As the survival rate is dismal for advanced
OvCa, novel therapies are urgently needed to combat this disease.
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I.A.2.b. Pancreatic Cancer
Pancreatic cancer (PaCa) is one of the worst cancer diagnoses because 1-year and 5year overall survival rates are 20% and 5%, respectively.(45) It is commonly
differentiated based on the anatomical location of the tumor where the tail, neck, and
head of the pancreas are distinct locations and the pancreatic head is the most common
site where tumors arise.(46) Similar to many of the cancer types discussed above,
common health ailments, i.e. pain, weight loss, and appetite-related problems, are used
in diagnosis, and patients are usually asymptomatic until metastases have already
developed thereby limiting the ability of surgery to cure PaCa.(47) Diabetes is also a
common diagnostic tool and is one of many risk factors, in addition to smoking,
pancreatitis, genetic predisposition, and nutritional status.(46) Tumor resection
dramatically improves outcome, but most cases involve metastases (liver and lymph
nodes commonly) that are very difficult to control and treat with standard care.(48)
Radiation and Gemcitabine is the standard of care for PaCa but elicits limited efficacy
outside of palliative care.(49) Combinational approaches with other chemotherapies
were also tested in clinical trials with some promising results but were not curative.(50)
Perhaps the most promising results that have been generated are with vaccines (peptide,
tumor lysate, or dendritic cells (DCs)) to boost resident immune responses to PaCa.(51,
52) Clinical data support that PaCa is sensitive to T cell responses and suggests that
direct adoptive transfer of PaCa-reactive T cells could result in robust clinical
responses.
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I.B. Tumor Associated Antigens
The choice of which tumor associated antigen (TAA) to target is crucial for the success
of the immunotherapy.(53, 54) The ideal TAA is not expressed on any normal tissues
but highly expressed on the tumor cell surface. Most TAAs known thus far are cell
surface glycoproteins that are involved in tumor growth or survival, e.g. growth factor
receptors, that drive proliferation of the tumorigenic cells. Furthermore, optimal TAAs
are often required for the growth of tumor cells meaning the cancer is dependent on the
TAA, and removal or inhibition of the TAA or elimination of cells expressing the
dependent TAA can lead to effective treatment. Dependence on the TAA is sought after
in order to avoid antigen escape of tumor cells, i.e. no longer expressing the targeted
TAA but continuing to proliferate, which can lead to relapse and disease
progression.(55) Ideally, the TAA would exist on multiple tumor types to allow for
targeting of many cancers with a single therapy. With these considerations in mind
these studies focus on two TAAs, CD19 and ROR1, which have great promise as targets
for cellular immunotherapy.

I.B.1. CD19
CD19 is a B-cell lineage-specific protein not expressed on other tissues and is,
therefore, an ideal TAA for B-cell malignancies because B cells are not required for
survival.(4, 6, 31, 56, 57) Similar to T cells, B cells have a B cell receptor (BCR)
expressed on the cellular surface specific for a single cognate Ag.(58) Upon BCR/Ag
binding, the B cell will proliferate and produce antibodies with specificity identical to
8
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that of the BCR that are secreted into the circulation for opsonization and pathogen
clearance.(59) The BCR complex is crucial for signal transduction, and is composed of
CD19, CD21, and CD81, where CD19 is crucial for intracellular signaling.(60-62)
CD19 is expressed from the early pro-B cell stage until memory stage and is lost as B
cells differentiate into plasma cells. Because of its importance in B-cell function and
persistence throughout B cell development, almost all (95%) of B-cell non-Hodgkin’s
leukemia (NHL) express CD19.(31) Successful removal of CD19+ tumors results in Bcell aplasia, which can be treated with serum immunoglobulin infusions to restore
humoral immunity.(4, 6, 32, 56, 63) Thus, targeting CD19 has proven to be safe and
effective means for eliminating B-cell neoplasms, albeit with diminished quality of life.

I.B.2 Receptor Tyrosine Kinase-like Orphan Receptor-1
In contrast to CD19, much less is known about ROR1, but what is known is that ROR1
(i) is a cell surface protein involved in Wnt5a signal transduction, (ii) plays a critical
role in development, (iii) is no longer expressed post-parturition and is not found on
almost all adult tissues, and (iv) has aberrant expression later in life on tumor cells
making it a candidate TAA target.(64-67) ROR1 and its redundant partner in
development, ROR2, were originally cloned and named neurotrophic tyrosine kinase
receptor-related-1 and -2 (NTRKR1 and NTRKR2), respectively.(68) An analysis of the
ROR1 protein structure reveals that it consists of signal peptide trailed by extracellular
Ig-like C2 domain, Frizzled cysteine-rich domain (Fz-CRD), and Kringle domain that
are followed by transmembrane (TM) alpha helix, intracellular protein kinase,
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serine/threonine-rich domain, and proline-rich domains (Figure 1a). Sequence
alignment shows that ROR1 is 57% identical and 81% homologous to ROR2 where
there is homology in signal peptide (62%), Ig-like C2 (85%), Fz-CRD (93%), Kringle
(90%), TM (95%), protein kinase domain (90%), serine/threonine-rich (87%), and
proline-rich (54%) domains between the two proteins (Figure 1b). Single and double
knockout mice for ROR1 and ROR2 were established that had multiple developmental
problems leading to death shortly after birth.(69, 70) More specifically, ROR1-/- mice
died of respiratory distress following birth, while ROR2-/- mice died of more advanced
cardiovascular problems as well as skeletal abnormalities, and ROR1-/-ROR2-/- double
knockout mice had exacerbated disease including transposition of the great arteries,
pubic bone dysplasia, and sternal defects. Furthermore, ROR2 continues to be critical
for skeletal development during life as autosomal recessive diseases resulting in bone
dysmorphia and have been mapped to ROR2 gene mutations (chromosome 9q22) but
not ROR1 gene (chromosome 1p32-31).(71-74) To date, ROR1 has not been linked to
inherited genetic disease in adults, indicating that its major roles are only in fetal
development. In 2008, three independent investigators published reports of ROR1
expression in tumors, and each described ROR1 expression in ~95% of CLL patients
with confirmation of absent expression on most normal tissues.(65, 75, 76)
Subsequently, ROR1 has been detected in breast cancer, pancreatic cancer, ovarian
cancer, melanoma, gastric carcinoma, non-small cell lung cancer, t(1;19) B-ALL, and
mantle cell lymphoma, but some reports indicate that cytosolic expression of ROR1
exists in some tissues and that there may be surface expression on hematogones (normal
B cell developmental precursors), the pancreas, and adipose tissue.(13, 66, 67, 77-81)
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The discovery of ROR1 expression on tumor cell lines enabled a number of
biochemical studies to determine the role of ROR1 in neoplastic transformation. IL6
leads to transcriptional activation of signal transducer and activator of transcription-3
(STAT3) that then increases gene expression of ROR1 transcripts, which may give
insight to a potential autocrine or paracrine loop for oncogenic transformation and/or
disease progression.(82) Wnt5a binding of ROR1 (presumably to the Fz-CRD) leads to
casein kinase-1ε (CK1ε) activation of phosphoinositol-3 kinase (PI3K) that
phosphorylates Akt and results in activation of the transcriptional activator cAMPresponse-element-binding protein (CREB), which upregulates genes important for
proliferation and, thus, is likely to result in oncogenic transformation (Figure 1c).(67,
79) The discovery of ROR1 on tumor cells is relatively new, so other signaling
pathways have not been elucidated and direct targeting of ROR1 in humans has not
been tested to date. Nonetheless, all indications suggest that ROR1 is an ideal TAA
target for cellular immunotherapy with broad applicability, and immunotherapies
targeting ROR1 in humans will be the ultimate test of its safety as a TAA.
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Figure 1. ROR1 Protein Structure. (a) Diagram of protein sequence of ROR1 protein
domains where abbreviations are as follows: SP; signal peptide, Fz-CRD; Frizzled
cysteine-rich domain, TM; transmembrane alpha helix, S/T; serine/threonine-rich
domain, P-rich; proline-rich domain. (b) Sequence alignment between ROR1 and ROR2
proteins by ClustalOmega (http://www.ebi.ac.uk/Tools/msa/clustalo/). Lines above text
correspond to colors in (a), (*) describes identical amino acids, (:) denotes analogous
closely related amino acids, and (.) describes similar amino acids. (c) Diagram for
ROR1 protein structure in the cellular membrane where Wnt5a binding Fz-CRD leads
to the following signal transduction pathway: casein kinase-1ε (CK1ε) 
phosphoinositol-3 kinase (PI3K)  Akt  cAMP-response-element-binding protein
(CREB)  transcriptional activation of genes for proliferation.
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I.C. T cell Immunity
The immune system is critical for pathogen clearance and prevention of disease. It is
broadly partitioned into innate and adaptive immune systems, but interplay between
innate and adaptive immunity is essential to an effective immune response.(83-86) The
innate immune system is composed of many cell types, e.g. macrophages, natural killer
(NK) cells, that have broad ranges of specificity to pathogens to remove them upon
their primary encounter, and therefore serve as the first line of defense.(87) In contrast,
the adaptive immune system is highly specific for a particular part of a pathogen and
develops as a secondary and long-lasting response to a individual pathogen. The two
major sections of adaptive immunity are the cellular and humoral immune systems.(88)
B cells mediate humoral immunity primarily through the production of antibodies (Ab),
which coat the surface of pathogens to label them as foreign for direct lysis through
complement activation, which forms holes in the membrane thereby destroying the
target cells, or by phagocytosis and elimination during the process known as
opsonization.(89) In contrast, T cells mediate cellular immunity through direct contact
with their target and either directly or indirectly mediate destruction of the pathogenic
cell. T cells are typically dichotomized into helper (TH) or cytotoxic/killer (TC) T cells
based on their expression of CD4 and CD8, respectively.(90) The combined interaction
of these components of the adaptive immune system allow for its unique characteristics
of (i) generating highly specific responses to pathogens, (ii) memory formation for more
rapid and stronger responses to pathogens upon a repeated or secondary exposure, and
(iii) adaptation to increase sensitivity through maturation.(88) Because T cells can exert
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direct cellular cytotoxicity and create memory responses, they have been used
successfully to target and kill cancer cells.

I.C.1. αβ T cells
The quintessential T cell lineage is the αβ T cell subset, which comprises up to 95-99%
of circulating T cells, and are the object of most canonical T cell paradigms.(58) In
addition to staining for either CD4 or CD8, these T cells are typically identified by costaining with CD3 and their αβ T-cell receptor (TCRαβ). Effector functions are
endowed upon αβ T cells through an extensive educational process that results in a
unique specificity to an antigen and a corresponding response in the form of T cell help
(CD4) or cytolysis (CD8). Therefore, it is important to understand the nuances of αβ T
cell development and education in order to maximize their impact in adoptive
immunotherapy.

I.C.1.a. T-cell Receptor Genetics
TCRs are subjected to genetic rearrangement events during development to randomly
arrange distinct gene segments into an extremely high number of combinations and thus
corresponding antigen affinities.(91) Four TCR loci, i.e. TCRα, TCRβ, TCRγ, and
TCRδ exist in the human genome, which lead to two distinct T cell lineages based on
TCR pairing.(92) More specifically, the αβ T cell lineage is defined by the pairing of
TCRα and TCRβ chains whereas the γδ T cell lineage is defined by T cells expressing
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TCRγ and TCRδ heterodimers. Each TCR allele is further compartmentalized into
variable (V), diversity (D), junction (J), and constant (C) regions.(93) TCRα and TCRγ
genes have V and J regions while TCRβ and TCRδ genes have V, D, and J regions and
all TCRs contain C regions (Figure 2). Each specific region is termed based on its
region and origin, i.e. Vα describes the variable region from the alpha locus or Jδ
describes the junction region from the delta locus. The V regions contain
complementarity determining regions (CDR) that confer high degrees of antigen
specificity, and are therefore important for defining T cell affinity.(94) These V, D
(where applicable), J, and C segments are recombined into unique combinations in each
T cell during T cell development in a process known as V(D)J recombination.(95, 96)
The TCRγ (Gene ID: 6965) and TCRβ (Gene ID: 6957) loci are in distinct locations at
7p14 and 7q34, respectively, but TCRδ locus (Gene ID: 6964) exists within the TCRα
(Gene ID: 6955) locus at 14q11.2 (Figure 2). Upon V(D)J recombination of the Vα and
Jα, the entire δ-chain locus is deleted from the T cell genome in a T-cell receptor
excision circle (TREC).(97) Thus, once the α-chain locus has recombined for a
particular T cell, it can no longer become a γδ T cell. Programmed mutation of the T
cell germline DNA allows for unbiased generation of many TCR specificities for
extremely high combinational probabilities (at least 1016 possible combinations for αβ
T cells) for binding any potential foreign pathogen.(98) It is in this random genetic
process through which T cells acquire exquisite abilities to mediate cellular immunity.
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Figure 2. Genetic Loci for TCR alleles. Simplified schematic of exons encoding V, J,
and C regions with D regions for β and δ chains for TCRγ (blue), TCRβ (red), TCRα
(green), and TCRδ (black). V(D)J recombination of Vα, Jα, and Cα results in excision
of the TCRδ locus in a T cell Receptor Excision Circle (TREC).
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I.C.1.b. αβ T cell Development
The thymus is crucial for T cell development as it is the location for both V(D)J
recombination and thymic selection. Thymic selection is important for maintaining
central tolerance by eliminating poorly-reactive T cells and over-reactive T cells from
the T cell pool by neglect and negative selection, respectively, following V(D)J
recombination.(99, 100) Positive selection only allows for T cells with intermediate
reactivity to their antigen to be released into the periphery.(101, 102) Thymic selection
is carried out by thymic cortical epithelial cells which express high levels of major
histocompatibility complex (MHC) molecules along with a wide array of proteins,
including self-antigens, that are then processed and presented in the context of MHC on
the epithelial cell surface.(103, 104) Both MHC Class-I (MHC-I) and Class-II (MHCII) are expressed by the thymic cortical epithelial cells to stimulate CD8 and CD4 T
cells, respectively. The developing T cells express both CD4 and CD8 in the thymus,
and based on their TCRαβ binding affinity to either MHC-I or MHC-II and subsequent
TCRαβ signaling they will become single positive for either CD8 or CD4,
respectively.(105, 106) In this way, both affinity and peripheral T cell function is
acquired in the thymic cortex.

I.C.1.c. αβ T cell Activation
T cells need to escape the thymus, encounter their corresponding antigen, and have a
licensing event towards the antigen in order to become functionally responsive. At least
two signals are required for T cell activation but 3 total signals are ideal for full T cell
17

Drew C Deniger
activation.(107-109) Signal 1 comes from TCRαβ interaction with MHC/peptide
complexes mediated by CD4 or CD8 co-receptors.(110) However, the intracellular
domain of TCR is very short and not able to generate its own intracellular signal.
Signaling comes from CD3 molecules that are bound to TCR in the transmembrane
through non-covalent interactions.(111) A complex of CD3 subunits surrounds the TCR
composed of CD3γ/CD3ε and CD3δ/CD3ε heterodimers and CD3ζ/CD3ζ homodimer.
Each of the CD3γ, CD3δ, and CD3ε subunits has an immunoreceptor tyrosine activation
domain (ITAM) motif and the CD3ζ subunit has three ITAM motifs for a total of ten
ITAMs surrounding each TCR. Upon TCRαβ binding to peptide/MHC complex, coreceptors (CD4 or CD8) bind to the constant regions of MHC and begin the signaling
process through Lck and Fyn phosphorylation of tyrosine (p-Tyr) residues on the
ITAMs.(112) Then ZAP70 can bind to p-Tyr through SH2 domains and becomes
activated by Lck. Activated ZAP70 leads to a cascade of downstream activation events
resulting in transcriptional and post-translational modifications for the molecules
responsible for T cell proliferation and differentiation.(113) However, only receiving
signal 1 will lead to functional unresponsiveness otherwise known as anergy.(114, 115)
Therefore, the second signal is required and is termed co-stimulation. Examples of
activating co-stimulatory molecules expressed on the T cell surface are CD27, CD28,
and CD137 (41BB), which bind to CD70, CD80/CD86, and CD137L (41BB-L),
respectively, expressed on the antigen presenting cell (APC).(116-118) Some costimulatory molecules are inhibitory, e.g. cytotoxic T-lymphocyte antigen-4 (CTLA4)
and programmed death-1 (PD1), for immune regulatory purposes.(119) Dendritic cells
(DCs) are professional APCs because of their ability to process and present a wide
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milieu of peptides, high expression of MHC molecules, and expression of costimulatory molecules.(120) DCs are present in tissues and following activation by the
innate immune system to foreign antigens/pathogens, they migrate to secondary
lymphoid organs to present their environmental data and license T cells to fight the
pathogens.(121, 122) It is also important to note that cytokine support, e.g. interleukin12 (IL12), IL15, and type I interferon (IFN), is generally regarded as signal 3 for T cell
activation.(123) In summary, the combination of (i) TCRαβ engagement with
MHC/peptide complex with appropriate co-receptor (CD4 or CD8) binding to MHC,
(ii) co-stimulation, and (iii) cytokine support licenses T cells to find their corresponding
antigen expressed on damaged or pathogenic cells and to eliminate those cells.

I.C.1.d. CD4+ αβ T cell Subsets
CD4+ T cell subsets are numerous and typically described by the effector cytokines they
release, and they can be stratified into TH0 (naïve), TH1, TH2, TH17, regulatory T cells
(TREG), and natural killer T (NKT) cells.(124) Naïve TH0 cells can be polarized to
differentiate based on environmental cues that then translate into distinct transcriptional
programs and result in lineage commitment.(125) TH1 encourage inflammation and help
promote CD8 memory responses by producing IL2, IL12, interferon-γ (IFNγ), and
tumor necrosis factor-α (TNFα) while TH2 cells inhibit inflammatory TC response and
foster humoral immunity by secreting IL4, IL5, IL6, and IL10.(126) The primary role of
TH17 cells is to enhance neutrophil responses, and these cells are most often
characterized by their ability to produce IL17.(127) There is plasticity between TH17
cells and TREG cells as both require transforming growth factor-β (TGFβ) but addition
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of IL6 polarizes towards TH17 lineage. TREG cells are infrequent and can exert strong
blockades against other T cell effector functions through both cell-to-cell contact
mechanisms and through production of IL10 and TGFβ.(128) Thus, they are critical for
maintaining peripheral tolerance, and when dysregulated can contribute to diseases such
as cancer (in the case of overactive TREGS) or autoimmune disorders (in the case of
underactive TREGS). An extremely rare subset of CD4+ T cells are NKT cells, which
express invariant TCRαβ alleles, e.g. Vα24/Jα18 with Vβ11, and are known to produce
both TH1 and TH2 cytokines.(129) The best described antigen for NKT cells is αgalactosylceramide (αGalCer) presented to NKT cells in the context of CD1d, a nonclassical MHC molecule, which leads to NKT expansion and effector function, but the
“natural” ligands for NKT in humans are not fully known to date.(130) Some NKT cells
express CD8 instead of CD4 and others express neither co-receptor, but their roles are
less well known. In aggregate, CD4+ T cells are an important arm of the cellular
immune response and can generate a wide range of effects towards eliminating
pathogens.

I.C.1.e. CD8+ αβ T cell Subsets
In contrast to CD4+ T cell subsets, CD8+ T cells subsets are usually defined in terms of
their memory response from previous encounters with antigens.(131) As mediators of
direct cellular cytotoxicity, CD8+ T cell memory responses are commonly studied in the
context of pathogenic infection or in the context of long-lived tumor-reactive T
cells.(132-134) After antigen exposure, naïve T cells (TN) proliferate rapidly and exert
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cytotoxicity as effector T cells (TEFF). The large numbers of antigen-specific T cells
then needs to be reduced as to not increase the total peripheral T cell pool each time a
pathogen elicits a response, so there is a contraction phase marked by TEFF sensitivity to
extrinsic apoptosis. However, the numbers of antigen-specific cells surviving the
contraction phase are greater than the initial antigen-specific T cell pool so that
exposure to the same pathogen will result in a faster and stronger attack on the
pathogen. These remaining cells are termed memory T cells (Figure 3). Three memory
T cell subsets have been described and are called central memory (TCM), effector
memory (TEM), and effector memory RA (TEMRA) T cells.(135) TN express CD45RA,
CD27, CD28, and CCR7 where CD45RA expression is lost on both TCM and TEM but is
re-expressed on TEMRA without CD27, CD28, and CCR7. The TEM and TCM groups can
be distinguished by CD28 and CCR7 where the former expresses neither and the latter
expresses both. TCM cells have the greatest proliferative capacity with limited effector
functions and serve as long-lasting antigen-specific pools. In contrast, TEM have
immediate effector functions, limited replicative capacity relative to TCM, and serve as
the main memory cytotoxicity mediators.(136) Lastly, TEMRA cells are terminally
differentiated cells that have effector functions without much proliferative capacity.
Even though CD4+ T cells are not typically stratified in this manner, memory
populations have been detected that could produce cytokines following subsequent
antigen exposure.(137, 138) Furthermore, CD4+ T cells are necessary for generating
CD8+ T cell memory, suggesting that even though they may not fit into clear subsets
they are present and required for memory cytotoxicity.(139) The application of these
groupings to cancer immunotherapy also comes with caveats due to the high degree of
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differences in their disease pathologies, i.e. virus versus cancer. CD27 expressed on TN,
TCM, and TEM was correlated with greatest responses in cancer immunotherapy, and can
be used to predict therapeutic efficacy.(134) While immediate effector function towards
cancer in adoptive T cell immunotherapies is desired, it appears that TN and TCM cells
are better for this particular task.(131) Generation of persistent CD8+ populations with
memory to the tumor, therefore, is an important consideration for immunotherapy
efficacy.
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Figure 3. CD8+ Memory T cell Subsets. (a) Limited quantities of antigen-specific
naïve T cell (TN) pool exist prior to exposure to antigen (Ag). Upon Ag contact, massive
Ag-specific T cell proliferation occurs in the effector T cell (TEFF), which is followed by
apoptotic contraction phase. Memory T cells (TM) are developed from the increase in
Ag-specific T cell population relative to the TN starting population. (b) Prior to Ag
exposure TN cells express CD45RA, CD27, CD28, and CCR7 where CD45RA
expression is lost in the formation of TCM and both CD28 and CCR7 are lost with TEM
cells. Terminally differentiated TEMRA cells lose CD27 expression and express CR45RA
again.
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I.C.2. γδ T cells
γδ T cells are a completely separate T cell lineage from αβ T cells, and γδ T cells have
both innate and adaptive immune cell functions.(140) In contrast to αβ T cells, γδ T
cells have predictable inherent anti-tumor immunity mediated directly through their
TCR.(141) However, γδ T cells comprise only 1 – 5% of the circulating T cell
repertoire, making them difficult to work with because of a relative lack of robust
protocols for polyclonal γδ T cell expansion and their infrequent quantities in peripheral
blood.(142, 143) They are identified by co-expression of CD3+TCRγδ+ where
expression of CD4 or CD8 is rare, and can be stratified into Vδ1, Vδ2, and Vδ3 subsets
based on TCRγδ alleles.(144) Targets of γδ T cells include tumor cells, viruses,
bacteria, mycobacteria, and cell stress-associated proteins.(145, 146) Therefore, γδ T
cells are a promising T cell immunotherapy option despite their limited frequencies in
blood if they can be expanded.

I.C.2.a. Unique Characteristics of γδ T cells
There are three variable TCRδ chains and 14 variable TCRγ chains expressed in
humans, and fewer unique TCRγδ combinations are observed in γδ T cells compared to
the immense combinational diversity seen with αβ T cells following V(D)J
recombination.(92, 144) Expression of TCRγδ heterodimers on the T cell surface in the
thymus inhibits recombination of β-chain locus during the CD4negCD8neg stage thereby
committing the T cell to the γδ T cell lineage.(147) This double negative status is often
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maintained after exit from the thymus, most likely because TCRγδ recognizes antigens
outside of MHC-restriction in many cases, making co-receptor expression dispensable
for function and endowing them with an ability to recognize antigens outside of the
signaling constraints imposed by classical thymic selection.(148) However, the thymus
is not required for all γδ T cell development, as many of these γδ T cells take up
residence in peripheral tissues and exhibit immediate effector functions against
pathogens.(149) Resident γδ T cells can be found in the mucosa, tongue, vagina,
intestine, lung, liver, and skin and can comprise up to 50% of the T cell populations in
intestinal epithelial lymphocytes (IEL).(144, 150) In contrast, circulating γδ T cells can
be found in the blood and lymphoid organs, and are canonically dominated by γδ T cells
expressing Vδ2 TCR isotype (called Vδ2 cells) with few γδ T cells expressing the Vδ1
TCR isotype (called Vδ1 cells) that are more frequently associated with resident γδ T
cells.(146) Moreover, Vδ2 cells most commonly pair with Vγ9, but Vδ1 and Vδ3 have
broad γ-chain pairing potential.(141, 146) Therefore, the location of γδ T cells can lead
to their subset diversity and effector functions that can be mediated through specific
combinations of γ and δ TCR chains to recognize pathogens upon encounter in their
resident or circulating locations.

I.C.2.b. Vδ1 γδ T cells
Vδ1 cells have a wide range of effector functions and are located in a variety of
anatomical locations.(151) They can, theoretically, pair with any of the TCRγ chains,
and there are a variety of known ligands for Vδ1 cells.(140) In fact, the crystal structure
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of Vγ1Vδ1 has been solved in combination with one of its antigens, MHC Class-I
chain-related A (MICA).(152, 153) Cellular stress and/or viral infection result in MICA
and its analog, MICB, to become expressed on the stressed/infected cell’s surface, so
MICA/B is commonly present on tumor cell surface.(154) MICA is also recognized by
NKG2D, a receptor expressed by γδ T cells, NK cells, and, less frequently, αβ T
cells.(155) Other non-classical MHC molecules and cell stress proteins are also
recognized by γδ T cells. For instance, Vγ4Vδ1 T cells have been shown to have
specificity towards heat shock proteins and the non-classical MHC molecule
CD1d.(156) Heat shock proteins are commonly over-expressed in tumor cells to handle
their high protein translation loads.(157) The CD1d molecule is best described in its
ability to expand NKT αβ T cells, but γδ T cells have also been described to have direct
NKT-like functions, enhance NKT αβ T cells reactivity to αGalCer, and have even
been shown to have specificity to cardiolipin with CD1d.(158-160) Also, murine
Vγ5Vδ1 cells are well described in their ability to serve as dendritic epidermal T cells
(DETCs) with APC function.(161-163) Lastly, correlative studies have implicated Vδ1
T

cells

to

have

immunity

towards

cytomegalovirus

(CMV)

and

human

immunodeficiency virus (HIV).(164, 165) In aggregate, Vδ1 cells have immunity
towards microbial pathogens, have antigen presenting capabilities, and can target
proteins expressed on the tumor surface.
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I.C.2.c. Vδ2 γδ T cells
The most extensively studied subset of γδ T cells is the Vδ2 lineage, which similar to
Vδ1 cells, recognize microbial pathogens, serve as APCs, and target cell-stress proteins
expressed on tumor cells.(141, 166) Bacterial alkylamines and Listeria monocytogenes
are recognized by Vδ2 cells when paired with Vγ2.(167-169) In contrast to Vδ1, a
strong preference towards Vδ2 heterodimerizing with Vγ9 has been well documented.
Vγ9Vδ2 cells have been shown to react to phospho-antigens (isopentenyl
pyrophosphate; IPP), F1-ATPase expressed on the cell surface, and Mycobacterium
tuberculosis.(170-172) Furthermore, Vγ9Vδ2 cells are reactive to cells treated with
aminobisphosphonates, e.g. Zoledronic Acid (Zol), which is the only current means of
propagating γδ T cells ex vivo in the clinic.(173, 174) Aminobisphosphonates inhibit
cholesterol synthesis and build up intermediates in the mevalonate-CoA pathway,
including IPP, which is a ligand for Vγ9Vδ2.(175) This process was serendipitously
discovered

when

patients

with

bone

disorders

who

were

treated

with

aminobisphosphonates to resume bone growth experienced large in vivo expansions of
Vγ9Vδ2 T cells, and aminobisphosphonates methods were subsequently translated into
laboratory practice to expand Vγ9Vδ2 cells ex vivo.(176) Thus, Vδ2 cells are the only
γδ T cells that have been used for adoptive T cell therapy. Utility of the Vδ1 and Vδ3
lineages is appealing, but there are no current means to rapidly expand them to
clinically-significant numbers and the existing polyclonal γδ T cell population is too
few in number for direct infusion. Nonetheless, numerous clinical trials treating cancer
patients with (i) infusions of Zol for in vivo Vγ9Vδ2 expansions and/or (ii) infusions of
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ex vivo expanded Vγ9Vδ2 cells have generated objective clinical responses but
complete responses have been unpredictable and have not always been directly
correlated to the Vγ9Vδ2 cells.(177-182) Thus, the extensive work studying Vδ2 cells
has generated much interest in using γδ T cells for adoptive immunotherapy.

I.C.2.d. Vδ3 γδ T cells
In contrast to Vδ1 and Vδ2 cells, very little is known about γδ T cells expressing Vδ3
TCR alleles (called Vδ3 cells). The limited quantities in peripheral blood and lack of
commercially available reagents for Vδ3 inhibit attempts to study this subset. Vδ3 cells
are indirectly correlated with CMV and HIV immune responses, but nothing is known
about their anti-tumor immunity.(165, 183) Developing a means with which to study
this lineage could have important scientific and clinical significance.

I.D. Chimeric Antigen Receptors
Chimeric Antigen Receptors (CARs) re-direct T cells to antigens independent of their
endogenous TCR specificity.(184, 185) These recombinant molecules contain in order
from N-terminus to C-terminus: (i) a single chain variable fragment (scFv) derived from
a monoclonal antibody with specificity to a TAA, (ii) an extracellular stalk, (iii) a
transmembrane domain, and (iv) T-cell signaling endodomains (Figure 4). Binding of
the scFv to its corresponding TAA leads to T cell activation resulting in proliferation,
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cytokine release, and cytotoxicity.(186) Thus, CAR+ T cells are re-directed to TAA
outside of their thymically-selected affinities.

I.D.1. CAR Generations
Successive modifications to the design of CARs have improved their ability to re-direct
T cells to TAAs.(187) CAR technology was invented by Dr. Zelig Eshhar (Weizmann
Institute of Science, Rehovot, Israel) in 1989, and the original CAR differed from the
more modern CARs by (i) having only CD3ζ and (ii) TCR constant domain
scaffold.(188) Second generation CARs have shown the most efficacy in re-directing T
cells and are superior to first generation CARs by adding in a co-stimulatory
endodomain, e.g. CD28 or CD137 (41BB), to supplement CD3ζ signaling strength
present in both generations (Figure 4).(189-193) Third generation CARs, therefore,
contain three endodomains, and the most common combination has been CD28, CD137,
and CD3ζ.(194-196) The order of endodomains does appear to have importance in the
ability to stimulate the T cell in both second and third generation CARs, where CD3ζ
works best at a position most distal to the membrane.(192, 197) The scaffold sequence
used has the most difference between investigators where IgG4 constant regions (used
in this dissertation), CD8α, no stalk, and flexible spacers have been used
successfully.(13, 32, 192, 193, 198, 199) Although there exist some differences between
groups in their CAR-modified T cell products in tumor killing, CARs in general have
been shown as a consistent and effective means to target desired antigens and change
the T cell response outside of their endogenous specificity.
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Figure 4. Schematic Representation of CARs. (a) First generation CARs were
constructed with single chain variable fragments (scFv) composed of heavy (VH) and
light (VL) variable fragments from monoclonal antibodies specific for TAA, followed
by IgG4 constant region (CH2 and CH3 domains displayed), a transmembrane α-helix,
and CD3ζ signaling endodomain. (b) Second generation CARs added a co-stimulatory
domain, e.g. CD28 or CD137, between CD3ζ and transmembrane domain. (c) Third
generation CARs use two co-stimulatory domains upstream of CD3ζ.
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I.D.2. Tumor-associated Antigens Targeted with CARs
Effective targeting of different TAAs using CAR-modified T cells has generated
enthusiasm around CAR-based immunotherapies. B-cell malignancies have been
targeted with CARs specific for ROR1, κ-light chain, CD19, CD20, CD22, CD23, and
CD30, which are all confined to the hematopoietic compartment and are not expressed
on solid tissues.(57, 77, 200-208) Moreover, CD30 is also expressed on T cells, making
CD30-specific CAR+ T cells candidates for T-ALL therapy, but no T-ALL-specific
CARs have been generated to date. Only one report of CARs targeting CML has been
made thus far but the actual TAA was not examined.(209) CARs specific for CD33 and
CD123 have been generated to target AML, but may have off-target effects due to the
importance of CD33 and CD123 in hematopoiesis and viral immunity because of their
expression on plasmacytoid dendritic cells that are critical producers of type-I
interferons needed for viral clearance.(210-214) OvCa has been the target of multiple
CARs including those specific for mesothelin, α-Folate Receptor (αFR), and folatebinding protein (FBP).(42, 215-219) Renal cell carcinoma has been targeted through the
carbonic anhydrase IX (CAIX), which has minimal expression in normal tissues and is
increased in hypoxia.(220-222) Carcinoembryonic antigen (CEA) is a developmental
antigen absent on normal tissue and up-regulated in malignant cells, and CARs
targeting CEA have been developed for pancreatic and colorectal cancers.(223, 224)
Similarly, the oncofetal antigens h5T4 and ROR1 (discussed in Chapter I.B.2) are only
expressed during development and CARs specific for these antigens can target multiple
tumor types.(77, 199, 223) The differences between published ROR1-specific CAR T
cells and the ones developed in this dissertation are discussed in detail in Chapter II.
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Both CAR and mAb immunotherapies have had much success targeting human
epidermal growth factor receptor-2 (EGFR2, HER2, or ERBB2), which is expressed
highly in many cancers.(194, 225-228) However, there is low-level expression of HER2
on normal tissues, which caused an “on-target/off-target” toxicity in the only trial to
date testing CAR+ T cells specific for this TAA on breast cancer, thereby limiting its
application.(229) Other EGFR members have been targeted with CARs, including
EGFRvIII, which is uniquely expressed on glioblastoma.(230-232) Even glycoproteins
(Lewis-Y antigen) can be targeted by CARs, and Lewis-Y antigens are typically studied
in the context of EGFR family members.(233) The ganglioside GD2 and L1-cell
adhesion molecule (L1-CAM) are common expressed on neuroblastoma, melanoma,
and sarcoma (GD2 only), and CARs targeting these TAA were shown to control
neuroblastoma growth.(234-239) In addition to GD2 and L1-CAM, high molecular
weight melanoma-associated protein was used as a target for melanoma.(240)
Melanoma is highly responsive to immunotherapy, and complete responses have been
generated from a single infusion of tumor infiltrating lymphocytes (TILs).(241, 242)
Prostate cancer has two specific antigens with limited expression outside of the prostate,
prostate stem cell antigen (PSCA) and prostate-specific membrane antigen (PSMA),
which were both targeted with CARs.(243-245) MUC1 was also another CAR target for
both prostate and breast cancers.(246, 247) Other ubiquitous tumor markers, e.g. tumor
associated glycoprotein-72 (TAG72) and epithelial glycoprotein-2 (EGP-2) have been
targeted by CARs for multiple cancer therapies.(248, 249) Angiogenesis is even the
target of a CAR via specificity for Vascular Endothelial Growth Factor Receptor 2
(VEGFR2), which is crucial for introducing new blood vessels into the tumors.(250,
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251) However, there are major concerns of long-term persistence of these VEGFR2specific cells in terms of regular vasculature growth. Lastly, receptors expressed on
tumors can be targeted by “zetakines,” which function like CARs but replace the scFv
of the CAR with the ligand for a receptor of interest. For example, IL13-Receptor-α-2
(IL13Rα2) was targeted by an IL13 fused to T cell signaling domains to target
glioblastoma multiforme and neuroblastoma.(252-255) As outlined, many tumor
antigens have been targeted by CARs, highlighting the enthusiasm given to this
immunotherapy.

I.D.3. Clinical Trials with CAR+ T cells
Many of the CARs described above have been translated into T cell immunotherapies
for cancer patients and have resulted in promising objective clinical responses.(200,
241, 242, 256, 257) The majority of the trials have been focused on CARs developed
from the FMC63 mAb specific for CD19.(186, 258, 259) CD19-specific CAR+ T cells
have eliminated tumor from patients resulting in B cell aplasia, a litmus test for longlived clinical responses.(4-7, 260) It was in this model that second generation CARs
proved to have superior anti-leukemia effects compared to first generation CARs.
Furthermore, long-lived persistence of CAR+ T cells has been achieved by rendering
them bi-specific to TAA and Epstein-Barr virus (EBV)-specific antigens through
skewing TCR repertoire in ex vivo co-cultures with EBV-transformed lymphoblastoid
cell lines (LCL).(206, 211, 212, 236, 237) The most striking clinical responses,
including maintained complete responses, have been achieved with second generation
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CD19-specific CAR+ T cells signaling through CD137 and CD3ζ.(4, 7, 32) The exact
reason why these cells out-performed other CARs signaling through CD28 and CD3ζ is
unknown at present, and pre-clinical models have not shown many differences between
CD28 and CD137 CARs.(5, 6) This is an active area of investigation and Chapter II
focuses on this question directly with ROR1-specific CARs that are in the approval
stages for a Phase I clinical trial. The focus of all Phase I clinical trials, of which most
CAR trials have been, is safety and establishing a maximum tolerated dose.
Unfortunately, there have been 2 deaths on CAR+ T cell clinical trials. The first death
followed administration of CD19-specific T cells to an elderly patient, who later died of
complications not thought to be directly linked to the immunotherapy.(261) In contrast,
the second death was directly attributed to the CAR+ T cells. In this study, a third
generation CAR (CD28, CD137, and CD3ζ) specific for HER2 (based on the
monoclonal antibody trastuzumab) was used to treat breast cancer, and following
infusion of 1010 T cells, the patient died of cytokine storm in response to basal levels of
HER2 on the lungs.(229) This tragedy has heightened the safety concerns around CAR+
T cell immunotherapy, and TAA choice, CAR design, and T cell dose are being closely
monitored in current and future trials.(262) Nonetheless, clinical trials are currently
accruing with CAR+ T cells targeting HER2 for sarcoma (NCT00902044), glioblastoma
multiforme (NCT01109095), and multiple cancer (NCT00889954) treatments
(http://www.clinicaltrials.gov/). Clinical trials with CAR-modified T cells specific for
αFR were not effective at treating advanced ovarian cancer, and the lack of efficacy
was attributed to lack of persistence of T cells in vivo.(42) Other trials targeting solid
tumors with TAA, e.g. GD2, L1-CAM, CAIX, and IL13Rα2, which are similar to
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HER2 expression in that there is some expression on normal tissues, have been safe and
sometimes effective at reducing tumor burden.(186, 220, 221, 235-237) Therefore, the
safety and efficacy of a particular CAR+ T cell clinical trial may vary from investigator
to investigator due to nuance in a number of variables surrounding propagation and
CAR design and/or from variability between individual patients.

I.E. Ex Vivo Propagation of T cells
Many platforms exist for the propagation of T cells ex vivo, and this dissertation focuses
on the use of Sleeping Beauty (SB) transposition for gene transfer into T cells followed
by propagation on artificial antigen presenting cells (aAPC). This non-viral system for
propagating T cells can be contrasted to viral-mediated gene transfer in that the latter
requires previous expansion, e.g. with agonistic antibodies or stimulating beads, in
order to transduce cells with the transgene of interest and the former does not require
previous expansion but rather propagates the T cells ex vivo following gene transfer.
The SB/aAPC strategy has been translated into the clinic, and modification of the
current SB/aAPC will be used to streamline translation of therapies developed in this
thesis to the clinic.

I.E.1. Sleeping Beauty Transposition-mediated Gene Transfer
Non-viral gene transfer with SB transposition establishes stable transgene expression in
human cells.(263, 264) SB genes are originally derived from fish that were undergoing
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active transposition in their evolutionary maturation and were adapted for transposition
into human cells.(265) In short, a DNA transposon with flanking inverted repeats and
direct repeats is ligated into the human genome at TA dinucleotide repeats by the SB
transposase enzyme.(266) TA dinucleotide repeats are randomly distributed in the
human genome, yielding potential for random integration into the genome and has
shown to be safe in regards to transgene insertion in pre-clinical studies.(267-269) This
is of particular importance in gene therapy as inappropriate integration at gene start sites
or promoters, within exons, or even distal to genes within enhancers or repressors can
cause cellular transformation. Lentiviruses and γ-retroviruses have higher efficiency in
transgene delivery than SB, but these vectors are known to integrate near genes or
within genes.(186) Moreover, this was a particular problem in gene therapy trials
treating X-linked severe combined immunodeficiency syndrome (X-SCID) where
roughly half of the patients receiving transduced cells later developed leukemia as a
result of integration near the LMO2 gene.(270, 271) In contrast, no preference towards a
particular chromosome or gene “hotspot” has been detected with SB.(267) Application
of SB to human T cells has worked as a two DNA plasmid system, where one plasmid
contains the SB transposon with the transgene of interest, e.g. CAR, and the other
plasmid encodes the SB transposase.(272) Electro-transfer of the DNA plasmids by
Amaxa nucleofection into quiescent peripheral blood mononuclear cells (PBMC) results
in transient expression of SB transposase that then ligates the CAR transposon into the
genome. As soon as the SB transposase mRNA is degraded translation of SB
transposase protein is halted, thereby limiting the chances of additional transposition
events. CAR expression can be encouraged through the co-culture of T cells on aAPC
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that express cognate antigen for the CAR.(273) aAPC serve as feeder cells, and
recursive stimulations with γ-irradiated aAPC promote CAR-specific growth. Typically,
after 30 days of co-culture >90% of cells will express CAR (Figure 5). Thus, SB
transposition is an efficient gene transfer modality in T cells and modified T cells can
be expanded ex vivo by aAPC co-culture.
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Figure 5. Schematic of CAR+ T cells Expansion on aAPC. PBMC are isolated by
Ficoll-Hypaque or steady state apheresis and are electroporated with plasmids encoding
either (i) Sleeping Beauty transposase or (ii) Sleeping Beauty transposon containing
CAR. Transient expression of CAR is observed the following day, and recursive
stimulations with K562-derived aAPC are performed weekly with exogenous IL2
and/or IL-21. Pictured here are the clone#1 aAPC that expresses CD19, ROR1, CD64,
CD86, CD137L, and IL15/IL15Rα. Following a month of co-culture on aAPC, stable
CAR expression is achieved and clinically-relevant numbers of CAR+ T cells are ready
for cryopreservation and then infusion into cancer patients.
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I.E.2 Artificial Antigen Presenting Cells
CARs stimulate T cells independent of their TCR specificity, and a primary aim of this
propagation schema is to stimulate the CAR without affecting TCR repertoire by
avoiding TCR/MHC interactions. Classical dendritic cells, thought of as “professional”
APC, are infrequent in peripheral blood, laborious to manipulate, have limited
replicative ability, and would need to be generated in the autologous setting for each
immunotherapy patient. For these reasons, an alternative means for CAR-specific
proliferation was sought after with the goal of serving as a global “off-the-shelf” bank
of aAPCs to stimulate T cells independent of their MHC typing.

I.E.2.a Unique Features of K562 for Antigen Presentation
K562 has become an efficient aAPC line because it (i) lacks most MHC Class-I
molecules, (ii) can be genetically modified easily, and (iii) proliferates robustly for easy
cell banking and scale-up purposes.(273-276) The lack of MHC Class-I molecules (no
A or B but limited C) on the K562 surface is advantageous because CD8-specific
allogeneic reactivity is minimized or could be tailored to certain HLA restriction for
TCR-specific responses.(277, 278) Expansion of T cells on aAPC has shown that
polyclonal TCR repertoire is readily achieved, suggesting that the aAPCs do not skew
endogenous TCR-response to a particular affinity or antigen.(263) Another important
characteristic of using K562-derived aAPC is their susceptibility to further gene
modification by either non-viral or viral mediated gene transfer. For instance, a master
aAPC cell bank was modified with both IL15 fusion protein to IL15 receptor-α
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(IL15/IL15Rα) and ROR1 antigen for memory formation and propagation of ROR1specific T cells, respectively (Chapter II). Also, HLA-Cw3 was detected on K562
cells, so Cw3 was efficiently removed with zinc-finger nucleases to create HLA-/- K562
cells (Torikai H, Cooper LJN, and Lee DA, unpublished observations) in order to
generate new aAPC completely devoid of HLA Class-I molecules. Thus, working cell
banks can be easily re-tooled to ask biological questions regarding aAPC mechanics
and/or maximize therapeutic cell output. Given the apparently unlimited proliferative
capacity of K562 cells and their genetically modified counterparts, optimization of
stimulations can be done easily and changed at will with options to use high ratios of
aAPC to T cells. Furthermore, γ-irradiation of aAPC prior to co-culture with T cells is
well tolerated by K562 in acute phases but eventually subjects the aAPC to death
(typically 3 days) thereby eliminating most risk for unintended transfer of this tumor
cell line into patients.(273) Therefore, K562 cells are an ideal source for antigen
presentation and T cell stimulation.

I.E.2.b. Established aAPC Cell Banks and Clinical Trials with aAPC
As of now, four clinical trials have used K562-derived aAPC as T cell and NK cell
expansion platforms at MD Anderson (NCT01653717, NCT01619761, NCT00968760,
NCT01497184). Clone#4 aAPC generated at University of Pennslyvania (UPenn) was
used successfully to expand CD19-specific CAR+ T cells in both autologous and
allogeneic settings.(57, 263, 272, 273, 279-281) The surface phenotype of clone#4 is
characterized by expression of: (i) CD19, (ii) CD32 (as an endogenous protein), (iii)
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CD64, (iv) CD86, (v) CD137L, and enhanced green fluorescence protein (eGFP;
surrogate marker for IL15 expression). Similarly, clone#9 aAPC was also generated at
UPenn and has a surface phenotype of: (i) CD19, (ii) CD32 (as an endogenous protein),
(iii) CD64, (iv) CD86, and (v) CD137L. Clone#9 aAPC was further modified to express
membrane-bound IL21 for trials propagating NK cells.(275) Translation of expansion
protocols into the clinic was readily achieved and validated this approach. Patients
treated with aAPC-expanded lymphocytes did not show toxicity, suggesting that this is
a safe approach (Cooper LJN, unpublished observations). Thus, aAPC will be used for
the propagation of T cells in this dissertation for direct clinical application.

I.F. Dissertation Specific Aims
This dissertation has three major specific aims, which attempt to solve the gaps in the
above knowledge and/or application of immunotherapy. More specifically, these aims
are directed at either harnessing the inherent anti-tumor immunity of T cells for cancer
therapy, modifying T cells with natural anti-tumor capacity with CARs for enhanced
specificity, or re-directing T cells with unpredictable anti-tumor immunity to cancer
through CAR expression. This multivariate approach has resulted in approval of one
Phase I clinical trial and holds the potential to result in other clinical trials for treatment
of both solid and hematological tumors.

I.F.1 Specific Aim#1: To evaluate whether ROR1-specific T cells can target ROR1+
tumor cells while sparing normal tissues. The hypothesis of this specific aim is that
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ROR1-specific CARs will re-direct the specificity of T cells to target ROR1+
malignancies and that CARs signaling through CD137 will be superior to CD28 in
therapeutic efficacy. The rationale for this specific aim is that (i) ROR1 is a candidate
TAA because it is expressed on a number of tumors but is not on most normal tissues,
(ii) the 4A5 monoclonal antibody specific for ROR1 can be adapted to generate a CAR,
(iii) CARs can re-direct T cells to TAA and empower them to kill TAA+ malignancies,
and (iv) cancer patients treated with CAR+ T cells have achieved complete responses.
Sub-Aim 1.1. To generate ROR1-specific CAR+ T cells. Sequences from 4A5 antibody
hybridoma will be constructed into second generation ROR1-specific CARs signaling
through (i) CD28 and CD3ζ (ROR1RCD28) or (ii) CD137 and CD3ζ (ROR1RCD137),
which will be part of SB transposons for stable CAR expression in T cells. CAR+ T
cells will be propagated on γ-irradiated ROR1+ aAPC (clone#1), and CAR+ T-cell
numeric expansion will be monitored by inferred cell counts and flow cytometry for 28
days. Sub-Aim 1.2. To phenotype ROR1-specific CAR+ T cells. Extended phenotyping
for memory and homing markers will be performed by flow cytometry at the end of the
co-culture period. Genotyping will also be performed with nCounter gene expression
platform for TCR isotype expression and lymphocyte-associated genes. Sub-Aim 1.3. To
assess whether CAR+ T cell function is specific for ROR1. Cytokine production and 4hour chromium release assay (CRA) will be used to evaluate CAR+ specificity in
responding to ROR1+ targets with ROR1neg targets as negative controls. ROR1+
leukemia xenografts will be established in immunocompromised mice which will be
treated with CAR+ T cells to evaluate tumor clearance in vivo.
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I.F.2. Specific Aim#2: To assess whether a CD19-specific CAR expressed on γδ T cells
will render them bi-specific to tumors through their TCR and CAR. The hypothesis of
this specific aim is that enforced CAR expression on γδ T cells would stimulate them
independent of their TCRγδ, thus leading to expansion of γδ T cells with polyclonal
TCRγδ repertoire, and would amplify the anti-tumor effects from TCRγδ towards TAA+
malignancies through the CAR. The rationale for this specific aim is that (i) γδ T cells
have inherent anti-tumor immunity through a number of combinations of TCRγ and
TCRδ pairings, (ii) the use of γδ T cells in the clinic is currently restricted to Vγ9Vδ2
even though other γδ T cell lineages have anti-tumor reactivity, (iii) CARs stimulate T
cells independent of their TCR, (iv) electroporation of SB transposons containing the
CAR can be achieved in quiescent PBMC with a polyclonal repertoire of γδ T cells, and
(v) CD19-specific CAR transposon plasmids and CD19+ aAPC are currently in clinical
trials at MD Anderson and these reagents can be used to quickly translate findings from
this specific aim into clinical trials. Sub-Aim 2.1. To propagate CAR+ γδ T cells on
aAPC. The second generation CD19-specific CAR (CD19RCD28) currently in clinical
trials is available as highly pure DNA and will be used for gene transfer into quiescent
PBMC from which CAR+ γδ T cells will be propagated on CD19+ aAPC. CAR
expression and inferred cell counts will be used to evaluate CAR+ γδ T cell numeric
expansion. Sub-Aim 2.2. To phenotype CAR+ γδ T cells. After a month of expansion on
aAPC, CAR+ γδ T cell surface phenotypes will be evaluated for T cell and memory
molecules by flow cytometry and TCRγδ allele expression will be assessed by nCounter
gene expression analysis. Sub-Aim 2.3. To determine the ability of CAR+ γδ T cells to
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functionally respond to tumors. Cytokine production and 4-hour CRA assays will be
tested against CD19+ tumor targets with CD19neg targets serving as negative controls.
Autologous CARneg γδ T cells will be used to compare CAR-specific responses to
CD19+ tumors. CD19+ leukemia xenografts will be established in immunocompromised
mice which will be treated with CAR+ γδ T cells to evaluate anti-tumor effects in vivo.

I.F.3. Specific Aim#3: To evaluate the inherent anti-tumor activity of aAPC-expanded
γδ T cells against solid and hematological cancers. The hypothesis of this specific aim is
that aAPC will expand polyclonal γδ T cells that will have broad anti-tumor immunity.
The rationale for this specific aim is that (i) CARneg polyclonal γδ T cells proliferated in
parallel to CAR+ γδ T cells described in specific aim#2 on aAPC, (ii) no current
expansion protocols exist for polyclonal γδ T cells for the clinic, (iii) aAPC are
currently in clinical trials and are available as a master cell bank in the manufacturing
facility at MD Anderson, (iv) γδ T cells expressing Vδ1 are correlated with long-term
remissions in cancer therapy but have not been directly infused as an adoptive
immunotherapy, (v) γδ T cells expressing Vδ2 have shown anti-tumor effects as direct
adoptive immunotherapies, (vi) γδ T cells expressing Vδ3 have not been described to
have direct anti-tumor immunity leaving a gap in the field of knowledge, and (vii) a
polyclonal approach to γδ T cell immunotherapy could target multiple ligands on the
tumor through a diverse repertoire of TCRγδ. Sub-Aim 3.1. To propagate γδ T cells on
aAPC. PBMC or UCB will be sorted for γδ T cells, and then co-cultured with aAPC
used in clinical trials at MD Anderson. Flow cytometry and inferred cell counts will be
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used to evaluate proliferation of γδ T cells. Subsets of γδ T cells will also be sorted and
expanded as co-cultures with clinical aAPC to assess differences in γδ T cell lineages.
Sub-Aim 3.2. To phenotype γδ T cells expanded on aAPC. After one month of co-culture
on aAPC, the surfaces of polyclonal or sorted γδ T cells will be evaluated for T cell and
memory markers by flow cytometry and TCR allele expression will be assessed on
nCounter gene expression platform. Sub-Aim 3.3. To examine the range of killing
capabilities by aAPC-expanded γδ T cells. Polyclonal or sorted γδ T cells will be
evaluated for their ability to produce cytokines in response to TCR stimulation or coculture with tumor cells derived from solid and hematological cancers. Standard 4-hour
CRA will be used to assess acute cytolysis and long-term co-cultures will evaluate
durable killing abilities. Neutralizing antibodies will be employed to determine the
specificity of killing. OvCa xenografts will be established in immunocompromised mice
which will be treated with polyclonal γδ T cells to test their tumor clearance in vivo.
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CHAPTER II
Clinical Implications for ROR1-specific T cells

II.A. Hypothesis and Rationale
The hypothesis of this chapter is that ROR1-specific CARs will re-direct the
specificity of T cells to target ROR1+ malignancies and that CARs signaling through
CD137 will be superior to those signaling through CD28 in therapeutic efficacy. The
rationale for this chapter is that (i) ROR1 is a candidate TAA because it is expressed on
a number of tumors but not on most normal tissues, (ii) the 4A5 monoclonal antibody
specific for ROR1 can be adapted to generate a CAR, (iii) CARs can re-direct T cells to
TAA and empower them to kill TAA+ malignancies, and (iv) cancer patients treated
with CAR+ T cells have achieved complete responses. This chapter describes preclinical testing of ROR1-specific T cells that have clinical implications as cancer
immunotherapies.

II.B. Introduction
Current clinical trials use T cells expressing CARs specific for CD19, an antigen
expressed on the surfaces of all B cells, to eliminate refractory B-cell malignancies.(4,
57, 184, 186) However, there is also loss of normal CD19+ B cells in patients
undergoing this therapy, which can result in serious health complications including loss
of humoral immunity.(7, 32) Furthermore, loss of CD19+ B cells in an elderly patient
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treated with CD19-specific CAR+ T cells resulted in death from an opportunist viral
infection.(261) ROR1 is absent on most normal B cells and other healthy tissues
(Chapter I.B.2.), but is expressed on many B-cell tumors (mantle cell lymphoma
(MCL), ALL with t(1:19) translocations, and >95% of CLL) and solid tumors (lung and
breast cancer, OvCa, PaCa, renal cell carcinoma, and melanoma) where ROR1
expression is required for cellular growth and survival.(13, 64, 66, 67, 75, 79, 80, 282)
Thus, CARs targeting ROR1 instead of CD19 would allow for tumor elimination while
sustaining the normal B cell repertoire, and ROR1-specific T cells have the potential for
use in a number of solid tumors.
The design of the CAR is a source of debate at present. Striking clinical data,
including complete responses, were observed in ALL and CLL patients treated with
second generation CD19-specific CARs having CD137 (41BB) endodomain or the
more frequently used CD28 region.(5-7, 32) However, the differences between the two
CARs or their mechanisms of improved efficacy over other CAR clinical trials are
unknown at present. CAR clinical trials targeting CD19 open at MD Anderson use the
CD28 moiety (NCT01653717, NCT00968760, NCT01497184), but are being adapted
to (i) directly compare CD28 to CD137 CARs and/or (ii) replace CD28 CARs with
CD137 CARs. These trials, and those performed at other independent centers, will aim
to validate these remarkable responses and determine whether CD28 or CD137 is the
ideal co-stimulatory domain for CD19-specific CARs.
However, these results may not necessarily hold true for targeting different
antigens due to differences in antibody affinity and/or antigen expression. Direct
immunotherapy of ROR1-specific antibody (through clone 2A2) has been proposed as
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an option for leukemia and broader cancer treatment, but this antibody appears to have
strong cytoplasmic staining in a number of normal tissues (despite absence of ROR1
mRNA expressed in these tissues) and directly binds to adipocytes that express small
amounts of ROR1 mRNA.(77, 81, 283) CARs have been developed from the 2A2
(mouse) and R12 (goat) antibodies, and CAR+ T cells were generated in central memory
T cells (TCM) that could then efficiently lyse ROR1+ tumor, but their reactivity towards
normal tissues outside of normal B cells was not evaluated.(77, 199) The optimal 2A2
and R12 CARs for expression in TCM cells had short extracellular domains (14 amino
acids) with CD137 and CD3ζ signaling endodomains. In contrast to other ROR1specific antibodies, the 4A5 clone developed by Dr. Thomas J Kipps (Moores Cancer
Center, UCSD) has not been shown to bind any normal tissues, except hematogones
(dispensable B-cell precursors), but is highly reactive to a number of cancers, including
leukemia, OvCa, and PaCa.(66, 67, 75, 79) Therefore, this clone was chosen for
generation of ROR1-specific T cells in the expansion system developed at MD
Anderson that has a number of differences to the previous studies, including (i) 4A5
antibody specificity, (ii) expression of CAR in polyclonal peripheral T cells containing
naïve and TCM reported to have maximal efficacy as CAR+ T cells,(131) (iii)
propagation of CAR+ T cells on aAPC containing membrane-bound IL15/IL15Rα
fusion protein for optimal cytokine signaling potency and memory formation, and (iv)
expansion schema without the need for sorting steps that can complicate clinical
translation. Thus, CARs developed based on this strategy are hypothesized to have
efficient killing of ROR1+ malignancies and could answer some of the same
fundamental CAR questions in a broader set of peripheral T cells.
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Clinical trials have not yet tested ROR1-specific CARs in humans, so this report
of pre-clinical testing of ROR1-specific CARs aims to directly test CD28 and CD137
signaling CARs to streamline trial design and clinical efficacy for cancer treatments.
“First-in-man” clinical trials open at MD Anderson translated (i) co-electro-transfer of
CD19-specific CAR Sleeping Beauty (SB) transposon with SB transposase and (ii)
expansion of CD19-specific CAR+ T cell on CD19+ aAPC into clinical manufacturing
and were successfully transplanted into leukemia patients without toxicity or adverse
event, suggesting that this is an effective and safe strategy (Cooper LJN, unpublished
observation). This study builds upon these successes and adapts current (i) CAR
plasmids, (ii) working aAPC cell banks expressing co-stimulatory molecules for
endogenous co-stimulation of CD28 and CD137, and (iii) protocols for direct clinical
application. A phase I clinical trial has been approved by the National Institutes of
Health (NIH) DNA Recombinant Advisory Committee (RAC) based on the data herein
and is currently under review at the MD Anderson Cancer Center Institutional Review
Board (IRB). Thus, ROR1-specific CARs are close to being tested for the first time in
cancer immunotherapy.

II.C. Results
II.C.1. ROR1 Surface Expression on Tumor Cells
Surface expression of ROR1 was detected on a number of leukemia cell lines, OvCa
cell lines, and primary leukemia patient samples before proceeding with generating
ROR1-specific CARs. The 4A5 monoclonal antibody has been shown to have high
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affinity binding to ROR1,(75) and it was provided by Dr. Thomas J Kipps (UCSD) for
testing ROR1 expression at MDACC. EL4 is a murine T-cell lymphoma cell line with
low cross-reactivity with human T cells most likely due to their differences in MHC
molecules. This cell line does not express human ROR1, thus they were genetically
modified to express ROR1 in order to assess CAR-specific responses independent of
their TCR interaction with MHC (Figure 6a). Human B-cell ALL cell lines were
readily accessible and were profiled for ROR1 expression. As expected, ROR1 was
present on some, but not all, B-ALL cell lines. More specifically, NALM6 and Kasumi2
tested negative and positive for ROR1, respectively (Figure 6b). ROR1 was also
expressed on most (11 of 12) OvCa cell lines tested, which are best exemplified by
ROR1+ EFO27 cells and the only ROR1neg OvCa cell line tested, A2780 (Figure 6c).
ROR1 was originally described as a cancer antigen in B-cell CLL, so primary B-cell
CLL patient samples were acquired for testing in parallel with LCL derived from
healthy donor B cells immortalized with EBV. Indeed, CLL samples stained for ROR1
while LCL did not (Figure 6d). These results corroborated the previous literature and
gave us confidence to go forward with generating a ROR1-specific CAR designed from
the 4A5 antibody.
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Figure 6. Surface Expression of ROR1 on Tumors. The 4A5 mAb specific for ROR1
was used to assess ROR1 expression on the surface of (a) EL4 parental (ROR1neg) and
genetically modified EL4-ROR1 cells, (b) B-ALL cell lines NALM6 and Kasumi2, (c)
OvCa cell lines A2780 and EFO27, and (d) primary patient B-CLL cells or healthy
donor LCL by flow cytometry. Mean fluorescence intensities (MFI) are displayed near
corresponding histograms and legends are displayed above corresponding graphs.

51

Drew C Deniger
II.C.2. ROR1-specific CAR Plasmid Construction
Two SB transposons were constructed with second generation ROR1-specific CARs for
side-by-side

comparison

between

the

CD28

(ROR1RCD28)

and

CD137

(ROR1RCD137) endodomains (Figure 7a and 7b, respectively). CD19 constructs were
prepared in parallel with the CD28 (CD19RCD28) and CD137 (CD19RCD137)
endodomains as controls for current standard T cell therapy and were identical to
ROR1-specific CARs except in two pieces. First, the single chain variable fragment
(scFv) differ between the CD19 and ROR1 constructs where the FMC63 and 4A5
monoclonal antibodies specific for CD19 and ROR1 were used, respectively. Second,
CD19 CARs use the colony-stimulating factor-2 receptor (CSF2R) signal peptide
whereas ROR1 CARs use the murine IgGκ signal peptide. Human elongation factor-1α
promoter was used to drive CAR expression of all CARs. Following the promoter, the
CAR open reading frame was composed of (from 5’ to 3’): signal peptide, scFv with
Whitlow linker, modified extracellular IgG4-Fc stalk,(272) CD28 transmembrane
domain, CD28 or CD137 endodomains, and intracellular CD3ζ containing three ITAM
domains. Interspaced between the STOP codons and the polyadenylation (polyA) tail
were unique oligonucleotides to distinguish the two CAR transposons by polymerase
chain reaction (PCR). The CD28 constructs could be distinguished from CD137
constructs by the “SIM” and “FRA” oligonucleotides, respectively. Thus, detection of T
cell persistence in patients undergoing ROR1-CAR T cell therapy can be monitored and
can corroborate flow cytometry data. SB indirect repeats flanking the promoter (5’ end)
and the polyA tail (3’ end) defined the CAR transposons to be integrated within TA
repeats in the human T cell genome. Lastly, kanamycin resistance was used to
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selectively amplify CAR plasmids in bacteria to large quantities (0.5 – 1.0 mg), which
were cleared for transfection after testing negative for endotoxin. In summary, these two
ROR1-specific CAR plasmids mimic current plasmids used for CD19-specific CAR
clinical trials at MD Anderson and should be directly translatable to the clinical setting.
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Figure 7. ROR1-specific CAR Transposons. DNA plasmid vector maps for (a)
ROR1RCD28 and (b) ROR1RCD137. Abbreviations are as follows, IR/DR: Sleeping
Beauty Inverted Repeat, hEF-1alpha/p: Human Elongation Factor-1 alpha region hybrid
promoter,
ROR1RCD28CD3z:
Human
codon
optimized
ROR1-specific
scFvFc:CD28zeta chimeric antigen receptor, ROR1RCD137CD3z: Human codon
optimized ROR1-specific scFvFc:CD137zeta chimeric antigen receptor, SIM: “SIM”
PCR tracking oligonucleotides, FRA: “FRA” PCR tracking oligonucleotides, BGH
polyA; bovine growth hormone polyadenylation sequence, ColE1: A minimal E.coli
origin of replication, Kanamycin (Kan/R): Bacterial selection gene encoding
Kanamycin resistance, Kanamycin promoter (Kan/p); Prokaryotic promoter. Digestion
with BsrGI enzyme can distinguish the two plasmids, which have high degrees of
similarity. The entire plasmid sequences were verified by Sanger-based sequencing
techniques.
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II.C.3. Development of ROR1+ aAPC (clone#1)
aAPC have been shown to propagate T cells ex vivo through (i) expression of cognate
antigen or (ii) activation through membrane-bound antibody. However, current clinical
K562-based aAPC cell banks at MD Anderson do not express ROR1. Therefore, a new
aAPC was developed to express ROR1 and an IL15 fusion protein to the IL15 receptorα (IL15/IL15Rα) along with the other molecules present on aAPC surfaces. Transpresentation of IL15 by IL15Rα has been shown to have higher signaling potency than
IL15 alone in other models.(284, 285) Clone#1 feeder cells were derived from the K562
cell line, which was previously made to express CD19 antigen, co-stimulatory
molecules (CD86 and CD137L), and Fc receptors (endogenous CD32 and introduced
CD64) for loading of agonistic anti-CD3 antibody (OKT3). Thus, the CAR+ T cells had
the potential to receive co-stimulation through the CAR and from endogenous binding
of CD28 and CD137 on the T cell to CD86 and CD137L, respectively, on the aAPC.
Prior to co-culture, aAPC were γ-irradiated (100 Gy) and typically die within 3 days of
co-culture. Clone#1 aAPC were phenotyped prior to co-culture to ensure that all
markers were present at >80% (Figure 8 right panels). Negative and positive controls
were parental K562 cells (Figure 8 left panels) and clone#4 aAPC (Figure 8 middle
panels) used in CD19-specific CAR+ T cell clinical trials at MD Anderson,
respectively. The expression of IL15 by clone#4 is detected with eGFP as a surrogate
marker but IL15 was directly detected on the surface of the clone#1 cells. Cytokine
support, co-stimulation, and antigen expression by clone#1 aAPC gave us confidence in
its ability for use in CAR+ T cell propagation.
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Figure 8. Surface Phenotype of Clone#1 aAPC Used for ROR1-specific T cell
Expansion. Parental K562 (left), clone#4 aAPC (middle), and clone#1 aAPC (right)
were stained for surface marker expression and were analyzed by flow cytometry. Top
plots are forward scatter (FSC; x-axes) by side scatter (SSC; y-axes). Other plots were
eGFP (x-axes) with the following on the y-axes from top to bottom: CD19, CD32,
CD64, CD137L, ROR1, IL15, and CD86. Quadrant frequencies are displayed in the
upper right corners.
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II.C.4. CAR+ T-cell Expansion on Clone#1 aAPC
Healthy donor PBMC were electroporated with (i) no DNA as a negative control for
CAR expression, (ii) SB11 transposase and ROR1RCD28 transposon plasmids, or (iii)
SB11 transposase and ROR1RCD137 transposon plasmids. The following day, cells
were phenotyped for CAR expression on their surfaces where “no DNA” and isotype
antibodies served as negative controls. Transient expression of CAR was detected in T
cells at 41% ± 6% and 41% ± 8% (mean ± SD; n=3) for ROR1RCD28 and
ROR1RCD137, respectively, as evidenced by co-staining for Fc (IgG4-Fc extracellular
stalk of CAR) and CD3 (Figure 9a). Co-cultures were then initiated with γ-irradiated
clone#1 aAPC and CAR+ T cells at a 1:1 ratio. Similarly, γ-irradiated OKT3-loaded
clone#4 aAPC and “no DNA” T cells were co-cultured at 1:1 ratio of total cells. Cocultures were supplemented with IL21 (30 ng/mL) at the outset of co-culture and every
2-3 days thereafter. Recursive stimulations were performed every 7 days as above for
four total stimulations, except that (i) IL2 (50 U/mL) was supplemented with IL21
starting at the second stimulation and (ii) NK cells were depleted from cultures with
CD56 microbeads at day 15. At day 29, stable CAR expression was observed
suggesting that clone#1 aAPC enforced CAR expression in T cells (Figure 9b). More
specifically, CAR was expressed in T cells at 90% ± 3% and 79% ± 11% (mean ± SD;
n=3) for ROR1RCD28 and ROR1RCD137, respectively, at the end of the co-culture.
There was a difference between the transient and stable populations for ROR1RCD28
(p = 0.006) and ROR1RCD137 (p = 0.009), but the populations did not have significant
differences in CAR expression (p = 0.184) following expansion. ROR1RCD137 had
consistently lower mean fluorescence intensity (MFI) compared to ROR1RCD28 (51 ±
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8 vs 102 ± 68, respectively) after expansion, but the reason for this is unknown at
present. Recombinant rROR1 (rROR1; soluble extracellular domain) was purified and
directly conjugated to a fluorescent marker (courtesy of Dr. Thomas J Kipps, USCD)
for detection of antigen binding by CAR+ T cells. CD19-specific CAR+ T cells were
expanded in parallel to serve as negative controls for rROR1 binding (Figure 10a). The
CD19RCD28 had higher CAR expression than did ROR1RCD28, which could be
explained by the differences in signal peptides used (human CSF2R and murine IgGκ,
respectively). Nonetheless, ROR1RCD28 bound to rROR1, but CD19RCD28 and
CARneg T cells did not bind to rROR1 (Figure 10b). Proliferation kinetics between the
two ROR1 CAR populations was similar in total cells counts (p = 0.66; Two-way
ANOVA) and in CAR+ T cell counts (p = 0.74). Total cell proliferation closely
coincided with CAR+ T cell proliferation kinetics for both ROR1RCD28 and
ROR1RCD137 (Figure 11). ROR1RCD28 resulted in an average of 2.5x109 total
inferred cell counts (range 1.4x109 – 4.0x109) and 2.2x109 CAR+ T cells (range 1.3x109
– 3.6x109), and ROR1RCD137 resulted in an average of 3.6x109 total inferred cell
counts (range 3.7x109 – 8.2x109) and 2.9x109 CAR+ T cells (range 2.4x109 – 6.7x109).
Thus, SB transposition resulted in stable CAR expression and co-culture on clone#1
aAPC led to clinically-relevant numbers of ROR1-specific T cells.
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Figure 9. CAR Expression in T cells Before and After Expansion on Clone#1
aAPC. (a) Transient expression of ROR1RCD28 (middle) and ROR1RCD137 (right) T
cells the day following electroporation where “no DNA” T cells (left) were used as
negative controls. (b) Stable CAR expression in ROR1RCD28 (middle) and
ROR1RCD137 (right) populations. T cells were marked by CD3 staining and
CAR+ cells were detected with anti-Fc antibody. Quadrant frequencies are displayed in
upper right corners.
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Figure 10. rROR1 Antigen Binding by ROR1-specific T cells. Recombinant ROR1
(rROR1) was purified and conjugated to fluorescent tag for detection of ROR1-specific
T cells (ROR1RCD28). CD19-specific CAR+ T cells (CD19RCD28) and “no DNA”
CARneg T cells were used as negative controls. (a) Fc detection of CARs and (b) rROR1
binding.
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Figure 11. Sustained Proliferation of CAR+ T cells. (a) Total cells and (b) CAR+ T
cell proliferation on clone#1 aAPC. ROR1RCD28 represented on the left and
ROR1RCD137 shown on the right. Each symbol represents a different healthy donor.
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II.C.5. Immunophenotype of ROR1-specific T cells
II.C.5.a. T cell Immunophenotype of ROR1RCD28 and ROR1RCD137
Following 29 days of expansion on irradiated clone#1 aAPC, ROR1RCD28 and
ROR1RCD137 cells were profiled for (i) gene expression using the nCounter gene
expression array platform (NanoString) and (ii) T cell surface proteins and memory
markers by flow cytometry. A unique panel of lymphocyte genes was assembled for
analysis on the nCounter and was termed “Lymphocyte CodeSet Array” or LCA
(Appendix A). As expected, both δ and ε isoforms of CD3 (CD3D and CD3E,
respectively) were highly expressed by both CAR+ T cell populations, and there was
higher expression of both CD3D and CD3E in ROR1RCD28 cells (Figure 12a).
Expression of CD3ζ was not evaluated at the mRNA level because it could not be
distinguished from CD3ζ on CAR intracellular domains. Nonetheless, >97% of CAR+ T
cells were CD3+ on the cell surface (Figure 12b). There was also a trend of decreased
expression of CD4 and CD8A transcripts in ROR1RCD137 cells relative to
ROR1RCD28 and there was ~100 times more CD8A transcript than CD4 (Figure 12a
middle panels). The same was observed at the protein level where both CARs
preferentially expanded CD8+ T cells over CD4+ T cells and on average there were
fewer CD4 and CD8 T cells in the ROR1RCD137 culture (Figure 12b top panels and
12c). This phenomenon of fewer CD4+ and CD8+ T cells is most likely attributed to
small frequencies of γδ T cells (identified by CD3+TCRγδ+) that were present in the
ROR1RCD137 cultures and not in the ROR1RCD28 cultures (Figure 12b bottom
panels), because γδ T cells are commonly negative for both CD4 and CD8 but express
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CD3.(286) Indeed, γδ T cells can proliferate on aAPC (Chapters III and IV), which
suggests that they may compete for clone#1 for proliferative signal and diminish
ROR1RCD137 cells from reaching >90% CAR+ T cells. NK cells were present in
cultures at Day 15 and were depleted with CD56 microbeads from all cultures, so
negligible quantities of CD3negCD56+ NK cells were detected at the end of the coculture period two weeks later (Figure 12b, middle panels). CD56 was also expressed
by T cells at the end of the co-culture period and is associated with MHC-unrestricted
cytolysis (Figure 12a and 12b).(287) Significant differences between T cell surface
protein expression were not observed (p = 0.322) between the two CARs in respect of
CD3, CD4, CD8, CD56, NK cells, or γδ T cells (Figure 12c). These results suggest that
CAR+ T cells have canonical T cell phenotype features and on the basis of these
evaluated markers were highly similar.
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Figure 12. Basic Immunophenotype of CAR+ T cells. After 29 days of expansion on
clone#1 aAPC, ROR1RCD28 and ROR1RCD137 cells were (i) lysed for mRNA
expression analysis or (ii) phenotyped for T cell surface markers by flow cytometry. (a)
RNA lysates were interrogated on nCounter gene expression array with “lymphocyte
CodeSet array” (LCA) and normalized CD3 (far left), CD4 (middle left), CD8A (middle
right), and CD56 (far right). mRNA expression are displayed for ROR1RCD28 (open
shapes) and ROR1RCD137 (closed shapes). Student’s paired, 2-tailed t-test was used
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for statistical analysis (n = 3). *p<0.05 (b) CD4 (x-axes) and CD8 (y-axes) expression
(top panels), CD3 (x-axes) and CD56 (y-axes) expression (middle panels), and CD3 (xaxes) and TCRγδ (y-axes) expression (bottom panels) of one of 3 representative donors.
Gate frequencies are in the upper right corners and correspond to gate quadrants. (c)
Frequencies of cells staining positive for each lymphocyte marker where each shape
represents an individual donor, ROR1RCD28 are in open shapes and ROR1RCD137 are
in closed shapes, NK cells were defined as CD3negCD56+, γδ T cells were defined as
CD3+TCRγδ+, and data are mean ± SD (n = 3).

66

Drew C Deniger
II.C.5.b. Memory Phenotype of ROR1-specific T cells
Naïve (TN) and central memory (TCM) T cells have been associated with long-term
CAR+ T cell therapeutic efficacy due to their ability to achieve persistence in vivo.(131)
Both ROR1RCD28 and ROR1RCD137 cells predominantly expressed memory markers
associated with TN and TCM memory phenotypes at Day 29 of co-culture (Figure 13).
The mRNA expression of memory-associated genes was first evaluated with LCA,
which identified a significant reduction in the inhibitory regulatory gene CTLA4 and an
increase in expression of the transcription factor Lef1, which has been described to
participate in CD8+ T cell memory formation, in ROR1RCD137 cells relative to
ROR1RCD28 cells (Figure 13a).(119, 288) As seen with the mRNA gene expression
data, surface protein expression of CD28 was significantly (p = 0.003; Student’s paired,
2-tailed t-test) higher in ROR1RCD137 cells compared to ROR1RCD28, whereas
CD27 was highly expressed in both CAR+ T cell populations suggesting they have not
reached terminal differentiation (Figure 13a, 13b, and 13d). CAR+ T cells populations
were also similar in their high surface protein expression of lymphoid organ homing
and memory markers CD62L and CCR7, suggesting they could home to organs
harboring leukemia (Figure 13a, 13c, and 13d). A trend of decreased gene expression
of SELL (CD62L) gene was observed in ROR1RCD137 cells, whereas CCR7
transcripts were roughly equivalent between the two CAR populations and protein
expression was roughly equivalent for both sets as well. There was also a trend of
higher expression of the antigen-experienced marker CD45RO over the more naïveassociated marker CD45RA in both populations (Figure 13d). Both groups were similar
overall (p = 0.251; Two-way ANOVA) in expression of CD27, CD28, CD45RA,
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CD45RO, CD62L, and CCR7. To further analyze memory potential, multi-parameter
gating

was

used

to

define

specific

memory

CD45RA+CD27+CD28+CCR7+),

central

CD45RAnegCD27+CD28+CCR7+),

effector

CD45RAnegCD27+CD28negCCR7neg),

and

effector

populations

as

naïve

memory

(TCM;

memory
memory

(TN;

(TEM;
RA

(TEMRA;

CD45RA+CD27negCD28negCCR7neg).(131, 289) Most CAR+ T cells belonged to TN and
TCM groups with few TEM and TEMRA (Figure 13e). ROR1RCD137 had a trend of higher
frequencies of cells belonging to TN and significantly higher TCM groups than
ROR1RCD28, and overall the two CAR+ T cell populations were different (p = 0.019;
Two-way ANOVA). In aggregate, the surface phenotypes of ROR1-specific CAR T
cells suggest their potential for memory and effector functions against ROR1+
malignancies.
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Figure 13. Memory Markers on CAR+ T cell Surfaces. After 29 days of expansion
on clone#1 aAPC, ROR1RCD28 and ROR1RCD137 cells were (i) lysed for mRNA
expression analysis or (ii) phenotyped for T cell surface markers by flow cytometry. (a)
RNA lysates were run on the nCounter LCA and normalized expression of CTLA4 (far
left), Lef1 (middle left), CCR7 (center), SELL (CD62L; middle right), and CD28 (far
right) are displayed. Student’s paired, 2-tailed t-tests were done for statistical analyses.
*p<0.05 (b) CD27 (x-axes) and CD28 (y-axes) expression and (c) CCR7 (x-axes) and
CD62L (y-axes) expression of one of 3 representative donors. (d) Frequencies of cells
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staining positive for each memory marker. Student’s paired, 2-tailed t-tests were done
for statistical analyses. ***p<0.001 (e) Frequencies of cells staining positive for
memory groups (TN: naïve, TCM: central memory, TEM: effector memory, TEMRA:
effector memory RA). Statistical analysis was Student’s paired, 1-tailed t-test between
CAR groups for each memory group. *p<0.05 For (a), (d) and (e), each shape
represents an individual donor, ROR1RCD28 are in open shapes and ROR1RCD137 are
in closed shapes, and data are mean ± SD (n = 3).
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II.C.6. TCR Repertoire of ROR1-specific T cells
Multiplex gene expression analysis was used to assay differences in TCR genes.
Skewing towards a particular TCR clonotype was evaluated between the two CAR
populations to assess whether CD28 or CD137 CARs particularly expand a select group
of TCRs (Figure 14). The “direct TCR expression array” or DTEA was developed to
analyze all 45 Vα and 46 Vβ TCR isotypes in a single reaction using the nCounter gene
multiplex array platform.(290) After 22 days of expansion on clone#1 aAPC,
ROR1RCD28 and ROR1RCD137 were assessed for TCR isotype expression by DTEA
(Figure 14). Frequencies of TCRα regions were not statistically different between the
two CARs (p = 0.25; Repeated measures Two-way ANOVA), no obvious trends were
observed, and comparisons for each TCRα (Student’s paired, two-tailed t-test) resulted
in p values >0.05 for all alleles (Figure 14a). Similarly, TCRβ isotypes were not
significantly different between ROR1RCD28 and ROR1RCD137 when analyzed
together (p = 0.33) or as individual genes (Figure 14b). TCRα and TCRβ were both
polyclonal suggesting that skewing to a particular TCR isotype did not occur.
Additionally, DTEA measured TCRγ and TCRδ expression where all Vδ counts were
0.9% and 1.9% of the ROR1RCD28 and ROR1RCD137 total TCR frequencies,
respectively, and Vγ counts were 6.2% and 8.1% of the ROR1RCD28 and
ROR1RCD137 total TCR frequencies, respectively. These results showed that γδ T
cells were minor contributors to the total CAR+ T cell pools, which were mainly αβ T
cells as determined by DTEA. Thus, CAR endodomain signaling was not preferential to
a particular TCRαβ clonotype but rather generated polyclonal αβ T cells.
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Figure 14. TCRα and TCRβ Expression in ROR1RCD28 and ROR1RCD137 cells.
nCounter gene multiplex array was used to interrogate TCR isotype expression with
“direct TCR expression array” (DTEA) in CAR-modified T cells after expansion on
clone#1 aAPC. Cells were lysed at day 22 of co-culture period. (a) TCRα and (b)
TCRβ expression in ROR1RCD28 (filled bars) and ROR1RCD137 (open bars) T cells.
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II.C.7. IFNγ Production by CAR+ T cells in Response to ROR1
In order to assess whether CAR+ T cells were functional and specific for ROR1+ tumor
cells, IFNγ production was measured by flow cytometry after activation with leukemia
cells or TCR agonists. Brefeldin-A was co-cultured with T cells to inhibit IFNγ
secretion. Collectively, the data suggest that CAR+ T cells were specific and functional
in responding to ROR1+ tumors.

II.C.7.a. TCR Stimulus with Leukocyte Activation Cocktail
Phorbol myristate acetate (PMA) and Ionomycin were used as leukocyte activation
cocktail (LAC) to stimulate the T cells for evaluation of maximal TCR response. LAC
mimics TCR activation by activating protein kinase C (PKC) and increasing
intracellular Ca2+ levels and, therefore, is a measure of non-specific T cell
activation.(291, 292) ROR1RCD28 and ROR1RCD137 T cells were mock activated
(media only) as a negative control or activated with LAC for 6 hours. Significant
expression of IFNγ was measured in response to LAC as seen in example histograms
(Figure 15a) and average mean fluorescence intensities (MFI) of IFNγ staining (Figure
15b). There was a trend of higher production of IFNγ by ROR1RCD28 compared to
ROR1RCD137 that was not statistically different (p = 0.120). These results established
that IFNγ was produced when CAR+ T cells were activated through canonical TCR
signaling pathways and suggested that ROR1RCD28 had higher propensity to express
IFNγ relative to ROR1RCD137 cells.
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II.C.7.b. Specific IFNγ Production to ROR1+ Leukemia Cells
Both Kasumi2 and NALM6 are B-cell ALL cell lines that express CD19, but only
Kasumi2 expresses ROR1 (Figure 6a). Thus, they were used to assess responsiveness
of CAR+ T cells to human leukemia cells in 6 hours of co-culture. As expected,
ROR1RCD28 and ROR1RCD137 T cells produced IFNγ when co-cultured with
Kasumi2 cells but not with NALM6 (Figure 15c). Similarly to LAC activation,
ROR1RCD137 cells produced less IFNγ than ROR1RCD28 cells (Figure 15d) in
response to the ROR1+ cell line. Nonetheless, ROR1-specific CAR+ T cells responded
specifically to ROR1+ leukemia.

II.C.7.c. CAR+ T cells Produce IFNγ in Response to Primary ROR1+ Leukemia Cells
but not Healthy ROR1neg B cell LCL
It was important to ensure that ROR1-specific T cells would respond to primary ROR1+
leukemia samples and spare normal B cells. LCL cell lines are immortalized healthy B
cells, which served as negative controls in experiments where primary patient samples
were used as targets. No IFNγ was produced by CAR+ T cells when co-cultured for 6
hours with allogeneic LCL cell lines (Figure 15e). In contrast, significant (p = 0.004,
Student’s paired, 2-tailed t-test) IFNγ was produced by ROR1RCD28 and there was a
trend of increased IFNγ production by ROR1RCD137 with CLL but did not reach a
measure for statistical significance (Figure 15e and 15f). This was the same
observation seen in an independent study testing ROR1-specific T cells, albeit with
CARs derived from different mAbs specific for ROR1, where less cytokine production
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was seen with CARs signaling through CD137 relative to those signaling through
CD28.(199) Thus, ROR1-specific CAR+ T cells were functionally responsive to
primary ROR1+ leukemia and not to healthy B cells.
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Figure 15. IFNγ Production by ROR1-specific T cells in Response to ROR1+
Targets. Brefeldin-A (GolgiPlug) was added to T cells to block IFNγ secretion in order
to measure functional responses to agonistic stimulation. At day 29 of co-culture, CAR+
T cells were co-cultured for 6 hours at 37oC and cells were gated for CD3+Fc+ to assess
CAR responses to: (a)/(b) complete media (Mock) or PMA and Ionomycin (leukocyte
activation cocktail; LAC), (c)/(d) B-ALL cell lines NALM6 (ROR1neg) or Kasumi2
(ROR1+), or (e)/(f) healthy donor LCL cell line (ROR1neg) or CLL patient sample
(ROR1+). Mean fluorescence intensities (MFI) are displayed next to histograms in (a),
(c), and (e), which are representative of three CAR+ T cell donors. Mean ± SD (n = 3)
are displayed in (b), (d), and (f). Student’s paired, 1-tailed t-test for statistical analysis.
*p<0.05 and **p<0.01
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II.C.8. ROR1-specific Cytotoxicity by CAR+ T cells
Cytotoxicity was another important assessment of ROR1-specific CAR+ T cell function.
Four-hour chromium release assays (CRA) are the gold-standard technique for in vitro
killing assays. Thus, CRA was used to test specific lysis of ROR1+ control cells,
established tumor cell lines, and primary tumor cells. Significant lysis was only
observed against ROR1+ cells suggested that CAR+ T cells were specific in their lytic
abilities.

II.C.8.a. CAR+ T cells Lyse Leukemia but not Healthy B cells
The clinical trial based on these data will treat patients with B-cell CLL, so primary Bcell CLL samples were tested as targets by allogeneic ROR1-specific CAR+ T cells.
ROR1neg LCLs were used for negative controls for CLL samples (Figure 6a). As
expected, minimal lysis was observed by ROR1RCD28 and ROR1RCD137 against
LCL (Figure 16a). In contrast, both ROR1RCD28 and ROR1RCD137 killed patient
CLL cells in a dose-dependent manner (Figure 16b). More variability was observed in
ROR1RCD28 samples in their lysis of CLL compared to ROR1RCD137, which was
almost identical amongst donors. These data indicated specific lysis of ROR1+ leukemia
by CAR+ T cells while sparing normal B cells.
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Figure 16. Specific Cytolysis of Primary ROR1+ B-cell CLL by CAR+ T cells. (a)
Established ROR1neg B-cell LCL and (b) Primary patient ROR1+ CLL cells were tested
for cytolysis by ROR1-specific CAR+ T cells in standard 4-hour CRA. Specific lysis by
ROR1RCD28 (left) and ROR1RCD137 (right) at decreasing effector to target (E:T)
ratios. Each line and shape represents a different effector donor. Data are mean ± SD of
triplicate measurements in CRA.
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II.C.8.b. ROR1-restricted Killing of Tumor Cell Lines
A number of established tumor cell lines express ROR1 as an endogenous or introduced
protein (Figure 6), so they were used for killing assays in parallel to cell lines lacking
ROR1 expression. As expected, both ROR1RCD28 and ROR1RCD137 efficiently
lysed EL4-ROR1+ but showed minimal lysis of EL4-ROR1neg cells (Figure 17a).
Similar to EL4 data, ROR1+ B-ALL cell line Kasumi2 was lysed at significantly higher
levels (p < 0.0001) compared to ROR1neg B-ALL cell line NALM6 by ROR1RCD28
(Figure 17b left). The same was observed for ROR1RCD137 where Kasumi2 was
lysed at significantly higher levels (p < 0.0001) compared to NALM6 (Figure 17b
right). In contrast to ROR1-specific CAR+ T cells, donor-matched CD19+ specific
CAR+ T cells lysed all three cell lines, which were all CD19+ (data not shown), and
suggested that ROR1RCD28 and ROR1RCD137 were more discriminant in their killing
abilities. Furthermore, ROR1+ OvCa cell line EFO27 was lysed at significantly
(p<0.0001) higher levels than ROR1neg OvCa cell line A2780 by both ROR1RCD28
and ROR1RCD137 (Figure 17c). In summary, ROR1-specific CAR+ T cells
demonstrated effective and specific lysis of ROR1+ tumor cells in vitro.
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Figure 17. Specific Cytolysis of Established ROR1+ Tumor Cell Lines by CAR+ T
cells. Standard 4-hour CRA were used to assess specific lysis of (a) EL4-ROR1neg
(circles) or EL4-ROR1+ (squares) cells, (b) ROR1neg NALM6 (circles) or ROR1+
Kasumi2 (squares) cells, and (c) ROR1neg A2780 (circles) or ROR1+ EFO27 (squares)
cells by ROR1RCD28 (left) and ROR1RCD137 (right) at decreasing E:T ratios. Each
line and shape represents a different target where data are mean ± SD of three donors
with triplicate measurements in CRA.
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II.C.9. In Vivo Leukemia Clearance by ROR1-specific T cells
In order to test the anti-tumor activity of ROR1-specific CAR+ T cells in vivo, a mouse
model of MRD was implemented for leukemia and ROR1-specific CAR+ T cells were
tested as treatment arms. Kasumi2 cells were sensitive to ROR1-specific T cells lysis,
so they were genetically modified to express mKate red fluorescence protein to sort
transduced cells (Figure 18a) and Firefly Luciferase (ffLuc; bioluminescence reporter)
for non-invasive bioluminescence imaging (BLI) of tumor burden in vivo (Figure 18b).
NOD.scid.γc-/- (NSG) mice were used because they lack functional adaptive immune
systems and can, therefore, accept human tumor xenografts well. Mice engrafted with
Kasumi2-ffLuc-mKate had consistent log10-fold increases in bioluminescence flux from
their tumors and succumbed to disease after 27 (average) days after engraftment
(Figure 18c circles and 18d top panel). ROR1RCD28 was able to diminish tumor
burden significantly (p = 0.0004) above untreated mice as measured by tumor BLI flux
(Figure 18c squares and 18d middle panel) and was able to increase survival
significantly (p = 0.002) to an average of 30 days post-engraftment. Furthermore,
ROR1RCD137 eliminated tumor burden significantly above both untreated mice (p =
0.0001) and ROR1RCD28-treated mice (p = 0.002) as measured by tumor BLI flux
(Figure 18c triangles and 18d bottom panels), and was able to increase survival
significantly longer compared to both untreated mice (p < 0.001) and ROR1RCD28treated mice (p = 0.03) to 34 days (average) post-engraftment and up to 11 days relative
to the first mouse that died in the untreated group and the last mouse that died in the
ROR1RCD137 group. ROR1RCD137 cells had consistently lower frequencies of CAR+
T cells (94%, 62%, and 46% at doses 1, 2, and 3, respectively) prior to infusion relative
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to ROR1RCD28 cells, which expressed CAR at >90% for all three doses. The T cell
doses were given based as 107 total cells/mouse, so a greater anti-tumor effect was seen
with ROR1RCD137 with fewer total CAR+ T cells, which highlights their ability to
outperform ROR1RCD28 in tumor killing in vivo. In summary, ROR1-specific CAR+ T
cells can efficiently treat ROR1+ leukemia and, therefore, can now be moved into the
clinic for testing in patients with ROR1+ malignancies.
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Figure 18. In vivo Tumor Clearance by ROR1-specific CAR+ T cells. ROR1+ BALL cell line Kasumi2 was transduced with mKate-ffLuc lentiviral particles and cells
were sorted for uniform mKate expression by FACS. (a) mKate expression in parental
cell line (black histogram) or transduced cell line (red histogram). (b) In vitro luciferase
activity of parental Kasumi2 cell line (without ffLuc) and transduced Kasumi2-ffLucmKate cells. NSG mice were engrafted with 4x104 Kasumi2-ffLuc-mKate cells
intravenously (i.v.) and were treated with three doses of 107 T cells i.v. to assess the
ability of ROR1-specific T cells to manage MRD. High dose (60 kIU) IL2 was given
intraperitoneally (i.p.) the day of T cell dosing and the following day. (c) Non-invasive
bioluminescence imaging (BLI) flux kinetics during experiment where untreated mice
are in circles, ROR1RCD28-treated mice are in squares, and ROR1RCD137-treated
mice are in triangles. Two-way ANOVA was used for statistical analysis. **p<0.01 and
***p<0.001 (d) Representative BLI images at day +23 post-engraftment.
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II.D. Discussion
II.D.1. Importance of Developing ROR1-specific T cells for Leukemia Patients
This work aimed to develop pre-clinical data to support a “first-in-man” Phase I clinical
trial of ROR1-specific T cell treatments for ROR1+ malignancies. The major advantage
of this therapy over the current anti-CD19 cellular therapies is that normal B cells
would be spared when targeting ROR1 as CD19 is uniformly expressed on most B cells
and is required for B cell function.(56, 57) B cells are the primary arm of the humoral
response and are critical for the adaptive immune response in clearance of microbial
pathogens.(89) However, people can survive without B cells, albeit under threat of
novel pathogens, if they receive serum immunoglobulin replacement therapy.(63) Thus,
quality of life would be certainly improved if CAR+ T cell therapy patients had a normal
repertoire of healthy B cells as would be achieved by targeting ROR1 instead of CD19.

II.D.2. ROR1 as a Tumor Target and Safety Concerns in Immunotherapy
ROR1 was originally identified on the surface of CLL cells with absent expression on
normal tissues, including cells in the hematopoietic compartment.(66, 75) Subsequently,
ROR1 has been described on t(1;19) B-ALL and a number of solid tumors, e.g. breast,
ovarian, and pancreatic cancers.(13, 67, 79) Some expression of ROR1 mRNA species
was identified in normal lung, pancreas, and adipose tissue, by qPCR of healthy donor
tissue panels, and protein expression was later corroborated on the cell surface in
adipocytes and in the cytoplasm in pancreatic islet cells and alveolar macrophages by
immunohistochemical staining with the 2A2 ROR1-specific antibody.(77, 81) However,
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this antibody also displayed cytosolic staining of a number of tissues that do not express
ROR1 mRNA transcripts, e.g. adrenal glands, cardiac muscle, neurons, colon,
endometrium, hypophysis, larynx, liver, ovary, salivary, small intestine, skin, stomach,
and thymus, which means that (i) the mRNA expression data is inaccurate or (ii) the
2A2 antibody is not completely specific for ROR1. Testing of the R12 goat antibody
specific for ROR1 binding to normal tissues has not yet been reported.(293) In contrast
to the 2A2 data, RNAseq analysis did not corroborate ROR1 mRNA presence in normal
healthy tissues (Kipps TJ, UCSD, unpublished observations). Moreover, the 4A5
ROR1-specific mAb from which the CAR was developed in this study did not detect
ROR1 in healthy tissues by both Western blot and immunohistochemistry.(67, 75) The
only reported staining of ROR1 with the 4A5 mAb outside of malignancies was
described on hematogones, which are B-cell precursors, and loss of hematogones would
impact B cell differentiation but not the mature B cell pool.(66) There is always the risk
of potential “on-target/off-target” toxicity of proper antigen recognition by CAR+ T
cells on undesired tissues expressing low levels of antigen, but we are confident that our
approach is safe because (i) 4A5 did not stain normal tissue and the CAR was derived
from this Ab, (ii) homing to pancreas and or adipose tissue is unlikely given the homing
repertoire expressed by CAR+ T cells which predicted for homing to lymphoid organs
(CCR7 and CD62L), and (iii) high tumor burden in many CLL patients will likely be
seen first and occupy the T cells from other organs. As a control for adverse events,
suicide genes, e.g. inducible Caspase9, can be co-expressed with CAR in order to
eliminate T cells in vivo with drugs specific for the suicide gene of choice.(294) In the
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end, these questions will only be answered once clinical trials test these hypotheses in
humans.

II.D.3. CD28 versus CD137 in CAR Design
A common debate in CAR immunotherapy at present is whether to use CD28
endodomain, as most investigators have done, or CD137 endodomain, both of which
have led to objective clinical responses.(4-7, 32) A direct comparison of CD28 versus
CD137 signaling in CD19-specific CARs developed at MDACC (and analogous to the
ROR1-specific CARs in design) resulted in almost indistinguishable characteristics in
vitro but CD137 was superior in vivo in leukemia clearance compared to CD28 (Singh
H, unpublished observations). In this study, the most notable differences between the
two ROR1-specific CARs were in (i) memory phenotype, (ii) in vitro IFNγ production,
and (iii) in vivo tumor clearance. In regards to surface phenotype, both ROR1RCD28
and ROR1RCD137 T cells were almost completely naïve (TN) and central memory T
cells (TCM) after ex vivo expansion, and there were more of both TN and TCM
populations in ROR1RCD137 cells (Figure 13). Indeed, both of these populations have
been correlated to limited effector functions including reduced cytokine production and
cytolysis.(132, 135) It is consistent then that ROR1RCD137 cells produced less IFNγ
when challenged with ROR1+ targets (Figures 15), and fewer cytokine mRNA
transcripts were produced by ROR1RCD137 relative to ROR1RCD28 as evaluated by
nCounter LCA (data not shown). Indeed, the ability to produce cytokines was inversely
correlated with CD8+ T cell efficacy in other T cell immunotherapies.(295) Again,
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reduced cytokine production was also observed with ROR1-specific CARs signaling
through CD137 that were derived from the 2A2 mAb and its higher affinity counterpart
R12 mAb.(199) Similar killing was detected by both CAR populations against ROR1+
targets, with a minor exception of primary cell lines where ROR1RCD28 was highly
variable in cytolysis between donors and exceeded ROR1RCD137 in killing for 2 out of
3 donors (Figure 16b). In contrast to the in vitro results, ROR1RCD137 was
significantly (p = 0.0001) better at eliminating ROR1+ leukemia compared to
ROR1RCD28, which was significantly better (p < 0.0001) than no treatment (Figure
18). Furthermore, these results were achieved with fewer total CAR+ T cells infused
into each mouse, because the same total number was injected but CAR percentage was
lower in ROR1RCD137 relative to ROR1RCD28. Possible explanations of the
differences are (i) higher frequencies of TN and TCM memory cells that are correlated
with highest CAR+ T cell responses relative to other classification,(131) (ii) lower
expression of inhibitory molecules like CTLA4 (Figure 13), (iii) production of other
inflammatory molecules other than IFNγ such as IL17, and/or (iv) longer persistence in
the mice which has been correlated to memory formation and increased anti-tumor
activity.(6, 189, 215, 237) The NSG mice used for in vivo studies lack human
homeostatic cytokines, e.g. IL7 and IL15, that can improve persistence in patients
treated with ROR1-specific T cells and therefore increase the potential of the anti-tumor
effects observed in the mouse studies. A side-by-side comparison of the two CARs in
clinical trials will be the ultimate test of which CAR is better for cancer treatment.
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II.D.4. Immediate Plans for ROR1-specific T cells in Leukemia Treatment
A Phase I clinical trial has been approved by the NIH RAC and is in process for MD
Anderson IRB approval. The trial design is to co-infuse ROR1RCD28 and
ROR1RCD137 cells in a competitive repopulation experiment to maximize potential
therapeutic efficacy and determine which CAR will persist longer in the patients. PCR
will be used as a highly-sensitive means to detect persistence of one population over
another based on unique oligonucleotides present in the two CAR transposons (SIM for
CD28 and FRA for CD137). As this will be the first time ROR1-specific T cells are
infused into humans, it is the primary endpoint to determine toxicity and maximum
tolerated doses. There is strong evidence that this will work as means to eliminate
leukemia while maintaining normal B cells, and will be the first time that ROR1 has
been a target of immunotherapy for cancer treatment.
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CHAPTER III
Bi-specific T cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell
Receptors and Introduced CD19-specific Chimeric Antigen Receptor

III.A. Hypothesis and Rationale
The hypothesis of this chapter is that enforced CAR expression on γδ T cells will
stimulate them independent of their TCRγδ, thus leading to expansion of γδ T cells with
polyclonal TCRγδ repertoire, and would amplify the anti-tumor effects from TCRγδ
towards TAA+ malignancies through the CAR. The rationale for this specific aim is that
(i) γδ T cells have inherent anti-tumor immunity through a number of combinations of
TCRγ and TCRδ pairings, (ii) the use of γδ T cells in the clinic is currently restricted to
Vγ9Vδ2 even though other γδ T cell lineages have anti-tumor reactivity, (iii) CARs
stimulate T cells independent of their TCR, (iv) electroporation of SB transposons
containing the CAR can be achieved in quiescent PBMC with a polyclonal repertoire of
γδ T cells, and (v) CD19-specific CAR transposon plasmids and CD19+ aAPC are
currently in clinical trials at MD Anderson and these reagents can be used to quickly
translate findings from this chapter into clinical trials. Therefore, using a polyclonal set
of γδ T cells for CAR-based immunotherapy would allow for targeting the tumor
through both CAR and multiple TCRγδ pairings to maximize anti-tumor immunity
through bi-specific T cells.
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III.B. Introduction
“Chimeric antigen receptors (CARs) re-direct T-cell specificity to tumorassociated

antigens

(TAAs),

such

as

CD19, independent

of

major

histocompatibility complex (MHC).(57, 186, 189, 272, 296) This genetic
modification of T cells has clinical applications as adoptive transfer of CAR+ T
cells with specificity for CD19 can lead to anti-tumor responses in patients with
refractory B-cell malignancies.(6, 7, 32, 56) Current trials administer CAR+ T
cells co-expressing αβ T-cell receptor (TCRαβ) derived from a population that
represents 95% of the peripheral T-cell pool. However, the remaining 1-5% of
circulating T cells expressing TCRγδ (γδ T cells) have clinical appeal based on
their endogenous cytotoxicity towards tumor cells as well as their ability to
present TAA and elicit an anti-tumor response.(177, 297, 298) This population
of T cells directly recognizes TAA, e.g., heat shock proteins, MHC class I chainrelated gene A/B (MICA/B), F1-ATPase, and intermediates in cholesterol
metabolism (phosphoantigens), in humans.(299) Therefore, broad recognition of
tumor cells and anti-tumor activity is achieved by these T cells expressing a
diverse TCRγδ repertoire (combination of Vδ1, Vδ2, or Vδ3 with one of
fourteen Vγ chains).(300)
More specifically, T cells expressing Vδ1 and Vδ2 have been associated
with anti-tumor immunity, but current adoptive immunotherapy approaches are
limited to the Vδ2 sub-population due to limited expansion methods of Vδ1 to
clinically-sufficient numbers of cells for human applications. For the most part,
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γδ T cells have been numerically expanded in vivo and ex vivo using Zoledronic
acid (Zol),(301) an aminobisphosphonate that results in selective proliferation of
T cells expressing Vγ9Vδ2 TCR.(175, 177, 297) This treatment modality has
resulted in objective clinical responses against both solid and hematologic
tumors, but has not been curative as a monotherapy. Vδ1 γδ T cells have not yet
been infused, but their presence has correlated with complete responses
observed in patients with B-cell acute lymphoblastic leukemia (B-ALL) after
undergoing

αβ

T

cell-depleted

allogeneic

hematopoietic

stem-cell

transplantation (HSCT).(302-305) As both of these sub-populations of γδ T cells
are associated with anti-tumor activity, but have not been combined for cell
therapy, we sought a clinically-appealing approach to propagate T cells that
maintain a polyclonal TCRγδ repertoire.
Recognizing that a CD19-specific CAR can sustain the proliferation of
αβ T cells on artificial antigen presenting cells (aAPC) independent of
TCRαβ usage,(280) we hypothesized that CAR+ γδ T cells would expand on
aAPC independent of TCRγδ. Our approach was further stimulated by the
observation that K562, the cell line from which the aAPC are derived, are a
natural target for γδ T cells.(303) We report that CAR+ γδ T cells can be
propagated to clinically-relevant numbers on designer aAPC while maintaining
a polyclonal population of TCRγδ as assessed by our "direct TCR expression
assay" (DTEA), a novel digital multiplexed gene expression analysis that we
adapted to interrogate all TCRγδ isotypes.(290) These CAR+ γδ T cells
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displayed enhanced killing of CD19+ tumor cell lines in vitro compared to
polyclonal γδ T cells not expressing CAR. Leukemia xenografts in
immunocompromised mice were significantly reduced when treated with CAR+
γδ T cells compared to control mice. This study highlights the ability of aAPC to
numerically expand bi-specific T cells that exhibit introduced specificity for
CD19 and retain endogenous polyclonal TCRγδ repertoire.

III.C. Results
III.C.1. CAR+ γδ T cells Numerically Expand on aAPC
To date, it has been problematic to synchronously manipulate and expand
multiple γδ T-cell subpopulations for application in humans. Viral-mediated
gene transfer typically requires cell division to achieve stable gene transfer and
CARs have been introduced into transduced T cells expressing just Vδ2 TCR
following the use of aminobisphosphonates to drive proliferation.(306) In
contrast, non-viral gene transfer with Sleeping Beauty (SB) transposition can be
achieved in quiescent peripheral blood mononuclear cells (PBMC) with the full
complement of peripheral γδ T cells initially present. Thus, stable expression of
CAR can be achieved without prior T-cell propagation, enabling us to
investigate if a population of T cells expressing polyclonal TCRγδ chains could
then be numerically expanded in a CAR-dependent manner on designer artificial
antigen presenting cells (aAPC). PBMC were electroporated (Day 0) with SB
transposon/transposase system to enforce expression of a second generation
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CD19-specific CAR (CD19RCD28)(57) that signals through chimeric CD28 and
CD3ζ. Electroporated cells were sorted using paramagnetic beads to separate the
4.0% ± 1.5% (mean ± standard deviation (SD); n = 4) CAR+ γδ T cells from the
majority of CAR+ αβ T cells. The CAR+ γδ T cells were selectively propagated
by the recursive additions of γ-irradiated K562-derived aAPC (clone #4,
genetically modified to co-express CD19, CD64, CD86, CD137L, and
membrane bound IL15)(57) with soluble IL2 and IL21. IL21 is included in the
manufacture of our CAR+ αβ T cells so it was used to propagate CAR+ γδ T
cells.(57) Prior experiments predicted that IL2 and IL15 enhance the
proliferative potential of γδ T cells, and synergy between IL2 and IL21 has led
to improved anti-tumor activity compared with γδ T cells grown with either IL2
or IL21 alone.(174, 178, 307-309) Sham electroporations were undertaken to
provide staining control T cells that were propagated by cross-linking CD3
using aAPC loaded with OKT3 to numerically expand CARneg αβ T cells.(310)
As expected, CAR was expressed on the day following electroporation (Day 1)
in most of the T cells, including γδ T cells, which comprised up to 10% of the
mononuclear cells (Figure 19a, left). After 36 days of co-culture on aAPC, the
majority of cells co-expressed CD3 and TCRγδ with 30.7% ± 23.3% (n = 4)
CAR expression (Figure 19a, right). The absolute CAR proportions at Day 36
varied in frequency depending on the donor, but increased compared to the
initial populations of CAR+ γδ T cells at Day 1 (Figure 19b). As we have
demonstrated, our aAPC co-culture system enforces CAR expression in αβ T
cells (>90% CAR+ T cells by 28 days of co-culture),(57) but the apparent lack of
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the same degree of selective pressure when combined with γδ T cells was
attributed to an inherent ability of CARneg γδ T cells to sustain proliferation on
aAPC derived from K562. Continuous proliferation of both CARneg and CAR+
γδ T cells was observed over the tissue culture period. Even so, we could
generate up to 1.5x109 ± 1.2x109 (n = 3) CAR+ γδ T cells from the 2.8x105 ±
1.5x105 (n = 3) CAR+ γδ T cells at the start of the culture (Figure 19c). Most of
the propagated cells co-expressed CD3 and TCRγδ, but did not express TCRαβ
(Figure 19d). These data demonstrate that aAPC could be used to sustain
proliferation of CAR+ T cells co-expressing TCRγδ.
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Figure 19. CAR+ γδ T cells Propagate on Designer aAPC. (a) Transient (Day
1) and stable (Day 36) expression of CAR in T cells (top) and γδ T cells
(bottom) in mock electroporated (“no DNA”) or CD19-specific CAR
electroporated cells (CD19RCD28). (b) Percentage of CAR+ γδ T cells in the
culture as transient (Day 1) and stable (Day 36) expression where each shape
represents an individual donor. (c) Rate of expansion of total γδ T cells
(triangles), CARneg γδ T cells (squares), and CAR+ γδ T cells (circles) over
tissue culture period following paramagnetic bead sorting (open arrow) and
recursive stimulation (closed arrows) with aAPC and exogenous IL2 and IL21
administration. (d) Percentage-positive cells and mean fluorescence intensity of
CD3, CAR, TCRαβ, and TCRγδ at day 36. Data are mean ± SD (n = 4) and
quadrant percentages of flow plots are in upper right corner. This work was
originally published in Molecular Therapy. Deniger, D. C., K. Switzer, T. Mi,
S. Maiti, L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin,
and L. J. Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire of
Endogenous gammadelta T-cell Receptors and Introduced CD19-specific
Chimeric Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature
Publishing Group
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III.C.2. Immunophenotype of Numerically Expanded CAR+ γδ T cells
Multi-parameter flow cytometry was used to gate on CAR+ T cells and analyze
their expression of cell surface markers (Figure 20). TCRγδ was expressed at
high and low densities (Figure 20a, top). CD56, a marker of MHC-unrestricted
lytic ability,(287) was also expressed on T cells, but the culture contained <1%
CD3negCD56+ NK cells and <1% CD3+Vα25TCR+ NKT cells (data not shown).
In contrast to αβ T cells, no CAR+ γδ T cells expressed CD4, some were CD8+,
but most were CD4negCD8neg, which is consistent with what is known for γδ T
cells.(286) The relative frequencies for each donor are shown in Figure 20b.
Markers associated with memory, e.g., CD27, CD28, CD62L, and CCR7, were
expressed by CAR+ γδ T cells (Figure 20a, bottom). Both naïve (CD45RA) and
antigen-experienced (CD45RO) cells were present after propagation on aAPC,
and the T cells were not exhausted as measured by low expression of CD57
(Figure 20b). In aggregate, cultures contained a heterogonous mixture of naïve
(CD45RA+CD27+CD28+CCR7+;

26.5%

±

6.2%),

central

memory

(CD45RAnegCD27+CD28+CCR7+;

7.8%

±

3.6%),

effector

memory

(CD45RAnegCD27+CD28negCCR7neg;

10.1%

±

5.4%),

and

EMRA

(CD45RA+CD27negCD28negCCR7neg; 7.6% ± 3.4%) T-cell phenotypes.(131,
289) Co-stimulation by enforced expression of CD86 and CD137L (4-1BBL) on
aAPC may be important for CAR+ γδ T-cell numeric expansion due to
expression of their receptors CD28 and CD137 (4-1BB), respectively.
Molecules associated with homing to bone marrow (cutaneous lymphocyte
antigen (CLA) and CXCR4) and lymph nodes (CD62L and CCR7) were present
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on CAR+ γδ T cells suggesting that they could migrate to sites known to harbor
leukemia. In sum, propagated CAR+ γδ T cells expressed T cell-associated
surface markers that indicate desired potential for memory and homing.
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Figure 20. Immunophenotype of Electroporated, Separated, and
Propagated CAR+ γδ T cells. (a) Expression by flow cytometry of cell-surface
markers associated with T cells and memory as gated on CD3+CAR+ cells. (b)
Percentages of CAR+ T cells expressing T-cell markers where each shape
represents a different donor. Data are mean ± SD (n = 4). Quadrant percentages
of flow plots are in upper right corner. This work was originally published in
Molecular Therapy. Deniger, D. C., K. Switzer, T. Mi, S. Maiti, L. Hurton, H.
Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin, and L. J. Cooper. 2013.
Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous gammadelta
T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor.
Mol Ther. 21(3): 638-647.(311) © Nature Publishing Group
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III.C.3. Direct TCR Expression Assay to Reveal γ and δ TCR Usage in CAR+
γδ T cells
We sought to determine that aAPC-propagated CAR+ T cells were indeed bispecific as defined by the presence of a polyclonal population of TCRγδ alleles.
Up to now, it has been difficult to determine the pattern of expression of the γ
and δ TCR chains. Therefore, we adapted our DTEA to assess the complete
TCRγδ transcriptome. This approach takes advantage of the nCounter assay
system to measure multiple bar-coded genes in a single reaction with high
sensitivity and linearity across a broad range of expression.(312) A multiplexed
CodeSet was designed with two sequence-specific probes for each allele to
evaluate TCRγδ isotypes. The DTEA was initially validated using Zol to
preferentially propagate Vγ9Vδ2 cells from PBMC and, as expected, the
resultant TCR usage was dominated by both Vδ2 and Vγ9 at protein (Figure
21a) and mRNA levels (Figure 21b and 21c). A second validation employed
antibodies directed against γδ T-cell subsets (Vδ1 and Vδ2; no commercially
available antibodies to Vδ3) to measure their mRNA expression. Vδ1negVδ2neg,
Vδ1+Vδ2neg, and Vδ1negVδ2+ cells were sorted from CARneg T cells (to
maximize the number of Vδ2 cells recovered by fluorescence-activated cell
sorting, FACS) and subjected to DTEA (Figure 22a). As expected, Vδ1+Vδ2neg,
Vδ1negVδ2+, and Vδ1negVδ2neg expressed Vδ1*01, Vδ2*02, and Vδ3*01 mRNA
species, respectively (Figure 22b). These two strategies supported the validity
of the DTEA panel enabling the identity of TCRγδ to be determined in CAR+ T
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cells. Therefore, we measured the mRNA levels for all three Vδ alleles as
present in electroporated, separated, and propagated CAR+ γδ T cells which
correlated with multi-parameter flow cytometry on gated CAR+ T cells to reveal
the frequencies of Vδ subsets based on protein expression. The three Vδ
populations were present in ascending frequency (Vδ1>Vδ3>>>Vδ2) in the
electroporated and propagated T cells (Figure 22c). CARneg γδ T cells displayed
similar frequencies of Vδ TCR usage as CAR+ γδ T cells. DTEA array also
assessed Vγ usage, which is of particular utility because only one antibody
against Vγ9 is commercially available, thus limiting the tools with which to
detect Vγ usage. Of note, Vγ2, Vγ7, Vγ8 (both alleles), Vγ9, and Vγ10 were
present in CAR+ T-cell cultures (Figure 22d). A lack of commercially-available
antibodies prevented assessment of pairing between individual Vδ and Vγ chains
on the T cells. The TCR usage described for γδ T cells was that which was
present at the time of functional assays. Our ability to digitally quantify the
presence of mRNA species enabled us to determine that the propagated CAR+ T
cells expressed a polyclonal population of TCRγδ chains.
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Figure 21. Distribution of Vδ and Vγ in γδ T cells Expanded on
Aminobisphosphonate. (a) Representative flow cytometry plot from T cells
following 36 days of numeric expansion with Zol. (b) Vδ and (c) Vγ allele
mRNA expression in Zol-expanded T cells. Data are mean ± SD (n = 3).
Quadrant frequencies of flow plot are displayed. This work was originally
published in Molecular Therapy. Deniger, D. C., K. Switzer, T. Mi, S. Maiti,
L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin, and L. J.
Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire of
Endogenous gammadelta T-cell Receptors and Introduced CD19-specific
Chimeric Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature
Publishing Group
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Figure 22. Distribution of Vδ and Vγ in CAR+ γδ T cells. (a) Representative
FACS of Vδ populations (top) into Vδ1negVδ2neg (left), Vδ1+Vδ2neg (middle),
and Vδ1negVδ2+ (right) populations and (b) Vδ allele mRNA expression in
sorted T cells. (c) Vδ1negVδ2neg, Vδ1+Vδ2neg, and Vδ1negVδ2+ frequencies in
gated CAR+ γδ T-cell populations from four donors. (d) Vγ allele mRNA
expression in CAR+ γδ T cells. Data are mean ± SD (n = 3). Quadrant
percentages of flow plots are in upper right corner. This work was originally
published in Molecular Therapy Deniger, D. C., K. Switzer, T. Mi, S. Maiti, L.
Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin, and L. J.
Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire of
Endogenous gammadelta T-cell Receptors and Introduced CD19-specific
Chimeric Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature
Publishing Group
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III.C.4. T cells Produced Pro-inflammatory Cytokines in Response to
Stimulation through Endogenous TCRγδ and Introduced CAR
The functional activity of the CAR+ T cells was assessed by activation with
leukocyte activation cocktail (LAC), which was comprised of PMA and
Ionomycin. LAC mimics activation through TCR by simulating protein kinase C
and increasing intracellular Ca2+ to activate phospholipase C (PLC).
Measurement of secreted and intracellular cytokines (in the presence of the
inhibitor GolgiPlug, which contains Brefeldin A) were performed on genetically
modified T cells with and without LAC (Figure 23a and 23b). A broad range of
cytokines were produced by γδ T cells, with the highest expression of IFNγ,
TNFα, and chemokines MIP-1α, MIP-1β, and RANTES (Figure 23b).
Interleukin-17 (IL17) has been shown to be important for anti-tumor efficacy of
γδ T cells and this cytokine was secreted by CAR+ γδ T cells. These results
suggest that TCRγδ can be activated to produce cytokines that could promote
inflammation within the tumor. Next, CAR-specific cytokine production was
assessed by activation using the murine T-cell lymphoma line EL4 and a
genetically modified derivative to enforce expression of human CD19. Both
TNFα and IFNγ were produced by CAR+ γδ T cells in response to CD19
(Figure 23c). A less diverse repertoire of cytokines was secreted following CAR
stimulation when compared with stimulation of TCRγδ, but IFNγ, TNFα, MIP1α, MIP-1β, and RANTES were all increased in response to activation through
CAR (Figure 23d). In aggregate, pro-inflammatory cytokines were upregulated
by bi-specific CAR+ γδ T cells through their TCR and CAR.
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Figure 23. Bi-specific γδ T cells Produce Pro-inflammatory Cytokines when
Endogenous TCR and Introduced CAR are Stimulated. (a) CAR+ γδ T cells
at Day 35 of co-culture on aAPC were stimulated for 4 hours with a mock
cocktail (media alone) or Leukocyte Activation Cocktail (LAC,
PMA/Ionomycin) to induce TCR stimulation and then analyzed by flow
cytometry. CAR+ T cells were gated and tumor necrosis factor-α (TNFα, top)
and interferon-γ (IFNγ, bottom) production is shown. (b) Luminex array (27Plex) of cytokines secreted by CAR+ γδ T cells in conditions described in (a).
(c) Similar to (a) except that EL4-CD19neg and EL4-CD19+ were used instead of
Mock/LAC. (d) Same as (b) but with EL4-CD19neg and EL4-CD19+ targets.
Student’s t-test for statistical analysis between (b) Mock and LAC and (d) EL4CD19neg and EL4-CD19+ where *p<0.05, **p<0.01, and ***p<0.001. Data are
representative of four donors for (a) and (c) and mean ± SD (n = 3) for (b) and
(d). This work was originally published in Molecular Therapy. Deniger, D.
C., K. Switzer, T. Mi, S. Maiti, L. Hurton, H. Singh, H. Huls, S. Olivares, D. A.
Lee, R. E. Champlin, and L. J. Cooper. 2013. Bispecific T-cells Expressing
Polyclonal Repertoire of Endogenous gammadelta T-cell Receptors and
Introduced CD19-specific Chimeric Antigen Receptor. Mol Ther. 21(3): 638647.(311) © Nature Publishing Group
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III.C.5. CAR+ γδ T cells Exhibit Enhanced Anti-tumor Effects against CD19+
Targets in vitro
It was anticipated that γδ T cells would display endogenous cytotoxicity to
leukemia cells. Therefore, γδ T cells without CAR were numerically expanded
on aAPC in order to test their anti-leukemia activity. Human CD19+ B-ALL cell
lines (REH, Kasumi2, and Daudi genetically modified to express β2M) were
lysed by CARneg γδ T cells while primary, healthy CD19+ B cells were not killed
by the same effectors (Figure 24a). However, not all B-ALL cell lines were
susceptible to efficient lysis by CARneg γδ T cells. In particular, EL4 and
NALM6 cells were largely resistant to cytolysis by γδ T cells. Thus, the ability
of the CD19-specific CAR to amplify the inherent anti-tumor activity of γδ T
cells was investigated. Enforced expression of CD19 on the surface of EL4 cells
improved targeting and killing of this cell line by CAR+ γδ T cells at
significantly higher (p = 0.0001) levels compared with the parental CD19neg EL4
cell line (Figure 24b). Similarly, CAR+ γδ T cells exhibited improved ability (p
= 0.001) to kill CD19+ NALM6 cells compared with CARneg γδ T cells (Figure
24c). In summary, the introduced CAR enhanced the specific killing capability
of genetically modified γδ T cells.
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Figure 24. Specific lysis of CD19+ Tumor Cell Lines by CAR+ γδ T cells. (a)
Standard 4-hour CRA of (a) CARneg γδ T cells against CD19+ B-ALL cell lines
(REH, Kasumi2, and Daudi-β2M) or primary CD19+ B cells from autologous
(Auto) or allogeneic (Allo) donors, (b) CAR+ γδ T cells against EL4-CD19neg
(open squares) and EL4-CD19+ (closed squares) tumor cells, and (c) CARneg γδ
T cells (open squares) and CAR+ γδ T cells (closed squares) against CD19+
NALM6 tumor cells. Data are mean ± SD from four healthy donors (average of
triplicate measurements for each donor) that were pooled from two independent
experiments. This work was originally published in Molecular Therapy.
Deniger, D. C., K. Switzer, T. Mi, S. Maiti, L. Hurton, H. Singh, H. Huls, S.
Olivares, D. A. Lee, R. E. Champlin, and L. J. Cooper. 2013. Bispecific T-cells
Expressing Polyclonal Repertoire of Endogenous gammadelta T-cell Receptors
and Introduced CD19-specific Chimeric Antigen Receptor. Mol Ther. 21(3):
638-647.(311) © Nature Publishing Group
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III.C.6. CAR+ γδ T cells can Target CD19+ Tumor in vivo
The ability of electroporated and propagated γδ T cells to target CD19+ tumor
was then investigated in vivo. NALM6 is an aggressive CD19+ B-cell leukemia
model and immunocompromised mice engrafted with 105 NALM6 are moribund
in 20 to 25 days when untreated. Control of disseminated NALM6 tumor in vivo
is dependent on the infused T cells homing to tumor and activating cytolytic
machinery in the tumor microenvironment. After adoptive immunotherapy, the
burden of tumor was significantly decreased in mice receiving CAR+ γδ T cells
(Donor#4 from Figure 22c) compared to untreated mice (Figure 25). Mice in
treatment group receiving CAR+ T cells displayed fewer characteristics of the
untreated and thus unwell mice, which included lethargy, ruffled coat,
temporary hind limb paralysis, and difficulty entering and exiting anesthesia at
late stages of the experiment. A uniform date for euthanasia was chosen to
measure the anti-tumor effect based on flow cytometry for NALM6 in lymphoid
tissue. There was significant anti-tumor activity by the CAR+ γδ T cell as
measured by bioluminescent imaging (BLI) of NALM6-eGFP-ffLuc (Figure
25b) as exemplified at 22 days after injection of tumor (Figure 25c). Noninvasive imaging was corroborated by analysis of presence of tumor cells at
necroscopy. Mice that received CAR+ γδ T cells exhibited significant reductions
in tumor burden (CD19+eGFP+) in the bone marrow, spleen, and peripheral
blood (Figure 25d and 25e). These data reveal that polyclonal CAR+ γδ T cells
exhibit therapeutic activity in vivo.
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Figure 25. In vivo Anti-tumor Activity of CAR+ γδ T cells. (a) Schematic of
experiment. (b) BLI derived from eGFP+ffLuc+CD19+ NALM-6 tumor and (c)
representative images of mice at day 22. (d) Post-mortem analysis of tissues and
blood where tumor cells (CD19+eGFP+) were detected by flow cytometry. (e)
Representative flow plots from (d). Data are mean ± SD (n = 3 to 5 mice per
group, representative of two independent experiments) and gating frequencies in
(e) are displayed. The percentage of tumor cells is derived from detecting
CD19+eGFP+ NALM-6 by flow cytometry from post-mortem samples. Statistics
performed with (b) two-way ANOVA with Bonferroni’s post-tests and (d)
Student’s t-test between treated and untreated mice. **p<0.01 and ***p<0.001
This work was originally published in Molecular Therapy. Deniger, D. C., K.
Switzer, T. Mi, S. Maiti, L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee,
R. E. Champlin, and L. J. Cooper. 2013. Bispecific T-cells Expressing
Polyclonal Repertoire of Endogenous gammadelta T-cell Receptors and
Introduced CD19-specific Chimeric Antigen Receptor. Mol Ther. 21(3): 638647.(311) © Nature Publishing Group
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III.D. Discussion
III.D.1. Polyclonal Bi-specific T cells for Immunotherapy
We established that introduction of a 2nd generation CAR could (i) drive the
numeric expansion of T cells independent of usage of TCRγδ chains and (ii)
augment the lytic potential of CD19+ tumors by γδ T cells. Propagating bispecific CAR+ T cells with a broad diversity of TCRγδ chains is desirable based
on their therapeutic potential. Indeed, γδ T cells other than those expressing
Vγ9Vδ2 have been generated from PBMC using TCRγδ-specific and CD3specific mAbs.(313-315) These prior approaches did not comprehensively
measure TCRγδ isotype expression nor did they yield Vδ1 and Vδ3 at
frequencies as high as seen in this study. The Vγ2 TCR chain was detected on
our T cells, which has been described to pair with Vδ2, and these T cells can
have antigen presentation capabilities.(166) Our CAR+ γδ T cells expressed
molecules consistent with antigen presentation, e.g., CD86, CD137L, and HLADR (data not shown), and Vγ9Vδ2 cells have served as aAPC for αβ T
cells.(298) Future experiments will investigate if our polyclonal CAR+ γδ T cells
also have an ability to serve as aAPC. Also present were T-cell sub-populations
expressing Vγ7, and Vγ8, and Vγ10, where the first two chains have been
associated with intestinal intraepithelial lymphocytes (iIEL)(316, 317) and the
latter chain’s functional significance is not yet apparent. In all, our approach is
the first to report expansion of CAR+ T cells that maintained a polyclonal
TCRγδ expression.
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III.D.2. Changes Observed in Vδ Populations Following Expansion on aAPC
The repertoire of TCRγδ chains employed by CAR+ T cells was similar to the
initial pool of γδ T cells in PBMC with two exceptions. We noted an increase in
Vδ3 usage, but this may be advantageous as it is associated with specificity for
viruses that could offer enhanced immune responses to viral infections in
immunocompromised patients receiving therapy.(165) A decrease in Vγ9Vδ2
usage was also observed compared to the starting frequency of this TCR in
PBMC, but this could potentially be increased by priming aAPC with Zol to
increase Vγ9Vδ2 ligand expression in the co-culture. Whether this loss of
Vγ9Vδ2 TCR expression was due to preferential activation induced cell death or
selective out-growth of T cells expressing Vδ1 and Vδ3 TCR is not known.
Nonetheless, Vγ9Vδ2 chains were still present in the final T-cell cultures
indicating that aminobisphosphonate therapy could drive expansion of this
subset of T cells after administration.

III.D.3. Improvements upon CAR Expression on γδ T cells
Recombinant retroviruses have been previously employed to achieve stable
expression

of

CARs

in

γδ

T

cells,

but

this

required

using

an

aminobisphosphonate to achieve numeric expansion of T cells before
transduction.(175, 318) We now demonstrate propagation of T cells after, rather
than before, gene transfer using SB-mediated transposition results in a
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polyclonal population of bi-specific γδ T cells capable of CAR-mediated (i)
production and secretion of pro-inflammatory cytokines in response to CD19,
(ii) enhanced lysis of CD19+ tumor targets, and (iii) in vivo anti-tumor activity
against a CD19+ tumor. The ability of these T cells to exhibit effector functions
was not correlated to a particular Vδ or Vγ usage as cells with different Vδ TCR
frequencies (Figure 22c) produced the same cytokines (Figure 23) and
displayed similar cytolysis of CD19+ targets (Figure 24b). We noted that
frequency of CAR expression was more variable on γδ T cells compared with
αβ T cells. This was likely due to an endogenous ability of K562 cells to sustain
proliferation of γδ T cells independent of CAR. Nevertheless, adoptive transfer
of γδ T cells of which 60% expressed CAR could still yield the same in vitro
lytic ability as 98% CAR+ γδ T cells (Figure 26). This indicated that (i) CAR+
γδ T cells are potent tumor killers and (ii) >90% CAR expression may not be a
critically limiting parameter for predicting therapeutic efficacy. Nonetheless, we
are undertaking improvements to increase the expression of CAR on propagated
γδ T cells. Furthermore, the chimeric signaling molecules in the CAR
endodomain could be specifically designed to enhance triggering of γδ T cells.
For example, γδ T cells can be activated through FcγRIIIA (CD16) in the TCR
complex,(319) which raises the possibility that signaling through chimeric FcRγ
(as compared with CD3ζ in our current design) in a CAR endodomain may
improve activation. However, CD16 was not detected on CAR+ γδ T cells in this
study (data not shown). Since clinical responses against CD19+ lymphocytic
leukemia have been achieved with T cells expressing a CAR that signaled
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through 4-1BB (CD137) endodomain,(7, 32) another option is to swap CD28 for
CD137 for activation of γδ T cells.
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Figure 26. Specific Lysis of CD19+ Tumor Cell Lines by CAR+, CAR++, and
CAR+++ γδ T cells. (a) Phenotype of T cells at day 19 of co-culture either
unsorted (left) or from CAR sorting at day 15 where CARneg and CAR+ fractions
are displayed in the middle and right, respectively. Four-hour CRA (Day 19 of
co-culture on aAPC) of γδ T cells genetically modified to enforce expression of
CD19-specific CAR with 6% (CAR+, circles), 60% (CAR++, triangles), and 98%
(CAR+++, squares) expression of CAR targeting (b) EL4-CD19neg, (c) EL4CD19+, and (d) CD19+ NALM-6 tumor cells. Data are mean ± SD (n = 3).
Quadrant frequencies of flow plots are displayed. This work was originally
published in Molecular Therapy. Deniger, D. C., K. Switzer, T. Mi, S. Maiti,
L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin, and L. J.
Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire of
Endogenous gammadelta T-cell Receptors and Introduced CD19-specific
Chimeric Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature
Publishing Group
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III.D.4. Improvements on Type of γδ T cell used for CAR Immunotherapy
In addition to improving CAR expression on γδ T cells, the type of γδ T cell
arising after electroporation with SB system and propagation on aAPC could be
manipulated to further improve anti-tumor activity. For instance, some γδ T cells
were observed to secrete IL17, a pro-inflammatory cytokine that has potent, yet
context-dependent, anti-tumor effects.(320-324) IL17 producing lineages of T
cells can be mutually exclusive from those that secrete IFNγ.(325) Inducible costimulator of T cells (ICOS) leads to IL17 polarization in CD4+ T cells and
CD28 co-stimulation overcame this effect to dictate that CD4+ T cells now
produce IFNγ.(326) CD86 is one of the co-stimulatory molecules on our aAPC
and the majority of CAR+ γδ T cells secrete IFNγ in response to CD19 with
diminished production of IL17. Furthermore, the CAR contains a chimeric
CD28 endodomain which may contribute to IFNγ polarization in genetically
modified T cells. Substitution of chimeric CD28 for ICOS in the CAR and
replacement of CD86 on the aAPC with ICOS-ligand (ICOSL) could potentially
reverse the polarization to IL17. Given that we can propagate CAR+ γδ T cells
on aAPC we are prepared to design aAPC to evaluate whether we can skew the
cytokine profile to reflect the propagation of desired T-cell subsets.

114

Drew C Deniger
III.D.5. Clinical Significance of Bi-specific T cells
The human application of CAR+ γδ T cells is appealing given their inherent
potential for anti-tumor effects and their apparent lack of alloreactivity.(304)
The CAR, SB system, and aAPC are all already in use in our clinical trials.
Therefore, we plan to modify our manufacturing scheme in compliance with
current good manufacturing practice to generate bi-specific CAR+ γδ T cells.
Our data provides a clinically-appealing approach to numerically expand and
manipulate CAR+ T cells with multiple Vγ and Vδ pairings enabling clinical
trials to evaluate their therapeutic potential.”

This work was adapted from published work in Molecular Therapy. Deniger, D. C.,
K. Switzer, T. Mi, S. Maiti, L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E.
Champlin, and L. J. Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire
of Endogenous gammadelta T-cell Receptors and Introduced CD19-specific Chimeric
Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature Publishing Group
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CHAPTER IV
Artificial Antigen Presenting Cells Propagate Polyclonal Gamma Delta T cells with
Broad Anti-tumor Activity

IV.A. Hypothesis and Rationale
The hypothesis of this chapter is that aAPC will expand polyclonal γδ T cells
that will have broad anti-tumor immunity. The rationale for this chapter is that (i)
CARneg polyclonal γδ T cells proliferated in parallel to CAR+ γδ T cells described in
Chapter III on aAPC, (ii) no current expansion protocols exist for polyclonal γδ T cells
for the clinic, (iii) aAPC are currently in clinical trials and are available as a master cell
bank in the manufacturing facility at MD Anderson, (iv) γδ T cells expressing Vδ1 are
correlated with long-term remissions in cancer therapy but have not been directly
infused as an adoptive immunotherapy, (v) γδ T cells expressing Vδ2 have shown antitumor effects as direct adoptive immunotherapies, (vi) γδ T cells expressing Vδ3 have
not been described to have direct anti-tumor immunity leaving a gap in the field of
knowledge, and (vii) a polyclonal approach to γδ T cell immunotherapy could target
multiple ligands on the tumor through a diverse repertoire of TCRγδ. Therefore,
development of an expansion protocol to generate clinically-relevant numbers of
polyclonal γδ T cells would have implications as both cancer immunotherapies and for
immunologists studying γδ T cells.
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IV.B. Introduction
Human γδ T cells exhibit inherent anti-tumor activity and hold promise for
immunotherapy of cancer. They are distinguished by the heterodimeric pairing of γ and
δ T-cell receptor (TCR) chains from the more prevalent αβ T cell lineage (~95% of
circulating T cells), which are defined by TCRα/TCRβ heterodimers.(327)
TCRαβ recognizes peptide complexed with MHC but TCRγδ ligands are recognized
independent of MHC restriction.(141, 146, 152) Many of these ligands are present on
cancer cells, thus raising the possibility that a culturing approach to propagating T cells
that maintains a polyclonal repertoire of γδ TCRs may have appeal for human
application.
γδ T cells represent 1% to 5% of the T-cell pool in peripheral blood, and many
standard T cell expansion protocols are not applicable to γδ T cells.(314, 328)
Proliferation of monoclonal γδ T cell populations (Vγ9Vδ2) can be sustained with
aminobisphosphonates, e.g. Zol, and clinical trials investigating their anti-tumor
efficacy have yielded objective responses treating both solid and hematological
cancers.(175, 179, 301) However, this subset of γδ T cells was not curative as a standalone therapy.(318) Novel polyclonal γδ T cell expansion protocols are needed to
improve upon these findings, but are lacking in clinically-relevant methods to expand
multiple γδ T cell subsets in one cellular therapy product.
Since many ligands that signal through γδ TCR are unknown, we hypothesized
that a tumor cell line may serve as a cellular substrate for activating these T cells and
sustaining their proliferation. aAPC are used to stimulate CAR+ T cell growth ex vivo
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and are derived from K562 cells, a natural cytolytic target of γδ T cells.(57, 280, 310,
329) As seen in Chapter III, CAR-modified γδ T cells expanded on aAPC while
expressing multiple TCRγδ alleles and displayed enhanced cytolysis to antigen-positive
tumors.(311) Moreover, γδ T cells not expressing CAR were present in CAR+ γδ T cell
cultures in high frequencies (Figure 19a, bottom right panels). Therefore, we
hypothesized that γδ T cells could expand on aAPC independent of CAR+ T cells and
that these γδ T cells would maintain a polyclonal TCRγδ repertoire. Given that the
aAPC are available as a master-cell bank, these data provide a translational pathway for
adapting γδ T cells for human application. Thus, this could be the first time that
polyclonal γδ T cells could be used for cancer immunotherapy.

IV.C. Results
IV.C.1. Propagation of γδ T cells on aAPC
As seen in Chapter III, aAPC clone#4 sustained the proliferation of γδ T cells in
cultures containing CD19-specific CAR+ γδ T cells.(311) To assess whether γδ T cells
could numerically expand on aAPC without expression of CAR, quiescent γδ T cells
were isolated from peripheral blood and stimulated by recursive additions of γirradiated aAPC clone#4 in presence of IL2 and IL21 (Figure 27a). It was observed
that γδ T cells represented a small fraction of PBMC (3.2% ± 1.2%; mean ± SD; n = 4),
but after 22 days of co-culture on aAPC the cultures contained a homogeneous
population of γδ T cells (97.9% ± 0.6%) as assessed by co-expression of CD3 and
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TCRγδ (Figure 27b). Cultures yielded >109 γδ T cells from <106 total cells in three
weeks of co-culture (Figure 27c), which represented a 4.9x103 ± 1.7x103 fold increase
over a 22-day culture period. Although γδ T cells were rare in peripheral blood, they
were readily sorted then expanded on aAPC to sufficient numbers for experiments and
potential clinical application.
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Figure 27. Sustained Proliferation of γδ T cells on aAPC and IL2/21. (a) Schematic
of experimental design where NK cells are in open shapes, αβ T cells are in light gray
shapes, and γδ T cells are in dark gray shapes. Columns represent paramagnetic
isolation. (b) Expression by flow cytometry of CD3 (y-axis) and TCRγδ (x-axis) in
PBMC prior to isolation of γδ T cells isolation (Day 0) and after 22 days of co-culture
on aAPC/IL2/IL21. One representative donor is shown and quadrant gate frequencies
are displayed in the upper right corners of flow plots. (c) Total inferred cell counts of
viable cells during co-culture period. Black lines are mean ± SD from 4 healthy donors,
gray lines are individual donors, and arrows represent addition of γ-irradiated aAPC.
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IV.C.2. Roles for Co-stimulation and Cytokine Support in γδ T cell Proliferation on
aAPC
The mechanism of γδ T cell proliferation on aAPC was unknown. Addition of cytokines
and co-stimulation by aAPC were likely candidates for supporting growth of on aAPC.
In order to assess which surface molecules on the clone#4 aAPC (membrane-bound
IL15 (mIL15), CD86, and CD137L) were important for γδ T cell expansion with IL2
and IL21, parental K562 cells were genetically modified to express (i) mIL15
(cloneA6), (ii) mIL15 and CD86 (clone A3), or (iii) mIL15 and CD137L (clone D4) and
were subcloned for uniform transgene expression (Figure 28a). Co-cultures with
exogenous IL2 and IL21 were initiated with γδ T cells and γ-irradiated (i) parental K562
cells, (ii) clone A6 aAPC, (iii) clone A3 aAPC, (iv) clone D4 aAPC (Figure 28b), or (v)
clone#4 aAPC (Figure 8 middle panels) in parallel with T cells receiving cytokines
only. IL2 and IL21 in combination sustained limited γδ T cell proliferation, which was
increased when K562 cells were added to co-cultures. Slightly less expansion was
observed when either mIL15 or mIL15 and CD86 were added to K562 cells. However,
significantly higher γδ T cell propagation was only observed with mIL15+CD137L+ and
mIL15+CD86+CD137L+ aAPC over IL2 and IL21 alone. After establishing that costimulation on aAPC was necessary for γδ T cell proliferation, IL2 and IL21 were added
separately or in combination to assess their contribution to growth on clone#4 aAPC.
No γδ T cell expansion was observed when both IL2 and IL21 were removed from cocultures, addition of IL2 alone resulted in more proliferation than IL21 alone, and
combination of both IL2 and IL21 displayed additive growth of γδ T cells (Figure 28c).
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This validated our approach to use both IL2 and IL21 for maximum γδ T cell yield
following co-culture on clone#4 aAPC and strongly suggested that both aAPC costimulation and cytokine support were critical for maximum γδ T cell proliferation ex
vivo.
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Figure 28. Co-stimulation and Cytokine Requirements for γδ T cell Expansion on
aAPC ex vivo. (a) Surface phenotype of aAPC expressing single co-stimulatory
molecules with membrane-bound IL15 (mIL15). (b) γδ T cell proliferation was
measured after 10 days of growth with IL2 and IL21 on (i) no aAPC, (ii) parental K562
cells, (iii) mIL15+ aAPC (clone A6), (iv) mIL15+CD86+ aAPC (clone A3), (v)
mIL15+CD137L+ aAPC (clone D4), or (vi) clone#4 aAPC. All aAPC were γ-irradiated
prior to co-culture. (c) Co-cultures were initiated with clone#4 aAPC and either (i) no
cytokines, (ii) 50 U/mL IL2, (iii) 30 ng/mL IL21, or (iv) 50 U/mL IL2 and 30 ng/mL
IL21. Fold changes were calculated relative to the input cell numbers. Two-way
ANOVA with Bonferroni’s post-tests was used for statistical analysis. *p<0.05 and
**p<0.01
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IV.C.3. UCB-derived γδ T cells Expansion on aAPC
Umbilical cord blood (UCB) is a source of γδ T cells with unique use for
immunotherapy because they have limited immunological education and thus potential
utility in allogeneic settings. Moreover, UCB-derived γδ T cells should have a younger
phenotype and could (theoretically) have a longer range of responsiveness before
anergizing or undergoing senescence. However, UCB has limited volumes and γδ T
cells are a small fraction of an already limited resource. Fluorescence activated cell
sorting (FACS) was used to isolate γδ T cells in order to maximize yields and purity of
this valuable resource. Indeed, clone#4 aAPC induced substantial proliferation of γδ T
cells derived from UCB (Figure 29a). After 35 days of co-culture on clone#4 with IL2
and IL21, there was a 10 million-fold increase in cell number as an average of 1011
UCB-derived γδ T cells (Range: 6x109 – 3x1011; n = 5) were propagated from just 104
γδ T cells at the start of the culture. Because few cells were isolated (104 per donor),
two more stimulations were performed for UCB compared to PBMC to highlight their
potential for proliferating to clinically relevant numbers. As expected, γδ T cell cultures
were pure as assessed by uniform expression of CD3 (Figure 29b) and TCRγδ (Figure
29c) without expression of TCRαβ (Figure 29d) or presence of CD3negCD56+ NK cells
(Figure 29b). Collectively, these data demonstrate that aAPC clone#4 when used with
IL2 and IL21 could sustain the proliferation of γδ T cells ex vivo from limited starting
populations.
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Figure 29. Expansion of UCB-derived γδ T cells on aAPC. γδ T cells were sorted by
FACS following staining with CD3 and TCRγδ and were stimulated weekly with
clone#4 aAPC, IL2, and IL21 (a) Total inferred cell numbers from co-cultures where
black line represents mean ± SD (n = 5) and gray lines are individual donors. Arrows
represent stimulations with aAPC. Expression of (b) CD3 (y-axis) and CD56 (x-axis),
(c) CD3 (y-axis) and TCRγδ (x-axis), and (d) TCRαβ (y-axis) and TCRγδ (x-axis) of
one representative donor by flow cytometry after 5 weeks of expansion on aAPC with
IL2 and IL21. Quadrant frequencies are displayed in upper right corners.
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IV.C.4. Frequency of γ and δ TCR Usage in aAPC-propagated γδ T cells
Previously, CAR+ γδ T cells expanded on clone#4 aAPC maintained polyclonal
repertoire of TCRγ and TCRδ chains, and γδ T cells proliferating in parallel to CAR+ γδ
T cells also maintained polyclonal TCRγδ distribution (Chapter III).(311) Whether the
aAPC-expanded γδ T cells would do the same was of great interest, because if so then
this would represent the first ever clinically-viable approach to expand multiple γδ T
cells subsets in one cellular product for cancer therapy.

IV.C.4.a. Vδ and Vγ mRNA Expression
Now that it is established that γδ T cells can expand on aAPC independently of CAR+ T
cells (Figures 27, 28, and 29), the TCR isotype variable (V) region repertoire was
evaluated at the mRNA level by DTEA. As anticipated, mRNA species for all three Vδ
alleles were identified (Figure 30a) and Vγ2, Vγ5, Vγ7, Vγ8 (two alleles), Vγ9, Vγ10,
and Vγ11 mRNA species were co-expressed in the aAPC-expanded γδ T cells from
PBMC (Figure 30b). Similar polyclonal TCR expression of Vδ (Figure 30c) and Vγ
(Figure 30d) was observed in γδ T cells expanded from UCB with fewer Vδ2 cells,
more Vγ2 and Vγ5 cells, and presence of Vγ3 cells not seen in PBMC. Thus, aAPC are
able to repeatedly expand γδ T cells with polyclonal TCR repertoire from both PBMC
and UCB.
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Figure 30. Pattern of Vδ and Vγ mRNA Usage on aAPC-expanded γδ T cells.
Quantification of mRNA species coding for (a) Vδ1*01, Vδ2*02, and Vδ3*01 alleles
from left to right, respectively, and (b) Vγ alleles in PBMC-derived γδ T cells by DTEA
at day 22 of co-culture on aAPC/IL2/IL21. Each circle represents an individual donor’s
γδ T cells and lines show mean (horizontal) ± SD (vertical). Quantification of mRNA
species coding for (c) Vδ and (d) Vγ alleles in UCB-derived γδ T cells by DTEA at day
34-35 of co-culture on aAPC/IL2/IL21 as described for PBMC. Numbers correlate with
identification of PBMC (1-4) and UCB (5-9) donors described further in Figure 31.
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IV.C.4.b. TCRγδ Surface Protein Expression
After establishing Vγ and Vδ mRNA expression from a number of different isotypes,
surface expression of TCRγ and TCRδ was investigated. However, there are only 3
commercially available antibodies specific for individual TCRγδ isotypes, which are
specific for TCRδ1, TCRδ2, and TCRγ9. As was seen in CAR+ γδ T cells, aAPCexpanded γδ T cells from PBMC stained for all three Vδ populations
(TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+, and TCRδ1negTCRδ2neg), corroborating DTEA
detection of Vδ1, Vδ2, and Vδ3 populations of γδ T cells, respectively (Figure 31a).
Moreover, TCRδ expression frequencies followed the trend of TCRδ1>TCRδ3>TCRδ2,
and most TCRδ2 chains paired with TCRγ9 (Figure 31b). Fewer TCRδ2 cells were
seen in UCB-derived γδ T cells (Figure 31c) compared to PBMC-derived γδ T cells
(Figure 31a), but UCB-derived γδ T cells followed the same TCRδ1>TCRδ3>TCRδ2,
trend and most Vδ2 paired with Vγ9 as expected (Figure 31d). Analysis of other Vγ
pairings with Vδ could not be performed because there are no other Vγ-specific
commercially antibodies available. Thus, aAPC-expanded γδ T cells were polyclonal at
both mRNA and protein levels, and this protocol therefore represents the first clinicallyrelevant expansion approach of polyclonal γδ T cells.
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Figure 31. TCRδ and TCRγ Isotype Surface Expression on aAPC-expanded γδ T
cells. Expression by flow cytometry of (a) TCRδ2 (y-axes) and TCRδ1 (x-axes) and (b)
TCRδ2 (y-axes) and TCRγ9 (x-axes) in PBMC-derived γδ T cells at day 22 of coculture on aAPC/IL2/IL21. Expression by flow cytometry of (c) TCRδ2 (y-axes) and
TCRδ1 (x-axes) and (d) TCRδ2 (y-axes) and TCRγ9 (x-axes) in UCB-derived γδ T
cells at day 35 of co-culture on aAPC/IL2/IL21. Numbers in lower right corners
correlate with identification of PBMC (1-4) and UCB (5-9) donors also shown in
Figure 30 and quadrant frequencies are displayed in upper right corners.
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IV.C.4.c. Validation of Vδ3 Subset and Vδ Lineage Propagation
Little is known about the Vδ3 lineage of γδ T cells and no reports have been made to
date about their role in anti-tumor immunity. Because this study has implications for
showing the first ever evidence that this subset can mediate anti-tumor effects, further
validation that the TCRδ1negTCRδ2neg cells were, in fact, Vδ3 cells was warranted.
Complicating this matter is the fact that no commercially available antibodies for
TCRδ3. However, an indirect means was successfully used by combining FACS and
DTEA. As there are only three Vδ populations in humans and there are antibodies to
two of the isoforms, a combination of DTEA and FACS was used to in two ways to
confirm the various populations. First, γδ T cells expanded in the presence of CAR+ T
cells (Chapter III) were sorted for TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+, and
TCRδ1negTCRδ2neg γδ T cells populations by FACS and they expressed only Vδ1*01,
Vδ2*02, and Vδ3*01 mRNA, respectively (Figure 22a and 22b).(311) The second
approach directly applied the same techniques to γδ T cells expanded on aAPC as
described in Chapter IV without CAR+ T cells. Again, TCRδ1+TCRδ2neg,
TCRδ1negTCRδ2+, and TCRδ1negTCRδ2neg populations isolated by FACS consisted
primarily of Vδ1*01, Vδ2*02, and Vδ3*01 mRNA, respectively, and were therefore
denoted Vδ1, Vδ2, and Vδ3, respectively (Figure 32a). It is important to note that
Vδ1*01 only resulted in ~150 mRNA counts whereas Vδ2*02 and Vδ3*01 ranged in
the ~1000-2000 mRNA count range (Figure 30), so the purity as measured by mRNA
counts appeared to have contaminating Vδ1 cells in Vδ2 and Vδ3 populations but these
populations were minor contributors in the Vδ1 population as measured by flow
130

Drew C Deniger
cytometry (Figures 32d and 32e). Furthermore, the FACS sorted Vδ1, Vδ2, and Vδ3
populations were expanded on clone#4 aAPC in the presence of exogenous IL2 and
IL21 as separate co-cultures populations and even after 15 days of isolated growth the
same Vδ mRNA signatures were observed suggesting the cells remained pure during
propagation (data not shown). As expected, all three Vδ populations proliferated well
on aAPC as separate populations (Figure 32b), where fold increase capability was
ranked as Vδ1>Vδ3=Vδ2 although there were no statistically different differences
(Figure 32c). Indeed, there are more Vδ1 cells in polyclonal populations (Figures 30
and 31), which may be due to a slight increase in their ability to proliferate on aAPC.
Importantly, populations expressed the appropriate TCR alleles on the γδ T cell surface
where Vδ1, Vδ2, and Vδ3 subsets were pure for TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+,
and TCRδ1negTCRδ2neg, respectively, after 15 days of isolated expansion on aAPC
(Figure 32d and 32e). All separated Vδ subsets co-expressed CD3 and TCRγδ
verifying that they were, in fact, γδ T cells (Figures 34a and 34b). Collectively, these
results showed that (i) TCRδ1negTCRδ2neg γδ T cells contained the Vδ3 lineage, (ii)
DTEA accurately measured Vδ mRNA, (iii) Vδ1, Vδ2, and Vδ3 lineages are stimulated
by aAPC leading to their proliferation, and (iv) aAPC-expanded γδ T cells are truly
polyclonal.
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Figure 32. Vδ Subset Separation, Propagation, and Resultant TCR Expression on
Sorted T cells. PBMC were sorted for γδ T cells with paramagnetic beads and were
expanded for 2 weeks on aAPC/IL2/IL21. They were then sorted into three populations
(Vδ1, Vδ2, and Vδ3) by FACS. Separated populations were stimulated for 2 weeks on
aAPC/IL2/IL21. (a) DTEA detection of Vδ1*01, Vδ2*02, and Vδ3*01 mRNA species
in Vδ1, Vδ2, and Vδ3 subsets following FACS purification. (b) Proliferation of Vδ
lineages on aAPC as separated populations. (c) Fold increases of each Vδ population
where each shape represents a different donor. (d) Representative flow cytometry plots
of TCRδ1 (x-axes) and TCRδ2 (y-axes) expression in Vδ1, Vδ2, and Vδ3 subsets (from
left to right). Quadrant frequencies are displayed in upper right corner. (e) Frequencies
of TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+, and TCRδ1negTCRδ2neg cells in Vδ1, Vδ2, and
Vδ3 subsets. Data are mean ± SD (n = 3-4).
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IV.C.5. Immunophenotype of γδ T cells Expanded on aAPC
Functional outcomes, e.g. memory formation, homing to tissues, and effector
mechanism, can be predicted by the expression of lymphocyte-specific proteins on the
T cell surface. Thus, a panel of markers was used to identify the immunophenotype of
γδ T cells cultures first as a polyclonal population to be used as therapy and then as
sorted Vδ populations to gain insight into lineage differences.

IV.C.5.a. Immunophenotype of Polyclonal γδ T cell Population
The ultimate goal for the clinic is to use a polyclonal population of T cells for
immunotherapy in order to have a multivariate approach to cancer immunotherapy, so
extensive phenotyping of the γδ T cell surfaces was performed as a mixed Vδ
population. After 22 days of co-culture on aAPC, few αβ T cells (TCRαβ) and NK cells
(CD3negCD56+) were detected in the cultures where strong staining for γδ T cells
(TCRγδ) was observed (Figure 33a). Most γδ T cells were CD4negCD8neg, as
expected,(286) but some CD8 and CD4 expression was observed (Figure 33b). These T
cells were highly activated as measured by expression of CD38 and CD95. IL2
receptors (CD25; IL2Rα and CD122; IL2Rβ) were detected, but limited surface
expression of IL7Rα (CD127) was identified. γδ T cells were not exhausted as
evidenced by the absence of CD57 and PD1. Most cells expressed CD27 and CD28 costimulatory ligands and had a preference towards antigen-experienced (CD45RO) over
naïve (CD45RA) characteristics. Homing to the skin, lymph nodes, and bone marrow
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has potential as evidenced by CCR4, CXCR4/CLA, and CCR7/CD62L expression,
respectively. In aggregate, the surface phenotypes of γδ T cells indicated that they were
highly activated and antigen experienced with potential for memory formation and
homing to tissues.
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Figure 33. Immunophenotype of Polyclonal γδ T cells Propagated on aAPC, IL2,
and IL21. (a) Gating (one representative of four donors is shown) and (b) frequency of
T cell surface makers by flow cytometry of T cells at Day 22 of culture. Lines show
mean (horizontal) ± SD (vertical) and symbols represent individual donors.
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IV.C.5.b. Immunophenotype of Vδ1, Vδ2, and Vδ3 Subsets
It is of interest to identify differences amongst Vδ1, Vδ2, and Vδ3 lineages that could
enable us to predict functional responses and therapeutic efficacy. In particular, distinct
differences were observed in TCRγδ cell surface density and memory-associated
markers. TCRγδ often stained as a two populations with distinct MFI when co-stained
with CD3 (Figure 27b). Separation of Vδ1, Vδ2, and Vδ3 subsets clearly identified
Vδ2 as the low (43 ± 9; mean ± SD; n = 4), Vδ3 as the medium (168 ± 40), and Vδ1 as
the high (236 ± 56) MFI populations in TCRγδ staining (Figure 34a). CD4 and CD8 are
not commonly expressed on γδ T cells, but there were differences detected in limited
surface expression of both CD4 and CD8 between the separated subsets (Figure 34b).
Vδ1 and Vδ3 cells consistently expressed more CD4 and CD8 than did Vδ2 cells (p =
0.001; Two-way ANOVA), and there were significantly more CD4+ Vδ1 and CD8+ Vδ3
cells than CD4+ Vδ2 and CD8+ Vδ2 cells, respectively (Figure 34c and 34d). CCR7
and CD62L mediate homing to the lymph nodes and other secondary lymphoid organs.
CD8+ T cells expressing CCR7 and/or CD62L were described as TCM cells but
CCR7negCD62Lneg were defined as TEM cells.(330, 331) Almost all Vδ1 and Vδ3 cells
were CCR7+CD62Lneg, but larger proportions of Vδ2 cells were CCR7negCD62Lneg with
roughly equal remaining proportions staining as single or double positive for CCR7 and
CD62L, suggesting Vδ1 and Vδ3 were TCM and Vδ2 cells were mostly TEM (Figure
34e). CD27 and CD28 are both memory markers for CD8+ T cells, especially in the
absence of CD45RA, and have important roles as co-stimulatory molecules for T cell
activation.(332) CD27 expression followed the order of Vδ1>Vδ3>Vδ2 but all were
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>80% CD27+ (Figure 34f y-axes). In contrast, there was almost no difference between
the three Vδ populations in CD28 expression (Figure 34f x-axes). Human γδ T cell
memory has been most extensively reported as combinations of CD27 and CD45RA
expression where CD27+CD45RA+, CD27+CD45RAneg, CD27negCD45RAneg, and
CD27negCD45RA+ correspond to TN, TCM, TEM, and TEMRA, respectively (Figure
34g).(151, 333) Indeed, these were the markers that showed the most convincing
differences between the Vδ populations although all subsets contained at least some of
each population. More specifically, the most TN cells were Vδ1, the most TCM were
Vδ3, the most TEM cells were Vδ2, and virtually no TEMRA were detected (Figure 34h).
Given these differences in surface memory phenotype, different functional abilities
were expected from the γδ T cell subsets and a polyclonal approach to adoptive T cell
therapy could utilize these different attributes as needed.
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Figure 34. Immunophenotype of Vδ Lineages Propagated on aAPC, IL2, and IL21.
After 15 days of proliferation as separated populations, Vδ1, Vδ2, and Vδ3 subsets
were stained for lymphocyte markers. (a) Representative flow cytometry plots of CD3
(x-axes) and TCRγδ (y-axes) expression in Vδ1, Vδ2, and Vδ3 subsets (from left to
right). (b) Mean fluorescence intensities (MFI) of TCRγδ staining in Vδ1 (red), Vδ2
(black), and Vδ3 (blue) subsets where each shape represents a different donor and data
are mean ± SD (n = 4). (c) Representative flow cytometry plots of CD4 (x-axes) and
CD8 (y-axes) expression in Vδ1, Vδ2, and Vδ3 subsets (from left to right) and (d)
summary of frequencies in Vδ1 (red), Vδ2 (black), and Vδ3 (blue) cells where data are
mean ± SD (n = 3) and each shape represents a different donor. Representative flow
cytometry plots of (e) CCR7 (x-axes) and CD62L (y-axes), (f) CD28 (x-axes) and
CD27 (y-axes), and (g) CD45RA (x-axes) and CD27 (y-axes) expression in Vδ1, Vδ2,
and Vδ3 subsets (from left to right). Plots are representative of three normal donors. (h)
Memory phenotypes based on CD27 and CD45RA displayed in lower right corner of
Vδ3 in (g) where each shape represents a different donor and data are mean ± SD (n =
3).
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IV.C.6. Polyclonal γδ T cells Secrete Pro-inflammatory Cytokines and Chemokines
To determine whether γδ T cells would foster an inflammatory environment during
therapy, a multiplex analysis (27-Plex Luminex) of cytokines and chemokines was
performed on polyclonal γδ T cells following culture on aAPC. LAC and mock
activation was used as described in Chapters II and III. There was no significant
production of anti-inflammatory TH2 cytokines IL4, IL5, and IL13, and there was a
small increase in IL10 production from baseline (Figure 35a). In contrast, IL1Ra, IL6,
and IL17 were significantly secreted by γδ T cells and have roles together for TH17
inflammatory responses (Figure 35b). Moreover, pro-inflammatory TH1 cytokines IL2,
IL12 (p70), IFNγ, and TNFα were all significantly produced by γδ T cells when TCR
was stimulated compared to mock stimulated controls (Figure 35c). High expression of
chemokines CCL3 (macrophage inflammatory protein-1α; MIP1α), CCL4 (MIP1β),
and CCL5 (regulated and normal T cell expressed and secreted; RANTES) were also
detected (Figure 35d). CCR5 binds to all three of these chemokines,(334) but only 6%
± 2% (mean ± SD; n = 4) of γδ T cells expressed this receptor. Nonetheless, recruitment
of other immune cells expressing CCR5 is possible based on γδ T cell’s production of
CCL3, CCL4, and CCL5. In aggregate, TCR stimulation in γδ T cells led to a largely
pro-inflammatory response desired for cell-based cancer therapies.
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Figure 35. Cytokines and Chemokines Secreted by Polyclonal γδ T cells. At Day 22
of culture on aAPC/IL2/21, T cells were incubated with complete media (mock) or
leukocyte activation cocktail (LAC; PMA/Ionomycin) for 6 hours at 37oC. Conditioned
media was interrogated on 27-Plex Luminex array to detect cytokines and chemokines.
(a) TH2 cytokines, (b) TH17 cytokines, (c) TH1 cytokines, and (d) Chemokines. Data are
mean ± SD from 4 healthy donors. Student’s t-test performed for statistical analysis
between mock and LAC groups for each molecule. *p<0.05, **p<0.01, and ***p<0.001
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IV.C.7 TCRγδ Involvement in Vδ1, Vδ2, and Vδ3 Production of IFNγ
After establishing that polyclonal γδ T cells produced pro-inflammatory cytokines upon
non-specific TCR stimulation, it was of interest to evaluate whether they would respond
to tumor cells through their TCRγδ. IFNγ was produced most highly of all the cytokines
interrogated by Luminex (Figure 35c), so it was chosen as a marker for γδ T cell
response to OvCa in a classical intracellular cytokine staining (ICS) assay. Co-cultures
with polyclonal γδ T cells and two different OvCa cell lines were incubated at 37oC for
6 hours in the presence of the secretory pathway inhibitor Brefeldin-A (GolgiPlug) in
order to trap IFNγ within the T cells. Parallel co-cultures were set up with (i) normal
mouse serum (NMS) for negative control or (ii) neutralizing TCRγδ antibody (clone
IMMU510) for 1 hour prior to co-culture and during the duration of co-culture. Surfaces
of T cells were stained for CD3, TCRδ1, and TCRδ2 in order to separate Vδ1, Vδ2, and
Vδ3 populations from tumor cells (Figure 36a, 36b, and 36c). Tumor cells alone and T
cells without tumor cells served as negative staining controls. As anticipated, each Vδ
subset produced IFNγ in response to OvCa in the NMS (negative blocking control)
treated cells (Figure 36d). Furthermore, the amount of IFNγ produced followed the
order Vδ2>Vδ1>Vδ3 as evidenced by IFNγ MFI of 855 ± 475, 242 ± 178, and 194 ±
182 (mean ± SD; n = 4), respectively. Addition of antibody neutralizing TCRγδ
significantly inhibited IFNγ production by all three Vδ subsets where Vδ2 was most
affected (Figure 36d, 36e, and 36f). Therefore, polyclonal γδ T cells responded to
tumor cells indicating that they have specific anti-tumor effects through their TCRγδ.
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Figure 36. TCRγδ-specific IFNγ Production by Vδ1, Vδ2, and Vδ3 Subsets.
Polyclonal γδ T cells were incubated for 1 hour prior to co-culture and during cocultures with normal mouse serum (NMS; negative control) or neutralizing TCRγδ
antibody (αTCRγδ; clone IMMU510). Co-cultures were initiated in the presence of the
secretory inhibitor BrefeldinA (GolgiPlug) where polyclonal γδ T cells and one of two
OvCa cell lines (CAOV3 or OC314) and were incubated at 37oC for 6 hours. Cells were
stained for TCRδ1, TCRδ2, CD3, and IFNγ in order to gate each T cell subset and
assess IFNγ production. The gating strategy was (a) separation of forward and side
scatter (FSC and SSC, respectively) in activated T cell gate, (b) isolation of CD3+ T
cells from contaminating tumor cells in T cell gate, and (c) separation into Vδ1, Vδ2,
and Vδ3 based on TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+, and TCRδ1negTCRδ2neg,
respectively. (d) Histogram comparisons of Vδ1, Vδ2, and Vδ3 gates (from left to
right) co-cultured with CAOV3 and treated with NMS (open) or αTCRγδ (shaded).
Numbers next to histograms are MFI. Flow plots are representative of 1 of 3 normal
donors and of co-cultures with OC314 cells. Percent inhibition for each Vδ subset was
calculated by the following equation: Inhibition (%) = 100 – 100 x [(MFITUMOR + T CELL
– MFIT CELL ONLY)αTCRγδ / (MFITUMOR + T CELL – MFIT CELL ONLY)NMS]. Data are mean ±
SD (n = 3).
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IV.C.8. Broad Anti-tumor Cytolysis by Polyclonal γδ T cells
After establishing that γδ T cells were functional in producing pro-inflammatory
molecules, their ability to lyse a broad range of tumor cell lines was investigated against
healthy donor cells and established hematological and solid tumor cell lines.

IV.C.8.a. Polyclonal γδ T cells Lyse Hematological Tumors
We previously established that γδ T cells could lyse B-ALL cell lines (Daudi-β2M,
Kasumi2, and REH) but not healthy autologous or allogeneic B cells.(311) This
observation was confirmed again with healthy autologous and allogeneic B cells, which
were not lysed by polyclonal γδ T cells (Figure 37a). However, the same effectors were
able to kill allogeneic B-ALL cell lines cALL2 and RCH-ACV (Figure 37b). T-ALL
cell lines (Kasumi3 and Jurkat) were also sensitive to γδ T cell killing suggesting that γδ
T cells could be used to kill T cell malignancies (Figure 37c). CML cell line K562 was
also killed by γδ T cells and has been a well-known target for γδ T cell cytolysis.(303)
Moreover, K562-derived clone#4 aAPC were lysed by γδ T cells, as expected (Figure
37d). Thus, polyclonal γδ T cells propagated on aAPC have anti-tumor immunity
towards hematological malignancies.
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Figure 37. In vitro Cytolysis of Hematological Tumor Cells by γδ T cells. Standard
4-hour CRA were performed with increasing effector (γδ T cells) to target (E:T) ratios
against (a) B cells from autologous donors or from an allogeneic donor (one of four
representative donors), (b) B-ALL cell lines cALL2 and RCH-ACV, (c) T-ALL cell
lines Kasumi3 and Jurkat, and (d) CML cell line K562 and its derivative clone#4 aAPC.
Each line represents an individual effector where data are mean ± SD (n = 3 wells per
assay).
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IV.C.8.b. Polyclonal γδ T cells Lyse Solid Tumors
After establishing that polyclonal γδ T cells could lyse hematological tumor cells, solid
tumor cell lines were evaluated for killing using standard 4-hour CRA. Established
PaCa and OvCa cell lines were tested because of their high likelihood for sensitivity to
anti-tumor immunity with a lack of current cellular therapies. Several PaCa cell lines
(CaPan2, MiaPaCa2, Su8686, and BxPc3) cell lines were lysed by γδ T cells in a dosedependent manner where BxPc3 cells were killed most efficiently (Figure 38a). Next,
eight OvCa cell lines were lysed by polyclonal γδ T cells in the following order:
CAOV3 > EFO21 > UPN251 > IGROV1 > OC314 > Hey > A2780 > OVCAR3
(Figure 38b). Moreover, there was an average of >60% maximum cytolysis observed
against CAOV3 in one donor after 4 hours at an effector to target (E:T) ratio of 20:1.
Therefore, polyclonal γδ T cells were able to kill solid tumors in vitro and other solid
tumor cell lines may also be sensitive to cytolysis by γδ T cells.
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Figure 38. In vitro Cytolysis of Solid Tumor Cells by γδ T cells. Standard 4-hour
CRA were performed with increasing effector (γδ T cells) to target (E:T) ratios against
(a) PaCa cell lines CaPan2, MiaPaCa2, Su8686, and BxPc3 and (b) OvCa cell lines
A2780, EFO21, Hey, IGROV1, OC314, OVCAR3, UPN251, and CAOV3. Each line
represents an individual effector where data are mean ± SD (n = 3 wells per assay).
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IV.C.8.c. Mechanism of Tumor Cytolysis by γδ T cells was Multi-factorial
We sought to determine if polyclonal γδ T cell cytolysis was directly dependent upon
the TCRγδ by neutralizing killing with antibodies. Confounding these assays was the
observation that γδ T cells displayed high levels of DNAM1 and NKG2D (data not
shown), which can mediate cytolysis by both T cells and NK cells.(335, 336) Moreover,
there was not a clear-cut choice for TCRγδ neutralizing antibody since the company
information for TCRγδ-specific antibodies did not report on neutralization. In the end,
the TCRγδ-specific antibody used for staining in this study (clone B1, BD Biosciences)
and clone IMMU510 TCRγδ-specific antibody (IM) from Thermo Fisher were used for
neutralization studies. Also, because there were many activating receptors (TCRγδ,
DNAM1, NKG2D) on the γδ T cell surface, a pool of all antibodies was used for
maximum inhibition and to assess if there was additivity or synergy between the
receptors in killing. Hematological tumor cell line (Jurkat) and solid tumor cell line
(OC314) were chosen as targets because of their reported expression of DNAM1 and
NKG2D ligands and their sensitivity to cytolysis by polyclonal γδ T cells (Figures 37c
and 38b).(337-339) An E:T ratio of 12:1 was chosen where effectors were preincubated with the antibodies and antibodies were present during the 4-hour CRA. NMS
was used as a negative control and parallel wells were initiated without antibodies to
determine maximum cytolysis for normalization purposes. Antibodies targeting
NKG2D, DNAM1, and TCRγδ (clone B1) had minimal effect on reducing cytolysis
against Jurkat (Figure 39a) and OC314 (Figure 39b) relative to NMS. However, there
was a statistically significant increase in killing against Jurkat with DNAM1 antibody
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and significant decrease in killing against OC314 with NKG2D antibody. In contrast,
TCRγδ (IM) antibody significantly neutralized killing of both Jurkat and OC314 cells
compared to NMS and reduced the killing by an average of 40% in both cell lines
(Figures 39a and 39c second bars from right). Furthermore, a pool of all four
antibodies (NKG2D, DNAM1, TCRγδ (B1), and TCRγδ (IM)) resulted in synergistic
inhibition of γδ T cell cytolysis of Jurkat (65% ± 8%) and OC314 (71% ± 10%) cells
(Figures 39a and 39c bars to far right). Moreover, dose-dependent inhibition was
observed by both TCRγδ (IM) and pooled antibodies when concentrations were diluted
from 3.0 µg/mL (shown in Figures 39a and 39c) to 1.0 µg/mL and 0.3 µg/mL against
Jurkat (Figure 39b) and OC314 (Figure 39d). Similar results were seen with targeting
IGROV1 (data not shown), which is also known to express DNAM1 and NKG2D
ligands and was sensitive to polyclonal γδ T cell killing (Figure 38b).(337, 339, 340).
In sum, these results suggested that killing by γδ T cells is multi-factorial with an
emphasis on the TCRγδ to mediate cytolysis.
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Figure 39. Neutralization of Polyclonal γδ T cell Cytolysis. Neutralizing antibodies to
NKG2D, DNAM1, TCRγδ (B1), TCRγδ (IM) were used to block killing of Jurkat or
OC314 tumor targets at an E:T ratio of 12:1 in standard 4-hour CRA. Antibodies were
pre-incubated with T cells for 1 hour and kept in the CRA at 0.3, 1.0, or 3.0 µg/mL.
NMS was used for antibody controls and specific lysis was normalized to wells without
antibody to yield relative cytolysis as defined by: Relative cytolysis (%) = (Specific
Lysis)With Antibody / (Specific Lysis)Without Antibody x 100. Relative cytolysis of Jurkat cells
by (a) all antibodies at 3.0 µg/mL and (b) NMS, TCRγδ (IM), and pooled antibodies at
tested concentrations. Relative cytolysis of OC314 cells by (c) all antibodies at 3.0
µg/mL and (d) NMS, TCRγδ (IM), and pooled antibodies at tested concentrations. Data
are mean ± SD (n = 4). Two-way ANOVA with Bonferroni’s post-tests were used for
statistical analysis.
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IV.C.8.d. Importance for TCRδ in γδ T cell Cytolysis
Because the separated Vδ subsets displayed differences in memory phenotype and
cytokine production, it was of interest to evaluate their ability to directly lyse solid and
hematological tumors. Acute killing was evaluated with standard 4-hour CRA against
Daudi-β2M, Jurkat, K562, clone#4 aAPC, and OvCa cell lines (CAOV3, IGROV1,
OC314, and UPN251) all of which displayed high levels of susceptibility to lysis by
polyclonal γδ T cells (Figures 37 and 38). All eight tumor cell lines were lysed by the
separated Vδ lineages, but a distinct order of lysis was observed against all targets
where Vδ2>>Vδ3>Vδ1 in killing capabilities (Figure 40). As the phenotype indicated
that Vδ1 cells were mainly naïve, it was expected that they would have the most limited
cytolytic ability, which is what was observed. Likewise, TCM have less immediate
effector function relative to TEM cells, and these memory populations were dominated
by Vδ3 and Vδ1, respectively. Importantly, this was the first report of anti-tumor
activity by Vδ3 cells. It was interesting that all three Vδ lineages lysed clone#4 aAPC
roughly equally which supports their similar proliferation (Figure 32). Long-term
killing assays were then set up to assess whether equivalent killing could be achieved
during 48 hours of co-culture between Vδ subsets and OvCa cell lines CAOV3, OC314,
and UPN251 (Figure 41). Indeed, >95% of CAOV3 and UPN251 cells were eliminated
by all three subsets in two days. Likewise, 96% ± 4% of OC314 cells were killed by
Vδ2 cells, and Vδ1 and Vδ3 achieved 76% ± 5% and 89% ± 5% (mean ± SD; n = 3)
killing, respectively, in 48 hours of culture. Collectively, the Vδ subset lineage was
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important for cytolysis in both acute and long-term conditions, and established that each
Vδ lineage propagated on aAPC was capable of tumor killing.
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Figure 40. γδ T cell Subset Acute Cytolysis. Vδ subsets were tested in 4-hour CRA
against (a) ALL cell lines Daudi-β2M and Jurkat, (b) CML cell line K562 and its
derivative clone#4 aAPC, and (c) OvCa cell lines IGROV1, OC314, UPN251, and
CAOV3. Vδ1 (circles), Vδ2 (squares), and Vδ3 (triangles) are displayed as mean ± SD
from averaged triplicate measurements from four normal donors.
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Figure 41. γδ T cell Subset Long-term Killing. CAOV3, OC314, and UPN251 cells
were seeded in wells of 6-well plates and incubated overnight so that they would adhere
to the wells. T cells from Vδ1, Vδ2, or Vδ3 subsets were then added and co-cultured in
the wells with tumor cells for 2 days. Remaining adherent cells were enzymatically
removed from the wells and counted for viable cells. Tumor cells without T cells were
positive control and T cells without tumor cells was the negative control. Killing (%) =
(Viable cells)Co-culture / (Viable cells)Tumor only x 100. Data are mean ± SD (n = 3).
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IV.C.9. Clearance of Established Tumor Xenografts by Polyclonal γδ T cells
As polyclonal γδ T cells are being proposed as a therapy for cancer patients, a model to
test their efficacy in vivo was evaluated. NSG mice were used for their ability to accept
human tumor xenografts well and were injected with CAOV3-ffLuc-mKate tumor cells
intraperitoneally (i.p.) then randomized into treatment groups to establish a model of
high tumor burden. This was a model for advanced OvCa disease as many women with
OvCa do not usually develop metastases outside of the peritoneal cavity but local tumor
growth and ascites result in disease pathology.(37) After 8 days of engraftment (denoted
Day 0) either PBS (negative control) or γδ T cells (escalating doses) were administered
i.p. to the mice (Figure 42). Tumor burden was monitored during the experiment with
non-invasive BLI following D-luciferin administration. Established tumors were clearly
visible by BLI after 8 days of engraftment at Day 0 (Figure 42a top panels), which
continued to grow in mock (PBS) treated mice (Figure 42a bottom left panels) but
were eliminated in mice treated with polyclonal γδ T cells (Figure 42a bottom right
panels) at 72 days post-treatment initiation. All mice treated with PBS had increased
BLI flux measurements (p = 0.018) whereas polyclonal γδ T cell-treated mice had
significantly decreased (p = 0.004) BLI flux (Figure 42b). Moreover, treatment with γδ
T cells improved overall survival (p = 0.0001) compared to mock-treated mice where
90% of mice survived OvCa and hazard ratio for mice without treatment was 20.4
(Figure 42c). In sum, polyclonal γδ T cells were effective in treating cancer in vivo and
represent an attractive approach to cell-based cancer treatment.
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Figure 42. In vivo Tumor Clearance by Polyclonal γδ T cells. CAOV3-ffLuc-mKate
tumor cells (3x106) were injected i.p. into NSG mice at Day -8 and were allowed to
engraft until Day 0 when treatment was started with either PBS (vehicle/mock) or
polyclonal γδ T cells. Four doses were given with 3x106, 6x106, 10x106, and 15x106 on
days 0, 7, 14, and 21, respectively, to create a dose escalation scheme. (a) BLI flux
images at Day 0 (top panels) or Day 72 (bottom panels) in PBS-treated (left 3 panels) or
polyclonal γδ T cell-treated (right 3 panels) mice. Mice displayed are representative of
10 total mice. (b) BLI flux measurements of mice at Day 0 (squares) and Day 72
(circles) where lines are drawn between the same mouse. Student’s paired, 2-tailed ttests were used for statistical analysis and p values are displayed above treatment
groups. (c) Overall survival of mice treated with PBS (open squares) or polyclonal γδ T
cells (closed squares). Gehan-Breslow-Wilcoxon Test was used to calculate p value. H
= hazard ratio.

155

Drew C Deniger
IV.D. Discussion
IV.D.1. Importance of Polyclonal γδ T cells for Immunotherapy
This study establishes clone#4 aAPC as a cellular platform for the sustained
proliferation of populations of γδ T cells that exhibit broad reactivity against
hematologic malignancies and solid tumors. T cells expressing certain Vδ TCR usage
have been associated with clinical responses against cancer. For example, the Vδ1 TCR
subset correlated with complete responses observed in patients with ALL and AML
who underwent αβ T cell-depleted allogeneic HSCT.(302, 304, 305) However, Vδ1
cells have not been directly infused for therapy. This chapter established direct evidence
that Vδ1 cells could mediate anti-tumor immunity and strengthens support for their use
in adoptive T cell cancer treatments. In contrast to Vδ1 and Vδ3 cells, T cells
expressing Vδ2 TCR have been directly infused and generated responses against solid
and hematological tumors, but complete responses were unpredictable and sometimes
not directly correlated to Vδ2 therapy (175, 318). Similarly, Vδ2 cells expanded in this
chapter had the most immediate anti-tumor cytotoxicity and cytokine production, and
aAPC-based expansions could build upon these early successes of Vδ2 T cell infusions.
A role for T cells expressing Vδ3 TCR in targeting tumors is unknown, but these
lymphocytes have been correlated with immunity to HIV and CMV.(165, 183) Thus
infusion of this T-cell subset could be beneficial to immunocompromised patients.
Importantly, these results are the first to directly show that Vδ3 cells have anti-tumor
activity and this study could, therefore, represent a significant contribution to both
translational research strategies and to immunologists studying γδ T cell function. In
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aggregate, the data herein lend impetus to adoptive transfer of γδ T cells that maintain
expression of all Vδ TCR types as investigational treatment for tumors and
opportunistic viral infections.

IV.D.2. Potential Ligands for TCRγδ on aAPC
The molecules on aAPC that stimulate TCRγδ for their numeric expansion are not
known. K562-derived aAPC express endogenous MICA and MICB molecules (329)
which are ligands for both Vδ1 and NKG2D.(152) NKG2D was expressed (40% ±
16%; mean ± SD, n = 4) on aAPC-expanded γδ T cells that were also predominantly
Vδ1 cells (Figure 31). Polyclonal γδ T cells also demonstrate expression (26% ± 7%)
for other activating NK receptors (NKp30, NKp44, and NKp46), which may contribute
to γδ T cell function. Two ligands described for Vδ2 TCR are surface mitochonrial F1ATPase and phosphoantigens, both of which are described in K562 cells.(171, 172, 297,
299) Indeed, enhanced responses of T cells expressing Vγ9Vδ2 were observed when
K562 cells were treated with aminobisphosphonates,(172) and a similar strategy could
be employed upon co-culture with clone #4 to increase the frequency of Vδ2 TCR
usage.(173) Otherwise, patients receiving polyclonal γδ T cells could be primed to
expand Vδ2 cells in vivo through administration of aminobisphosphonates. Now that
aAPC have been established as a means to propagate polyclonal γδ T cells, these
molecular questions can be answered and used for future therapies.
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IV.D.3. Co-stimulation in Polyclonal γδ T cell Expansion
We introduced co-stimulatory molecules to improve the ability of aAPC to propagate γδ
T cells. CD28 and CD137 (4-1BB) expressed on γδ T cells bind CD86 and CD137L,
respectively, expressed on aAPC. The absence of both CD86 and CD137L abrogated γδ
T-cell proliferation and expression of single co-stimulatory molecules only partially
restored the ability of γδ T cells to proliferate (Figure 28b). The benefit of using other
molecules’ involvement in co-stimulation has not been evaluated to date. CD70 is
expressed on γδ T cells (36% ± 15%) concurrently with its receptor CD27 (Figure 33),
which may allow for trans- or cis- stimulation independent of the aAPC that does not
express CD70. CD27 has been described as a marker for γδ T cells that produce IFNγ,
and CD27neg γδ T cells commonly secrete IL17, a potent cytokine that has powerful, yet
context-dependent anti-tumor activities.(127, 333, 341) Current studies are investigating
whether other co-stimulation combinations, i.e. ICOS without CD86, can improve the
propagation and/or change the phenotype of γδ T cells – especially in regards to
improving production of IL17 that can have potent anti-tumor effects. It may be that a
cocktail of cytokines and neutralizing antibodies is required to propagate IL17producing γδ T cells, which was required for expansion of CD4+ TH17 cells ex vivo on
stimulating beads.(326) Indeed, the addition of IL2 and IL21 was also crucial for the
numeric expansion of γδ T cells so the strategy will likely need addition of these two
exogenous cytokines (Figure 28c). In the end, the aAPC co-culture system provides a
clinically relevant methodology to tailor the type of therapeutic γδ T cell produced for
adoptive T cell therapy.
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IV.D.4. Polyclonal γδ T cells Apparently Lack Allogeneic Responses to Healthy Tissue
An attractive therapeutic strategy is to employ third party allogeneic γδ T cells as an
“off-the-shelf” therapy. This may be feasible, as γδ T cells have reduced potential to
cause graft-versus-host disease (GvHD) resulting from inappropriate TCR-mediated
recognition of normal host tissue (305). Unlike TCRαβ that recognizes peptides in the
context of MHC, TCRγδ is not known to be subject to MHC restriction.(141, 298, 299)
Thus, matching recipient and donor T cell MHC may not be needed, raising the
possibility that propagated γδ T cells from one donor can be infused into multiple
recipients. Autologous T cells expressing Vγ9Vδ2 TCR have been adoptively
transferred and intravenous administration of aminobisphosphonates was used for in
vivo numeric expansion of this T-cell subset.(175, 179, 318) To date, the infusion of
allogeneic γδ T cell has not been reported. We have evaluated aAPC-expanded γδ T
cells for allogeneic responses and are not able to detect such reactivity. For example, γδ
T cells proliferate (Figure 43a) and secrete IFNγ (Figure 43b) when co-cultured with
OKT3-loaded aAPC, but not when co-cultured with autologous or allogeneic B cells.
Allogeneic tumor cell lines were lysed by our γδ T cells, but healthy B cell donors were
spared (Figures 24a and 37a). Further, formation of colonies from hematopoietic stem
cells was inhibited by allogeneic NK cells, but not by allogeneic γδ T cells (Figure
43c). Autologous EBV-transformed LCL stimulated γδ T cells suggesting they may
react with EBV antigens (data not shown) as indicated by previous studies.(342, 343)
Bi-specific αβ T cells expressing CARs specific for GD2 or CD19 and grown on LCL
have shown excellent anti-tumor immunity and could be applicable for the γδ T cell
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population using aAPC.(236, 344) The ability to infuse donor-derived γδ T cells when
needed, rather than wait the availability of an autologous product raises the therapeutic
potential of this T-cell subset. This adds to our development of “off-the-shelf” cells as
we previously reported that zinc finger nucleases can be used to eliminate expression of
TCRαβ to help generate “universal” CAR+ T cells.(345)
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Figure 43. Absence of Allogeneic Responses by Polyclonal γδ T cells to Partially
Mis-matched Donors’ Healthy Cells. (a) Polyclonal γδ T cells were labeled with red
fluorescent dye (PKH-26) and co-cultured with (i) media only (mock), (ii) autologous B
cells, (iii) allogeneic B cells from normal donors (n = 5), or (iv) OKT3-loaded clone#4
aAPC (positive control) for 3 days at 37oC without exogenous cytokines. Proliferation
was measured by dilution of PKH-26 dye MFI and each group was normalized to mock
treated T cells after gating for CD3+TCRγδ+ cells. Each shape represents a polyclonal γδ
T cell effector (n = 3). Representative flow cytometry plot is displayed to the right. (b)
The same co-cultures set up in (a) were initiated overnight in an IFNγ ELISpot assay
plate, except that cells were not labeled with PKH-26. Spots were enumerated and
normalized to mock-treated cells for each donor, which is represented by an individual
shape. (c) Hematopoietic stem cell (HSC) colony forming unit assays were set up with
co-cultures of donor-matched NK cells or γδ T cells and PBMC containing a fixed
number of HSC and co-cultures were added to semi-solid media supplemented with
cytokines for colony formation. HSC cultures without co-cultured lymphocytes were
used as negative controls for inhibition of colony formation and to normalize co-culture
colony formation. Student’s paired, 1-tailed t-tests were used for statistical analysis.
*p<0.05 and **p<0.001.
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IV.D.5. Application of Polyclonal γδ T cells for Immunotherapy
These data demonstrate that our aAPC can be used to generate large numbers of γδ T
cells that maintain polyclonal TCR repertoire and have an ability to kill tumor cells.
Clone#4 has been produced as a master cell bank and thus there is a clear path to
generating clinical-grade γδ T cells for human application. A polyclonal approach to γδ
T cell immunotherapy is supported by the ability to of aAPC generate TN, TCM, and TEM
γδ T cells from Vδ1, Vδ2, and Vδ3 lineages (Figure 34) that could then produce a
range of effector functions including production of pro-inflammatory cytokines
(Figures 35 and 36), exerting direct cytotoxicity against tumors (Figures 37, 38, 39, 40
and 41), and eliminating solid tumor xenografts (Figure 42). Thus, immediate tumor
cytotoxicity can be achieved mainly through effector and TEM cells and long-lived antitumor immunity could be repopulated in patients with TN and TCM γδ T cells. Clinical
trials can now, for the first time, test the efficacy of polyclonal γδ T cell transfers in
cancer treatments of both solid and hematological tumors.
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CHAPTER V
General Discussion and Future Directions

V.A. Dissertation Summary
The central aim of this dissertation was to develop and test novel cellular
immunotherapies for cancer treatment. This was tested in three independent specific
aims. First, ROR1-specific CARs were able to re-direct αβ T cells towards leukemia
without affecting normal B cells, and this represented an improvement from current
CD19-specific CAR strategies that result in normal B cell aplasia (Chapter II). Current
CD19-specific CAR and CD19+ aAPC are currently in clinical trials at MD Anderson
and were the fastest way to translate a strategy to use CAR+ γδ T cells for
immunotherapy. Therefore, the second approach used polyclonal γδ T cells expressing
TCRγδ with anti-tumor reactivity as sentinels of CD19-specific CAR anti-tumor
immunity. These CAR+ γδ T cells may have clinical bi-specific anti-leukemia efficacy
due to targeting the tumor through both TCR and CAR (Chapter III). The last aim
evaluated the broad anti-tumor activity of polyclonal γδ T cells expanded on aAPC, and
established that they can be an effective option for leukemia, PaCa, and OvCa (Chapter
IV). The translation of these pre-clinical methods into the clinical trials will give people
facing cancer treatment new, safe, and effective options.
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V.B. Combinational Cellular Immunotherapies
Using more than one cell immunotherapy product in therapy may lead to therapeutic
additivity, or better yet, synergy. Indeed, clinical trials have already combined HSCT
with CD19-specific CARs to target B-cell leukemia.(263, 346) The trials are still in the
enrolling stages, so it will take time to determine whether they are better than historical
controls. Similar to HSCT and CD19-specific CAR+ T cells, CARs can be paired to
other cellular products to increase anti-tumor efficacy. For instance, polyclonal γδ T
cells had inherent anti-tumor immunity towards ovarian and pancreatic cancers
(Chapter V) and ROR1 is a TAA expressed on both PaCa and OvCa where ROR1+
OvCa cells were lysed by ROR1-specific CAR+ T cells (Figure 16c),(67) so a
combinational immunotherapy of ROR1-specific αβ T cells and polyclonal γδ T cells
could be used. In fact, the 4A5 mAb specific for ROR1 and from which the CAR was
derived detected ROR1 at some level in 11 of 12 OvCa cell lines (Figure 6c and data
not shown). Given the potent anti-tumor activity of polyclonal γδ T cells towards OvCa
(Figure 38b), the two approaches could be done together to increase tumor clearance.
Moreover, patients with low ROR1 antigen expression and resistance to γδ T cellmediated cytolysis may be sensitive to synergistic killing by ROR1-specific CAR+ αβ T
cells and polyclonal γδ T cells. Also, γδ T cells are unlikely to participate in GvHD in
allogeneic transplantation, so a universal bank of polyclonal γδ T cells could be
established that was known to have high anti-tumor immunity or containing a particular
set frequency of Vδ1, Vδ2, and Vδ3 populations with maximum efficacy.(305)
Polyclonal γδ T cells could also be used as front-line therapy before addition of HSCT,
CAR+ T cells, TILs, etc. in order to prime the tumor microenvironment for adaptive
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immune cells with broader tumor specificity or to reveal neo-tumor antigens.
Furthermore, the bystander effects of γδ T cells in the microenvironment are largely
unknown, and tumor lysis could lead to other resident cell types, e.g. NK cells,
macrophages, DCs, etc. to have renewed reactivity to the tumor.(347) Indeed, B-ALL
cell lines coated with mAb were lysed by CD16+ Vγ9Vδ2 cells via antibody-dependent
cell-mediated cytotoxicity (ADCC), and subsequently the Vγ9Vδ2 had APC function to
generate antigen-specific CD8+ αβ T cell responses to known B-ALL peptides, e.g.
PAX5.(348, 349) The advantage of polyclonal γδ T cells expanded on aAPC is that
there may be sufficient direct tumor lysis that ADCC would not be necessary. However,
the APC function of aAPC-expanded polyclonal γδ T cells has not yet been studied.
Lastly, melanoma may be an ideal target for combinational cellular immunotherapy
because it is one of the most responsive tumors to immunotherapy and many T cells
specific to melanoma peptides, e.g. MART1 and gp100, have been well characterized
for rapid detection of antigen-specific responses. As aAPC have already been adapted
for melanoma TIL studies (Forget MA, unpublished observation),(274) it is a logical
next step to evaluate whether polyclonal γδ T cells can induce antigen-specific CD8+ T
cell responses to melanoma. If successful, this approach could impact the TIL
expansion protocols to adapt them to a wider range of patients. In aggregate, there are
many combinatory approaches that can be taken to increase the therapeutic payload to
cellular immunotherapy.
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V.C. Generation of IL17-producing T cells for Adoptive Immunotherapy
IL17 has been shown to have potent anti-tumor effects when used in the tumor
microenvironment, and therefore secretion of IL17 by transferred T cells homing to the
tumor may have potent anti-tumor immunity.(321, 323, 350) T cells that produce IL17
can be mutually exclusive from those who produce IFNγ. Indeed, most of the T cells
expanded on aAPC in this dissertation, with or without CARs, produced IFNγ, and the
expanded γδ T cells secreted IL17 in diminished quantities compared to IFNγ (Figures
23 and 35). CD27 has been a marker for these cytokines in γδ T cells where CD27neg
and CD27+ are associated with IL17 and IFNγ, respectively.(333, 351, 352) It holds
then that ~80% of polyclonal γδ T cells stain positive for CD27 (Figures 33 and 34).
CD28 co-stimulation was shown to inhibit TH17 polarization in CD4+ T cells through
ICOS co-stimulation,(326) and so it may be that CD86 co-stimulation by aAPC and/or
CD28 endodomains in the CAR lead to polarization towards IFNγ in polyclonal γδ T
cells, CAR+ γδ T cells, and CAR+ αβ T cells. Replacement of CD28 for ICOS in the
CAR(s) and CD86 for ICOSL in the aAPC can be tested to see if these can generate T
cells that secrete IL17. Another strategy comes out of the observation that ROR1specific CAR+ T cells signaling through CD137 produce less IFNγ than do those
signaling through CD28 (Figure 15). This may be due to (i) CD137 signaling yielding
less inflammatory cells or (ii) CAR-CD137 cells expressed other cytokines that have yet
to be detected. Clinical trials out of The University of Pennsylvania (PI: June, CH)
using CD19-specific CAR+ T cells for ALL and CLL treatment have shown that
responders had high serum IL6.(4, 7) This cytokine has importance for macrophages,
inflammatory response (of particular interest in his trials as patients underwent massive
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fevers from T cells attacking their leukemia), and polarization of CD4+ T cells from
TREG to TH17.(127) In regards to the latter, release of immunosuppression by TREG and
production of IL17 could explain these impressive complete responses. Chapter II did
not directly evaluate the influence of TREG cells on CAR+ T cell function or IL6 and
IL17 production, but experiments using intracellular cytokine staining or multiplex
arrays can be used to pursue this line of questioning. Development of an aAPC-based
expansion of IL17 secreting T cells would allow for direct testing of their benefit
relative to IFNγ-producing cells, and may lead to rationales to use one or both of them
in the clinic for cancer therapies.

V.D. Importance of Polyclonal γδ T cells to Immunology
One of the major accomplishments of this dissertation was creating a method for
expanding polyclonal γδ T cells (Chapter IV), which has broader applications outside
of immunotherapy to the immunology and cancer biology fields. For example, few mAb
exist that are specific for TCRγδ isotypes, which limits their detection in correlative
studies and other assays.(165) Given the ability of aAPC to expand large numbers of
polyclonal γδ T cells, mice can be immunized to generate mAb specific for desired
TCRγδ isotypes, e.g. Vδ3 and Vγ isotypes outside of Vγ9. Commercial and academic
use of these detection antibodies have tangible outcomes, including diagnostic and/or
prognostic profiling of γδ T cell TIL within tumors. Other major unknowns are the
ligands for many TCRγδ heterodimers. Generation of γδ T cell clones could be used to
determine the specific ligands of Vδ/Vγ combinations and therefore lead to future
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studies on γδ T cell affinity towards a particular disease. Moreover, the ligands on the
K562-derived aAPC that TCRγδ binds are unknown. Likely candidates include IPP
(Vδ2) and MICA/B (Vδ1) but their exact roles have not been determined.(155, 172)
Elucidation of these interactions could assist attempts to tailor the aAPC for total γδ T
cell expansion, expansion of a particular γδ T cell lineage, or polarization towards a
certain γδ T cell phenotype. Thus, aAPC could be an excellent source for the study of
fundamental γδ T cell immunobiology and could yield answers not currently accessible
because of limited starting cell numbers and ineffective polyclonal expansion protocols.

V.E. Potential Benefits and Issues with Cellular Immunotherapy
Although promising, there may be some limitations to the immunotherapies created in
this dissertation. First, patients with advanced B-cell leukemia disease often have few T
cells in their peripheral blood, and have even fewer γδ T cells.(6) In some cases, the
residual autologous T cells are functionally unresponsive and difficult to expand to
clinically-relevant doses.(353) Preliminary studies using CD19-specific CAR have
indicated that CAR+ T cells can be generated from CLL patients with <5% T cells at the
start of culture (Huls MH, unpublished observation). Other options would be to use
haplo-identical or MHC-matched T cells. However, this is not always feasible, so
allogeneic γδ T cells could be an ideal choice because of they are generally thought to
recognize antigens outside of MHC-restriction.(304, 342) Of course, if normal
hematopoiesis resumes in the patients then the γδ T cell graft may be rejected, but there
may still be a therapeutic window. Another unknown is whether γδ T cells will be
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subjected to the same regulation by TREG cells or other immunosuppressive forces.
Some γδ T cells have been reported to have immunosuppressive function, and it would
be of interest to identify these cells and eliminate them from the adoptive T cell product
prior to infusion.(354) The tumor microenvironment is also of interest because it often
contains hypoxic areas containing malignant cells resistant to conventional
treatments.(355, 356) In preliminary experiments, the co-culture system was adapted to
assess γδ T cell proliferation as a function of oxygen tension. No difference in
proliferative capacity (p = 0.404) was observed when the cultures were in hypoxia (1%
O2) or normoxia (20% O2) and stimulated with clone#4 aAPC, IL2, and IL21, indicating
that γδ T cells have potential to operate within the bone marrow or hypoxic tumor
milieu (Figure 44). Thus, administration of graded doses of autologous and allogeneic
γδ T cells in humans will test the ability of γδ T cells to home and recycle effector
function in the tumor microenvironment. In the end, clinical trials will be the ultimate
test of whether these potential pitfalls out weight the anti-tumor benefits to cancer
patients.
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Figure 44. Proliferation of γδ T cells in Hypoxia Compared to Normoxia. Cocultures were initiated in parallel with γδ T cells and aAPC in the presence of
exogenous IL2 and IL21 in incubators set with either 1% O2 (hypoxia) or 20% O2
(normoxia) and were normalized to starting quantities 10 days after culture initiation.
Student’s paired, 2-tailed t-test was used for statistical analysis.
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V.F. Clinical Applications of Dissertation Immunotherapies
As of June, 2013 there are immediate plans to use immunotherapies detailed in
Chapters II and IV in the clinic. A Phase I clinical trial was written to co-administer
autologous ROR1RCD28 and ROR1RCD137 T cell populations into CLL patients after
lymphodepletive (Cytoxan and Fludarabine) chemotherapy. Proof-of-principle studies
have established protocols for expanding CAR+ T cells from patient samples by using
an “electroporation-then-sort” strategy used for growing CAR+ γδ T cells (Chapter
III). Patient PBMC will be electroporated with SB transposase and SB transposase
plasmids and sorted on paramagnetic beads the following day to deplete CD19+ T cells.
Co-culture on aAPC led to CAR+ T cell growth in the translation research lab (TRL)
built to translate lab protocols to the current good manufacturing practices (cGMP)
facility. As more data has arrived, the support for utilizing only ROR1RCD137 in the
clinical trial has gained momentum and may be the treatment modality tested instead of
a competitive re-population experiment of both CAR+ T cell populations. This
investigational new drug (IND) application passed rigorous examination by the National
Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) with
approval in December 2012. Review at the MD Anderson IRB is underway before
sending the trial for final IND approval by the Food and Drug Administration (FDA). A
second CAR trial has been proposed for treatment of leukemia with both ROR1-specific
T cells and the chemotherapy dasatinib, which leads to increased surface expression of
ROR1 in t(1;19) B-ALL cells and could minimize the risk for ROR1 antigen
escape.(13) In regards to Chapter IV translation, a compassionate IND (CIND) has
been written to treat a late stage CLL patient with autologous or allogeneic polyclonal
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γδ T cells in the case that the autologous γδ T cells do not proliferate or respond to the
tumor. If allogeneic γδ T cells are infused into this patient, this will represent the first
time that purified polyclonal γδ T cells from an allogeneic host were ever infused into a
human. There is great optimism that the polyclonal γδ T cells can home to secondary
lymphoid tissues harboring CLL and that they can eliminate the leukemia. These two
trials are, hopefully, the beginning of the trials to come that will apply ROR1-specific T
cells, CAR+ γδ T cells, and polyclonal γδ T cells for human cancer immunotherapies.
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CHAPTER VI
MATERIALS AND METHODS

VI.A. DNA Plasmids and Construct Cloning
All plasmids in this study were propagated in dam-/- bacteria (C2925, Invitrogen, Grand
Island, NY) and purified as single cell bacteria clones with EndoFree Plasmid Maxi Kit
(Qiagen, Valencia, CA). Plasmids were cleared for transfection when (i) identity was
confirmed by analytical digestion, (ii) samples were negative for endotoxin, and (iii)
had spectrophotometer readings of 1.80 < A260/A280 < 2.00.

VI.A.1. Tumor Antigens
VI.A.1.a. ROR1
The extracellular and transmembrane domains of ROR1 (Accession: NM_005012),
termed dROR1, were cloned into a SB vector (pSBSO). The open reading frame (ORF)
was codon optimized for expression in human cells and cloned into a shuttle vector
(pMK-RQ) by GeneArt (Invitrogen). Codon-optimized dROR1/pMK-RQ and GlySerEGFP-mIgG1(CooP)/pSBSO plasmids were digested with NheI and XhoI restriction
enzymes and were purified from pMK-RQ and GlySer-EGFP-mIgG1 fragments,
respectively, by gel electrophoresis. Purified dROR1 and pSBSO fragments were
ligated with T4 DNA Ligase (Promega, Madison, WI) to create dROR1/pSBSO
plasmid, which was then amplified in the presence of kanamycin for large-scale
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purification. Identity of the purified plasmid was confirmed with digestions of (i) ClaI,
(ii) ClaI and SmaI, (iii) PvuII, and (iv) PvuI and SmaI enzymes to distinguish between
parental plasmids and dROR1/pSBSO.

VI.A.1.b. CD19
The extracellular and transmembrane domains of human CD19 (Accession: M84371),
termed Delta-CD19, were cloned into a pSBSO with linked F2A cleavage site and
neomycin resistance (NeoR) for enforced dCD19 expression (performed by Olivares S).
As with dROR1, the ORF was codon optimized for expression in human cells and
cloned into a shuttle vector by GeneArt. In order to create the final vector, codonoptimized dCD19 from plasmid vector Delta-CD19(CoOp)-F2A-SStomato/pSBSO and
Neomycin resistance from plasmid vector Myc-FFLuc(CoOp)-Neo/pSBSO, were
digested with ZraI/SpeI and EcoRV/SpeI restriction enzymes respectively.

The

fragments (Neo-insert and Delta-CD19(CoOp)-F2A-X/pSBSO-vector) were purified by
gel electrophoresis. Purified fragments were ligated with T4 DNA Ligase to create
Delta-CD19(CoOp)-F2A-Neo/pSBSO plasmid, which was then amplified in the
presence of kanamycin for large-scale purification. Identity of the purified plasmid was
confirmed with digestions of SacI restriction enzyme to distinguish between parental
plasmids and Delta-CD19-F2A-NeoR/pSBSO.
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VI.A.2. Co-stimulatory Molecules
VI.A.2.a. CD86 and CD137L
The entire ORF for CD86 (Accession: EF064748.1) and CD137L (Accession:
NM_003811.3) were codon optimized and synthesized by GeneArt and were then
cloned into pSBSO (performed by Ang S).

VI.A.2.b. IL15-IL15Rα Fusion Construct
This construct will produce an IL15 that is membrane-bound, but also presented in the
context of IL15Rα. A fusion of IL15 (NM_000585.4) to the full length IL15Rα
(NM_002189.3) was constructed with a serine-glycine linker and a C-terminal Flag (x3)
motif attached to generate membrane bound IL15 (mIL15). The signal peptides for IL15
and IL15Rα were omitted and the IgE signal peptide (gb|AAB59424.1) was used for the
mIL15 fusion protein. As with dROR1, mIL15 was codon optimized and synthesized by
GeneArt and was then subcloned into GlySer-EGFP-mIgG1(CooP)/pSBSO using NheI
and XhoI restriction sites.

VI.A.3. Chimeric Antigen Receptors
Cloning of second generation CD19-specific CAR signaling through CD28 and CD3ζ
(CD19RCD28) has been previously described.(57, 272, 281) The CAR was modified to
replace CD28 endodomain for CD137 endodomain as a synthetic cDNA sequence
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(GeneArt) that was cloned back into the original plasmid with SmaI and SpeI restriction
endonucleases to create another second generation CD19-specific CAR signaling
though CD137 and CD3ζ (CD19RCD137). These plasmids were further manipulated to
contain “SIM” and “FRA” oligonucleotides at the 3’ end of the CD19RCD28 and
CD19RCD137 transposons, respectively, by shuttling the entire CARs into new pSBSO
backbones with NheI and XhoI enzymes (CD19-specific CAR work performed by
Olivares S). Heavy and light chain immunoglobulin sequences from the 4A5 mAb
hybridoma were provided by Dr. Thomas J Kipps (UCSD) and were used to assemble
the following ROR1R sequence de novo (GeneArt) from 5’ to 3’ (i) murine IgGκ signal
peptide, (ii) VL, (iii) Whitlow linker, (iv) VH, and (v) the first 73 amino acids of the
IgG4

stalk,

and

ROR1R

sequence

ROR1R(CoOp)/pMK-RQ

plasmid.

ROR1R(CoOp)/pMK-RQ

was

was

shipped

Amplification

done

by

PCR

of
with

to

MD

ROR1R
the

Anderson
fragment

following

as

from

primers:

ROR1RCoOpF (GCTAGCCGCCACCATGGGCTGGTCCTGCATC) and ROR1Rrev
(GCTCCTCCC GGGGCTTTGTCTTGGC). The PCR product was cloned into pCR4TOPO with TOPO TA Cloning Kit (Invitrogen) to generate ROR1R(CoOp)/pCR4TOPO and the sequence was verified with T7 and T13-0 primers by Sanger sequencing
(DNA Sequencing Core, MDACC). Then NheI and SmaI were used to digest
ROR1R(CoOp)/pCR4-TOPO

and

CD19RCD28mZ(CoOp)/pEK

plasmids

and

appropriate bands were purified by gel electrophoresis and ligated with T4 DNA Ligase
to generate ROR1RCD28mZ(CoOp)/pEK. The ROR1-specific CAR was then
transferred into a SB transposon by digestion of CD19RCD28mZ(CoOp)/pSBSO-MCS
and ROR1RCD28mZ(CoOp)/pEK with NheI and SpeI, removal of phosphates by
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Antarctic Phosphatase from pSBSO-MCS digestion, isolation of ROR1RCD28mZ and
pSBSO-MCS bands by gel electrophoresis, and ligation with T4 DNA Ligase to
generate ROR1RCD28mZ(CoOp)/pSBSO-MCS. The final ROR1RCD28 transposon
plasmid was constructed by digesting CD19RCD28mZ(CoOp)/pSBSO-SIM with NheI,
XmaI, and Antarctic Phosphatase and ROR1RCD28mZ(CoOp)/pSBSO-MCS with
NheI, XmnI, and XmaI, purifying appropriate bands by gel electrophoresis, and ligating
them together with T4 DNA Ligase to generate ROR1RCD28CD3z/pSBSO-SIM
plasmid. Similarly, the final ROR1RCD137 transposon plasmid was constructed by
digesting CD19R-CD28Tm-41BBCyt-Z(CoOp)/pSBSO-FRA with NheI, XmaI, and
Antarctic Phosphatase and ROR1RCD28mZ(CoOp)/pSBSO-MCS with NheI, XmnI,
and XmaI, purifying appropriate bands by gel electrophoresis, and ligating them
together with T4 DNA Ligase to generate ROR1RCD137CD3z/pSBSO-FRA plasmid.
Identities of final ROR1R plasmids were distinguished from CD19R plamids by PmlI
enzyme and pSBSO-SIM and pSBSO-FRA plasmids were distinguished by BsrGI
enzyme (Figure 7).

VI.B. Cell Culture
Three media formulations were used herein for tissue culture. First, RPMI-CM was
composed of RPMI (Gibco, Grand Island, NY), 10% heat-inactivated fetal bovine
serum (FBS; Hyclone, Logan, UT), and 1% Glutamax-100 (Gibco). Similarly, RPMINaPyr-CM was RPMI, 10% FBS, 1% sodium pyruvate solution (Gibco), and 1%
Glutamax-100. Last, DMEM-CM was made with DMEM (Sigma, St. Louis, MO), 10%
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FBS, 1% sodium pyruvate solution, and 1% Glutamax-100. All tissue culture work was
performed with 5% CO2 at 37oC in humidified conditions unless otherwise stated.

VI.B.1. Established Tumor Cell Lines
Jurkat, HCT-116, Kasumi3, and K562 cell lines were acquired from American Type
Culture Collection (ATCC; Manassas, VA). K562-derived aAPC (clone #4 and
clone#9) were acquired as previously described from the University of Pennslyvania
courtesy of Dr. Carl June.(57, 275, 278, 279) B-cell acute lymphoblastic leukemia (BALL) cell lines cALL2, Kasumi2, REH, and RCH-ACV cell lines were gifts from Dr.
Jeff Tyner (OHSU), pancreatic cancer cell lines (BxPC3, CaPan2, MiaPaCa2, and
Su8686) were donated by Dr. Viji Ramachandran (MDACC), and ovarian cancer cell
lines (A2780, CAOV3, EFO21, Hey, IGROV1, OC314, OVCAR3, and UPN251) were
provided by Dr. Robert Bast (MDACC). Cell cultures were maintained in (i) RPMICM: K562 parental cells, clone#1 aAPC, clone#4 aAPC, clone A6 aAPC, clone A3
aAPC, clone D4 aAPC, Jurkat, cALL2, Kasumi2, REH, RCH-ACV, and Kasumi3, (ii)
RPMI-NaPyr-CM: A2780, EFO21, EFO27, Hey, IGROV1, OC314, OVCAR3,
SKOV3, and UPN251, or (iii) DMEM-CM: CAOV3, BxPC3, CaPan2, MiaPaCa2, and
Su8686. UPN251 cells were supplemented with insulin-transferrin-selenium solution
(Gibco). Identities of all cell lines were confirmed by STR DNA Fingerprinting at
MDACC’s Cancer Center Support Grant (CCGS) supported facility “Characterized Cell
Line Core.”
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VI.B.2. Genetic Modification of Cell Lines
VI.B.2.a. ROR1 aAPC (clone#1)
Clone#9 aAPC was generated though enforced expression of CD19, CD64, CD86, and
CD137L on K562 cells (June CH, UPenn). This aAPC was further modified to express
IL15/IL15Rα fusion protein (Chapter VI.A.2.b) on their surfaces and was sub-cloned
to generate clone#27. Then clone#27 was made to express dROR1 (Chapter VI.A.1.a),
and single cell clones were isolated based on expression of ROR1, CD137L, and IL15.
The clone#1 aAPC uniformly expressed CD19, CD32, CD64, CD86, CD137L, IL15,
and ROR1 and was cleared for co-culture following negative testing for mycoplasma
and other microbial pathogens.

VI.B.2.b. HLA-/- aAPC
Zinc-finger nuclease (ZFN) specific for HLA-C was used to remove all MHC Class I
expression from K562 cell surface (Torakai H, Lee DA, Rosoff H, and Cooper LJN).
Clone#4 aAPC expresses IL15, CD86, and CD137L, so in order to investigate the roles
of these molecules on γδ T cell proliferation new aAPC were constructed on K562
background (Figure 28). SB transposon containing IL15/IL15Rα fusion protein and
SB11 transposase were electro-transferred into K562 cells (CD86neg and CD137Lneg)
using Amaxa nucleofection and Kit V (cat#VCA-1003, Lonza, Basel, Switzerland).
FACS was used to isolate IL15+ cells, which were electroporated with SB11 and SB
transposons containing either CD86 or CD137L. Cells were sorted again by FACS to
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obtain

IL15+CD86+

or

IL15+CD137L+

as

single

cell

clones

A3

(IL15+CD86+CD137Lneg) and D4 (IL15+CD86negCD137L+), respectively. Single cell
sorting FACS was also used to make a single cell clone (A6; IL15+CD86negCD137Lneg)
of cells electroporated once. Each cell line was negative for mycoplasma and microbial
pathogens.

VI.B.2.c. Lenitviral Packaging and Gene Transduction
Lentivirus particles were packaged according to a modified version of a protocol
described elsewhere.(357) Briefly, packaging cells (293-METR) were plated on flasks
and transfected the following day with pCMV R8.2, VSV-G, and pLVU3G-effLucT2A-mKateS158A (Figure 45) plasmids in conjunction with Lipofectamine 2000
transfection reagent according to manufacturer’s instructions (Invitrogen). Virus-like
particles were harvested 48 and 72 hours post-transfection and were concentrated on
100 kDa NMWL filters (cat#UFC810096, MilliPore, Billerica, MA). CAOV3 cells
were plated on wells of a 6 well plate, and the following day ffluc-mKate virus particles
were added with 8 µg/ml polybrene then plate was spun at 1,800 rpm for 1.5 hours. The
same was done for Kasumi2, except that polybrene was not added. Six hours later, the
viral-conditioned supernatant was removed and the tissue culture media was
immediately changed and changed the following day. Transduced CAOV3 were subcultured and single-cell clones were derived from limiting dilution that displayed the
same morphology as the parental cell line and had uniform mKate fluorescence with
high (>106 signal to noise ratio) ffLuc activity. CAOV3 clone 1C2 was used for mouse
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experiments. Kasumi2 were sorted for mKate and were used as a bulk population for
mouse experiments (Figure 17a and 17b).
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Figure 45. DNA Plasmid Map for pLVU3G-effLuc-T2A-mKateS158A. Annotations
are, LTR: long terminal repeat; HIV cPPT: HIV central polypurine tract; B1: Gateway
donor site B1; effLuc: enhanced firefly Luciferase; T2A: T2A ribosomal slip site;
mKate S158A: enhanced mKate red fluorescence protein; B2: Gateway donor site B2;
HBV PRE: Hepatitis B post-translational regulatory element; HIV SIN LTR: HIV selfinactivating long terminal repeat; ampR: ampicillin resistance (β-Lactamase).
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VI.B.3. Primary Tumor Cells
PBMC were isolated by Ficoll-Hypaque (GE Healthcare) from patients with CLL
diagnosis after informed consent was granted. Samples were cryopreserved and were
thawed and used the day of the experiments. All cells frozen at the Cooper Lab were
cryopreserved in 50% FBS, 40% RPMI, 10% dimethylsulfoxide (DMSO) termed “free
media.” All patient samples were maintained in RPMI-CM.

VI.B.4. Lymphocyte Cultures
All PBMC from adult donor blood or UCB used in this dissertation were obtained after
informed consent and were isolated from whole blood by Ficoll-Hypaque or steadystate apheresis. PBMC were cryopreserved and thawed for experimental use whereas
UCB were freshly isolated and immediately used. All aAPC were γ-irradiated (100 Gy)
prior to co-culture and were then used immediately or were cryopreserved then thawed
at the time of the co-culture. Validation of co-expression of cell surface markers (for
example CD19, CD64, CD86, CD137L, and IL15 (co-expressed with eGFP) for clone
#4) were performed before addition to T-cell cultures. All lymphocyte cultures were
maintained in RPMI-CM.

VI.B.4.a. CARneg αβ T cells
γ-irradiated clone#4 aAPC were loaded with OKT3 antibody, which is agonistic for
CD3 thereby leading to T cell proliferation independent of the TCR specificity, by
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OKT3 antibody docking on CD64 (high-affinity Fc Receptor) expressed on aAPC.
CD3+ T cells were stimulated with an equal number of OKT3-loaded clone#4 cells in
the presence of exogenous IL2 (50 U/mL; Aldeleukin; Novartis, Switzerland) and IL21
(30 ng/mL; cat#AF20021; Peprotech, Rocky Hill, NJ) unless otherwise stated.
Exogenous IL2 and IL21 were added back to cultures every 2-3 days along with at least
half of the current volume of RPMI-CM.

VI.B.4.b. CAR+ αβ T cells
CAR+ T cells were propagated based on modified standard operating protocols as
previously described.(57, 273) Cryopreserved PBMC were thawed the day of the
electroporation (designated day 0) and rested for 2 hours in RPMI-CM at 37oC. Cells
for electroporation were spun at 200g for 10 minutes, enumerated, and 2x107 cells were
mixed with DNA (5 µg SB11 transposase and 15 µg SB transposon) in Human T cell
Nucleofector Solution (cat#VPA-1002, Lonza) then added to a cuvette, which was then
electroporated on the U-014 program of Amaxa Nucleofector II (Lonza). Transfected
cells were then added to wells of a 6-well plate containing phenol-free RPMI, 20%
FBS, and 1x Glutamax-100. The following day, electroporated T cells were phenotyped
and stimulated with aAPC according to their CAR expression. A ratio of 2:1 of clone#4
to CD19-specific CAR+ T cells was used and a 1:1 ratio of clone#1 to ROR1-specific
CAR+ T cells was used. Each co-culture was supplemented with IL21 during the first
week (given every 2-3 days) and with both IL2 and IL21 for the subsequent weeks.
CAR expression was evaluated each week in order to do the stimulation according to
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CAR+ T cells. If NK cells reached >10% of the total populations, they were depleted
from co-cultures with paramagnetic CD56 microbeads (cat#130-050-401, Miltenyi
Biotec, Auburn, CA) and LS columns (cat#130-042-401, Miltenyi Biotec). Stocks were
made of CAR+ T cells at days 14, 21, 28, and 35 (where applicable), and inferred cell
numbers were calculated by the number of cells that were generated multiplied by the
fold change from the previous week relative to the number of cells that were carried
forward. Phenotyping and functional analyses were performed between days 21 – 28
unless otherwise stated. For ROR1-specific CAR+ T cell studies, 3 normal donors were
tested in 3 independent experiments.

VI.B.4.c. CAR+ γδ T cells
CAR+ γδ T cells were generated as previously described.(311) Briefly, 108 PBMC were
electroporated as described above for CAR+ αβ T cells (Chapter VI.B.4.b.), and were
then sorted for γδ T cells using TCRγ/δ+ Isolation Kit (cat#130-092-892, Miltenyi
Biotec). Co-cultures were established with clone#4 along with IL2 and IL21 from the
start of the cultures where cytokines were added every 2-3 days and clone#4 aAPC was
added every 7 days at a 2:1 ratio with CAR+ γδ T cells. NK cells were depleted from cocultures when they reached >10% of total cells as described above. T cells were
phenotyped for CD3, Fc (CAR), CD56, and TCRγδ every week to monitor the cocultures. Cells were cryopreserved at days 21, 28, and 35 and inferred cell numbers
were calculated as described above. Functional assays were performed between the
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third and fifth weeks of stimulation. Six donors were tested in 3 independent
experiments.

VI.B.4.d. Polyclonal γδ T cells
Experiments were initiated to expand γδ T cells on aAPC that did not express a CAR.
Thawed PBMC (108) were depleted of NK cells as described above and were then
labeled with TCRγ/δ+ T-cell isolation kit and placed on LS columns to separate γδ T
cells in the unlabeled fraction from other cells attached to magnet. γδ T cells were
stimulated at a ratio of one T cell to two aAPC (clone #4) in presence of exogenous IL2
and IL21. Cells were serially re-stimulated with addition of aAPC every 7 days for three
weeks. FACS was used to isolate Vδ1 (TCRδ1+ TCRδ2neg), Vδ2 (TCRδ1neg TCRδ2+),
and Vδ3 (TCRδ1neg TCRδ2neg) populations, which were stimulated as above with
clone#4 aAPC twice and then phenotyped and used for functional assays. UCB-derived
mononuclear cells were isolated from fresh Ficoll-Hypaque gradients by FACS
following staining for TCRγδ and CD3, and were stimulated for five weeks on aAPC as
per PBMC. Ten PBMC donors were tested in six independent experiments and five
UCB donors were tested in four independent experiments. Four donors were tested in 2
independent experiments for Vδ sorting assays.
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VI.B.4.e. NK cells
As controls for killing and allogeneic reactivity, NK cells autologous to γδ T cells were
separated from healthy donor PBMC with CD56 microbeads and LS columns and were
then stimulated at a 1:2 ratio with clone#4 aAPC in cultures that were supplemented at
the initiation of culture and every 2-3 days later with IL2 and IL21.

VI.B.4.f. γδ T cell Proliferation in Hypoxia
A dedicated incubator set to 1% O2, 5% CO2, and 37oC under humidified conditions
was used to assess proliferation in hypoxia in parallel to “normal” tissue culture
incubators set at 20% O2, 5% CO2, and 37oC under humidified conditions. Parallel cocultures were added to the incubators and were analyzed after the reported times.

VI.B.5 γδ T cell Co-culture Deconstruction
Experiments were implemented to assess the relative contribution of co-culture
molecules to γδ T cell proliferation. This was dissected by cytokine dependence and
dependence upon molecules on the aAPC using new aAPC described in Chapter
VI.B.2.b. (Figure 28).
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VI.B.5.a. Effects of Cytokines on γδ T cell Proliferation
In order to assess the dependence of γδ T cells on cytokines for proliferation, cocultures were initiated with 105 γδ T cells and 2x105 clone#4 aAPC and then were
added to an equal volume of (i) complete media (CM), (ii) CM and 100 U/mL IL2, (iii)
CM and 60 ng/mL IL21, or (iv) CM, 100 U/mL IL2, and 60 ng/mL IL21. Co-cultures
were counted 9 days after initiation to determine yields. Three donors were tested in
two independent experiments.

VI.B.5.b. Effects of Co-Stimulation on γδ T cell Proliferation
HLA-/- aAPC (Chapter VI.B.2.b) were used to assess effects of co-stimulation on γδ T
cell growth. Co-cultures were then initiated with 105 γδ T cells in CM, 100 U/mL IL2,
and 60 ng/mL IL21 and were added to 2x105 γ-irradiated (i) parental K562 cells, (ii)
clone A6, (iii) clone A3, (iv) clone D4, (v) clone#4 aAPC, or (vi) no aAPC. Co-cultures
were counted 9 days as above with cytokine experiments. Three donors were tested in
two independent experiments.

VI.C. Multiplex Gene Expression Analysis
At Day 22 of co-culture on aAPC, >105 T cells were lysed at a ratio of 5 µL RLT Buffer
(Qiagen) per 3x104 cells and frozen at -80oC in replicate vials for one time use. RNA
lysates were thawed and immediately analyzed using nCounter Analysis System
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(NanoString Technologies, Seattle, WA) with “designer TCR expression array”
(DTEA) as previously described or with “lymphocyte codeset array” (LCA; Appendix
A).(290, 311) DTEA data was normalized to both spike positive control RNA and
housekeeping genes (ACTB, G6PD, OAZ1, POLR1B, POLR2A, RPL27, Rps13, and
TBP) where 2 normalization factors were calculated and applied to the raw coutns. Each
normalization factor was calculated from the average of sums for all samples divided by
the sum of counts for an individual sample. Reported expression of TCR frequencies for
ROR1-specific T cells (Figure 14) was calculated as counts for each TCRα or TCRβ
allele over the total sum of TCRα or TCRβ counts, respectively. Total counts for LCA
genes described in ROR1-specific CAR+ T cells (Figures 12 and 13) and for TCRδ and
TCRγ alleles in polyclonal γδ T cells were directly reported as normalized counts
(Figure 30). For Vδ sorted γδ T cells, the normalized counts were reported at
frequencies of each Vδ population per donor for each TCRδ or TCRγ allele (Figure
32). For example, %Vδ1*01 = (Vδ1*01)Vδ1 / [(Vd1*01)Vδ1 + (Vδ1*01)Vδ2 +
(Vδ1*01)Vδ3].

VI.D. Immunostaining
Antibodies directly conjugated to FITC, PerCP/Cy5.5, PE, and APC were used at 1:20,
1:33, 1:40, and 1:40 dilutions, respectively, in 100 µL FACS buffer (PBS, 0.1% FBS,
0.1% sodium azide) unless otherwise stated. A complete list of antibodies, clonotypes,
and vendors can be found in Appendix B. CAR detection was primarily performed with
anti-human Fc antibody (Invitrogen). CD19-specific CAR was stained with an idiotypic
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antibody conjugated to AlexFluor-647 in some instances.(259) BD FACS CAlibur was
used for most flow cytometry. Samples were analyzed with FlowJo software (version
7.6.5). BD FACS Aria Ilu II was used to sort cells where appropriate and was used to
isolate single cell clones in 96 well plates for aAPC cloning strategies. Tumor cells
transduced with ffLuc-mKate lentivirus particles were sorted for mKate expression on
BD Influx for bulk populations or as single cell clones as appropriate.

VI.E. Cytokine Production
Expression of cytokines was assessed by intracellular cytokine staining (ICS) and
secretion of cytokines into tissue culture supernatants was evaluated by Luminex
multiplex analysis. Co-cultures were set up with T cells and targets as described for
each experiment and were incubated at 37oC. For ICS, Brefeldin-A (GolgiPlug; BD
Biosciences) was added to co-cultures to block exocytosis and secretion of cytokines
produced in response to agonists. All ICS experiments were incubated for 6 hours and
were then (i) stained for surface markers, e.g. CD3 and CAR, (ii) fixed and
permeabilized with BD Cytofix/Cytoperm (BD Biosciences), (iii) stained for
intracellular proteins, e.g. IFNγ and TNFα, and (iv) analyzed by flow cytometry. Cocultures to assess cytokine secretion were incubated for 24 hours and supernatants from
triplicate wells were pooled and analyzed by Bio-Plex Human Cytokine Group I 27plex Assay (#L50-0KCAF0Y, BioRad Technologies, Hercules, CA) using Luminex100
(xMap Technologies, Austin, TX).
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VI.F. In Vitro Killing Assays
VI.F.1. Chromium Release Assay
In vitro specific lysis was assessed using a standard 4-hour CRA, as previously
described.(57) Purified antibodies specific for NKG2D (clone 1D11; BD Biosciences),
DNAM1 (clone DX11; BD Biosciences), TCRγδ (clone B1; BD Biosciences), and
TCRγδ (clone IMMU510; Thermo Fisher, Pittsburg, PA) were used for neutralization
experiments at 0.3, 1.0, and 3.0 µg/mL final concentrations in CRA at E:T ratios of
12:1. Normal mouse serum was used as a negative control at the same concentrations.

VI.F.2. Long-term Killing Assay
Tumor cells were seeded in wells of 12-well plates at a density of 4x104 cells/well. The
following day, 5x105 γδ T cells were added to each well of the plate and an equal
number was added to a well without tumor cells (media only). One well of tumor cells
had an equal volume of RPMI-CM added as a positive control for growth. After 2 days,
supernatants were harvested, wells were washed in PBS, and remaining tumor cells
were harvested with trypsin-EDTA and were then enumerated. The frequencies of cells
remaining were normalized to mock treated tumor cells.
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VI.G. Mixed Lymphocyte Reactions
B cells from healthy donors were isolated with CD19 microbeads (cat#130-050-301,
Miltenyi Biotec) the day of each assay and were used as target cells in proliferation,
IFNγ production (ELISpot), and cytolysis assays. Standard 4-hour CRA were used for
the latter as described above. For proliferation assays, effector cells were labeled with
PKH26 red fluorescent dye according to manufacturer’s instructions (Sigma) and were
co-cultured with target cells for 4 days at 37oC at an E:T ratio of 5:1. Co-cultures were
stained for CD3, CD19, and CD56 then were analyzed by flow cytometry. Similarly,
IFNγ ELISpot plate (Mabtech, Mariemont, OH) was set up with effector (γδ T cells)
and target (B cells) at an E:T ratio of 0.3:1 and plate was incubated for 24 hours at 37oC
then stained according to manufacturer’s instructions, and spots were counted on
Immunospot (CTL, Shaker Heights, OH). OKT3-loaded aAPC were used as positive
controls and mock treated were used as negative controls along with autologous B cells.
Co-cultures of effectors and allogeneic PBMC (normalized to equal CD34+ cells) at a
4:1 ratio of effectors to CD34+ HSC were incubated at 37oC for 4 hours and were then
plated in wells of 6-well plates in semi-solid HSC-CFU Complete without EPO
(Miltenyi Biotec). After 12 days, individual colonies were counted under inverted
microscope. Colonies formed with effectors alone or targets alone were used to
normalize the relative number of colonies formed for each donor.

192

Drew C Deniger
VI.H. In Vivo Anti-tumor Activity
In vivo anti-tumor efficacy was assessed in NSG mice (NOD.Cg-Prkdcscid
Il2rγtm1Wjl/SzJ; Jackson Laboratories). Non-invasive BLI was performed during the
course of the experiments to measure tumor burden of cell lines expressing ffLuc
following

subcutaneous

D-Luciferin

(cat#122796,

Caliper,

Hopkinton,

MA)

administration with IVIS-100 Imager (Caliper). BLI was analyzed using Living Image
software (version 2.50, Xenogen, Caliper).

VI.H.1. ROR1-specific Anti-leukemia Effects
Kasumi-2-ffLuc-mKate cells (4x104 per mouse) were engrafted into NSG mice (n = 15)
intravenously (i.v.) the day before the first T cell dose (designated Day -1). The
following day (Day 0), treatment groups for mice with tumors were set up with (i) no
treatment (n = 5), (ii) ROR1RCD28 T cells (n = 5), and (iii) ROR1RCD137 T cells (n =
5). Mice were injected with T cells only as controls for xenogeneic reactivity (one
mouse per T cell type). T cell doses (107 total cells per mouse) were given on days 0, 7,
and 14. Frequencies for CAR expression for ROR1RCD28 were 96%, 91%, and 90%
and for ROR1RCD137 were 94%, 62%, and 46% on days 0, 7, and 14, respectively.
Survival was the primary endpoint for the study and BLI from tumor ffLuc was
monitored twice per week as above.
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VI.H.2. CD19-specific Anti-leukemia Activity
The anti-tumor effects of CD19-specific CAR+ γδ T cells were evaluated as previously
described.(311)

VI.H.3. γδ T cells Clearance of Ovarian Cancer
CAOV3-ffLuc-mkate (clone 1C2; 3x106 cells/mouse) tumors were established by
intraperitoneal (i.p.) injection and mice were randomly distributed into treatment
groups. Eight days later (designated Day 0), a dose escalation regimen was initiated
with polyclonal γδ T cells administered i.p. and PBS administered i.p. as a negative
control. T cell doses infused were 3x106, 6x106, 107, and 1.5x107 on days 0, 7, 14, and
21, respectively. BLI was monitored during the course of the experiment by weekly
monitoring of tumor ffLuc activity as above. Survival was the primary endpoint for the
experiment.
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APPENDICIES
Appendix A. Lymphocyte CodeSet Array
GENE ID
ABCB1

ABCG2

ACTB

ADAM19

AGER

AHNAK

AIF1

AIM2

AKT1

ALDH1A1

ANXA1

ANXA2P2

AP1

Apaf1

ARG1

ATM

ATP2B4

B2M

BACH2
BAD

Accession
NM_000

Target
Region
3910-

927.3

4010

NM_004
827.2
NM_001

285-385
1010-

Target Sequence
TATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAGAAAC
AACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGC
AGGATTTAGGAACGCACCGTGCACATGCTTGGTGGTCTTGTTAAGTGGAAACT
GCTGCTTTAGAGTTTGTTTGGAAGGTCCGGGTGACTCATCCCAACAT
TGCAGAAGGAGATCACTGCCCTGGCACCCAGCACAATGAAGATCAAGATCAT

101.2

1110

TGCTCCTCCTGAGCGCAAGTACTCCGTGTGGATCGGCGGCTCCATCCT

NM_023

1690-

GAGAAGGTGAATGTGGCAGGAGACACCTTTGGAAACTGTGGAAAGGACATG

038.3

1790

NM_001
136.3

340-440

NM_001

15420-

620.1

15520

NM_032
955.1
NM_004
833.1

315-415

607-707

NM_005

1772-

163.2

1872

NM_000
689.3
NM_000
700.1
NR_003
573.1
NM_002
228.3

11-111

515-615

257-357

140-240

AATGGTGAACACAGGAAGTGCAACATGAGAGATGCGAAGTGTGGGAAGA
GAAAGGAGACCAAGTCCAACTACCGAGTCCGTGTCTACCAGATTCCTGGGAA
GCCAGAAATTGTAGATTCTGCCTCTGAACTCACGGCTGGTGTTCCCAA
GGATTTGACCTGAATGTTCCTGGGGGTGAAATTGATGCCAGCCTCAAGGCTCC
GGATGTAGATGTCAACATCGCAGGGCCGGATGCTGCACTCAAAGTCG
AAAAGCGAGAGAAAAGGAAAAGCCAACAGGCCCCCCAGCCAAGAAAGCTAT
CTCTGAGTTGCCCTGATTTGAAGGGAAAAGGGATGATGGGATTGAAGGG
ACGTGCTGCACCAAAAGTCTCTCCTCATGTTAAGCCTGAACAGAAACAGATG
GTGGCCCAGCAGGAATCTATCAGAGAAGGGTTTCAGAAGCGCTGTTTG
TTCTTTGCCGGTATCGTGTGGCAGCACGTGTACGAGAAGAAGCTCAGCCCACC
CTTCAAGCCCCAGGTCACGTCGGAGACTGACACCAGGTATTTTGATG
ATTGCTGAGCCAGTCACCTGTGTTCCAGGAGCCGAATCAGAAATGTCATCCTC
AGGCACGCCAGACTTACCTGTCCTACTCACCGATTTGAAGATTCAAT
GAAATCAGAGACATTAACAGGGTCTACAGAGAGGAACTGAAGAGAGATCTG
GCCAAAGACATAACCTCAGACACATCTGGAGATTTTCGGAACGCTTTGC
ATATTGTCTTCTCCTACCAGAGAAGGACCAAAAAGGAACTTGCATCAGCACT
GAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTGGGCCTATT
ACACAGCCAGCCAGCCAGGTCGGCAGTATAGTCCGAACTGCAAATCTTATTTT
CTTTTCACCTTCTCTCTAACTGCCCAGAGCTAGCGCCTGTGGCTCCC

NM_181

1160-

TTCTGATGAAACTGCAGAATCTTTGCACACGGTTGGATCAGGATGAGAGTTTT

869.1

1260

TCCCAGAGGCTTCCACTTAATATTGAAGAGGCTAAAGACCGTCTCCG

NM_000
045.2
NM_000
051.3

505-605

30-130

AAGGAACTAAAAGGAAAGATTCCCGATGTGCCAGGATTCTCCTGGGTGACTC
CCTGTATATCTGCCAAGGATATTGTGTATATTGGCTTGAGAGACGTGG
ACGCTAAGTCGCTGGCCATTGGTGGACATGGCGCAGGCGCGTTTGCTCCGAC
GGGCCGAATGTTTTGGGGCAGTGTTTTGAGCGCGGAGACCGCGTGATA

NM_001

7640-

CTTCCCATAGTATCATCTGTCCTCTGGAATGACTCTCCTGTCCCTAAAGGGGTT

684.3

7740

AAGAGAGAGATCACCTAGAAATCCCTCTGGACACTTGTGGGTTCTT

NM_004
048.2

25-125

CGGGCATTCCTGAAGCTGACAGCATTCGGGCCGAGATGTCTCGCTCCGTGGCC
TTAGCTGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTATCCA

NM_021

3395-

TGTGGCACTGTTCATCTGCTGTCCCGAAGAAACCGAGAACACATTTGGTGCAC

813.2

3495

ACTACAGCGGTCTTAGCAGCAATACTGTTCCGAAGTATCCTCTCCTC

NM_004

195-295

CAGCTGTGCCTTGACTACGTAACATCTTGTCCTCACAGCCCAGAGCATGTTCC
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322.2
BATF

BAX

BCL10

Bcl2

BCL2L1

BCL2L11

Bcl6
Beta-arrestin
(ARRB2 and
ARRB2)
BHLHE41

BID

BIRC2

BMI1

BNIP3

C10RF24

C11ORF17

C5ORF13

C80RF70

CA9

CASP1

Caspase 9

CAT

CCL3

NM_006
399.3
NM_138
761.2
NM_003

AGATCCCAGAGTTTGAGCCGAGTGAGCAGGAAGACTCCAGCTCTGCA
825-925

694-794
1250-

CACTGTGGGTTGCAGGCCCAATGCAGAAGAGTATTAAGAAAGATGCTCAAGT
CCCATGGCACAGAGCAAGGCGGGCAGGGAACGGTTATTTTTCTAAATA
ATTTTTCTGGGAGGGGTGGGGATTGGGGGACATGGGCATTTTTCTTACTTTTG
TAATTATTGGGGGGTGTGGGGAAGAGTGGTCTTGAGGGGGTAATAAA
TGAAAATACCATCTTCTCTTCAACTACACTTCCCAGACCTGGGGACCCAGGGG

921.2

1350

CTCCTCCTTTGCCACCAGATCTACAGTTAGAAGAAGAAGGAACTTGT

NM_000

1525-

CCAAGCACCGCTTCGTGTGGCTCCACCTGGATGTTCTGTGCCTGTAAACATAG

633.2

1625

ATTCGCTTTCCATGTTGTTGGCCGGATCACCATCTGAAGAGCAGACG

NM_138

1560-

CTAAGAGCCATTTAGGGGCCACTTTTGACTAGGGATTCAGGCTGCTTGGGATA

578.1

1660

AAGATGCAAGGACCAGGACTCCCTCCTCACCTCTGGACTGGCTAGAG

NM_138

2825-

TGTTGGCACCAGAACTTAAAGCGATGACTGGATGTCTCTGTACTGTATGTATC

621.2

2925

NM_001
706.2

675-775

TGGTTATCAAGATGCCTCTGTGCAGAAAGTATGCCTCCCGTGGGTAT
GTTGTGGACACTTGCCGGAAGTTTATTAAGGCCAGTGAAGCAGAGATGGTTT
CTGCCATCAAGCCTCCTCGTGAAGAGTTCCTCAACAGCCGGATGCTGA

NM_004

1652-

CATTAATTTTTTGACTGCAGCTCTGCTTCTCCAGCCCCGCCGTGGGTGGCAAG

313.3

1752

CTGTGTTCATACCTAAATTTTCTGGAAGGGGACAGTGAAAAGAGGAG

NM_030
762.2

655-755

CGCCCATTCAGTCCGACTTGGATGCGTTCCACTCGGGATTTCAAACATGCGCC
AAAGAAGTCTTGCAATACCTCTCCCGGTTTGAGAGCTGGACACCCAG

NM_197

2095-

GCTTAGCTTTAGAAACAGTGCAACACTGGTCTGCTGTTCCAGTGGTAAGCTAT

966.1

2195

GTCCCAGGAATCAGTTTAAAAGCACGACAGTGGATGCTGGGTCCATA

NM_001

1760-

TGGGATCCACCTCTAAGAATACGTCTCCAATGAGAAACAGTTTTGCACATTCA

166.3

1860

TTATCTCCCACCTTGGAACATAGTAGCTTGTTCAGTGGTTCTTACTC

NM_005

1145-

CCTGGAGAAGGAATGGTCCACTTCCATTGAAATACAGAGTTCGACCTACTTGT

180.5

1245

AAAAGAATGAAGATCAGTCACCAGAGAGATGGACTGACAAATGCTGG

NM_004
052.2

325-425

NM_052

3526-

966.2

3626

NM_020
642.3

570-670

NM_001

990-

142474.1

1090

NM_016
010.2

665-765

NM_001

960-

216.2

1060

NM_033
292.2
NM_052

575-675
1850-

CACCTCGCTCGCAGACACCACAAGATACCAACAGGGCTTCTGAAACAGATAC
CCATAGCATTGGAGAGAAAAACAGCTCACAGTCTGAGGAAGATGATAT
TGCCCAATAGATTCAAGAGAAGCTAAGCGGAAATGGAGGGTGGAAGGTGTG
ATCTGTGGGACTGTCTGGGCCTGTTACTCATCCTGCTATCAATTTCTTA
GAACATCTCTAAGGACCTCTACATAGAAGTATATCCAGGGACCTATTCTGTCA
CTGTGGGCTCAAATGACTTAACCAAGAAGACTCATGTGGTAGCAGTT
AAACTCATTGTTTCCTTGTGGTAAGTGACCGAGATGCTGCCACAGGACCTGAG
ACACTGATGAATGGTGCTATTTTGGACTTTCAACATGCTCCTTGGCG
ACGATTACCGCAGCCAAGTGGCGCTGGCAAAACTGTTGTAGGTGTTCCTTCAG
GTAAAGTGTCTTCAAGTAGCAGCTCTTTGGGAAACAAACTTCAGACC
CAGGTCCCAGGACTGGACATATCTGCACTCCTGCCCTCTGACTTCAGCCGCTA
CTTCCAATATGAGGGGTCTCTGACTACACCGCCCTGTGCCCAGGGTG
ACAGGCATGACAATGCTGCTACAAAATCTGGGGTACAGCGTAGATGTGAAAA
AAAATCTCACTGCTTCGGACATGACTACAGAGCTGGAGGCATTTGCAC
CGCTGACTTGGCCTGGAACGAGGAATCTGGTGCCCTGAAAGGCCCAGCCGGA

813.2

1950

CTGCCGGGCATTGGGGCCGTTTGTTAAGCGGCACTCATTTTGCGGAGG

NM_001

1130-

ATGCTTCAGGGCCGCCTTTTTGCCTATCCTGACACTCACCGCCATCGCCTGGG

752.2

1230

NM_002
983.2

681-781

ACCCAATTATCTTCATATACCTGTGAACTGTCCCTACCGTGCTCGAG
CTGTGTAGGCAGTCATGGCACCAAAGCCACCAGACTGACAAATGTGTATCGG
ATGCTTTTGTTCAGGGCTGTGATCGGCCTGGGGAAATAATAAAGATGC

196

Drew C Deniger

CCL4

CCL5

CCNB1

CCND1

CCR1

CCR2

CCR4

CCR5

CCR6

CCR7

CD11b

CD16

CD160

CD19

NM_002
984.2
NM_002
985.2
NM_031
966.2
NM_053
056.2
NM_001
295.2
NM_001
123041.2
NM_005
508.4

CD276

CD28

CD38

CD3D

535-635

20-120

35-135

CACTGGAAACATGAGAGCCATCCTAATTGACTGGCTAGTACAGGTTCA
TTGAACACTTCCTCTCCAAAATGCCAGAGGCGGAGGAGAACAAACAGATCAT
CCGCAAACACGCGCAGACCTTCGTTGCCCTCTGTGCCACAGATGTGAA
CATCATTTGGGCCCTGGCCATCTTGGCTTCCATGCCAGGCTTATACTTTTCCAA
GACCCAATGGGAATTCACTCACCACACCTGCAGCCTTCACTTTCCT
ACATTCTGTTGTGCTCATATCATGCAAATTATCACTAGTAGGAGAGCAGAGAG
TGGAAATGTTCCAGGTATAAAGACCCACAAGATAAAGAAGCTCAGAG
GGTCCTTCTTAGCATCGTGCTTCCTGAGCAAGCCTGGCATTGCCTCACAGACC
TTCCTCAGAGCCGCTTTCAGAAAAGCAAGCTGCTTCTGGTTGGGCCC
TAGGAACATACTTCAGCTCACACATGAGATCTAGGTGAGGATTGATTACCTA

2830

GTAGTCATTTCATGGGTTGTTGGGAGGATTCTATGAGGCAACCACAGG

NM_031

935-

CTTTAACTGCGGGATGCTGCTCCTGACTTGCATTAGCATGGACCGGTACATCG

409.2

1035

CCATTGTACAGGCGACTAAGTCATTCCGGCTCCGATCCAGAACACTA

NM_001

1610-

TTCCGAAAACCAGGCCTTATCTCCAAGACCAGAGATAGTGGGGAGACTTCTT

838.2

1710

GGCTTGGTGAGGAAAAGCGGACATCAGCTGGTCAAACAAACTCTCTGA

NM_000
632.3
NM_000
570.3
NM_007
053.2

515-615

73-173

500-600

GCCCTCCGAGGGTGTCCTCAAGAGGATAGTGACATTGCCTTCTTGATTGATGG
CTCTGGTAGCATCATCCCACATGACTTTCGGCGGATGAAGGAGTTTG
CCTATTCCTGTTCTATGGTGGGGCTCCATTGCGAGACTTCAGATTGAGAAATC
AGATGAAGTTTCAAGAAAAGGAAACTGGCAGGTGACAGAGATGGGTG
TTGATGTTCACCATAAGCCAAGTCACACCGTTGCACAGTGGGACCTACCAGTG
TTGTGCCAGAAGCCAGAAGTCAGGTATCCGCCTTCAGGGCCATTTTT

NM_001

1770-

AGATTCACACCTGACTCTGAAATCTGAAGACCTCGAGCAGATGATGCCAACC

770.4

1870

TCTGGAGCAATGTTGCTTAGGATGTGTGCATGTGTGTAAGTGTGTGTG

0002.1

CD274

690-790

GAGATGAGCTAGGATGGAGAGTCCTTGAACCTGAACTTACACAAATTT
AACTTGAGGAAGAGCAAGCAGTCAGACCAAAATACCTACTGGGTCGGGAAGT

2730-

MDA_0

CD247

715-815

TGCGTGACTGTCCTGTCTCTCCTCATGCTAGTAGCTGCCTTCTGCTC
AGTGTGTGCCAACCCAGAGAAGAAATGGGTTCGGGAGTACATCAACTCTTTG

579.1

8CAR

CD244

280-380

TTCTGCAGCCTCACCTCTGAGAAAACCTCTTTGCCACCAATACCATGAAGCTC

NM_000

CD19RCD2

CD2

35-135

2-102

CAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACT
ACTGTGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACT

NM_001

1400-

TGGGTCTCACTACAAGCAGCCTATCTGCTTAAGAGACTCTGGAGTTTCTTATG

767.2

1500

TGCCCTGGTGGACACTTGCCCACCATCCTGTGAGTAAAAGTGAAATA

NM_016

1150-

AAGAGGAACCACAGCCCTTCCTTCAATAGCACTATCTATGAAGTGATTGGAA

382.2

1250

AGAGTCAACCTAAAGCCCAGAACCCTGCTCGATTGAGCCGCAAAGAGC

NM_198

1490-

TGGCAGGACAGGAAAAACCCGTCAATGTACTAGGATACTGCTGCGTCATTAC

053.1

1590

AGGGCACAGGCCATGGATGGAAAACGCTCTCTGCTCTGCTTTTTTTCT

NM_014
143.2

684-784

TAGGAGATTAGATCCTGAGGAAAACCATACAGCTGAATTGGTCATCCCAGAA
CTACCTCTGGCACATCCTCCAAATGAAAGGACTCACTTGGTAATTCTG

NM_001

2120-

ACATTTCTTAGGGACACAGTACACTGACCACATCACCACCCTCTTCTTCCAGT

024736.1

2220

GCTGCGTGGACCATCTGGCTGCCTTTTTTCTCCAAAAGATGCAATAT

NM_006
139.1

305-405

GCTTGTAGCGTACGACAATGCGGTCAACCTTAGCTGCAAGTATTCCTACAATC
TCTTCTCAAGGGAGTTCCGGGCATCCCTTCACAAAGGACTGGATAGT

NM_001

1035-

CCTTGACTCCTTGTGGTTTATGTCATCATACATGACTCAGCATACCTGCTGGTG

775.2

1135

CAGAGCTGAAGATTTTGGAGGGTCCTCCACAATAAGGTCAATGCCA

NM_000
732.4

110-210

TATCTACTGGATGAGTTCCGCTGGGAGATGGAACATAGCACGTTTCTCTCTGG
CCTGGTACTGGCTACCCTTCTCTCGCAAGTGAGCCCCTTCAAGATAC
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CD3E

CD4

CD40LG

CD44

CD58

CD63

CD69

CD80

CD86

CD8A

CDH1

CDK2

CDK4

CDKN1A

CDKN1B

CDKN2C

CEBPA

CFLAR

CIITA

CITED2

CLA

CLIC1

CMRF-35H

NM_000
733.2
NM_000
616.3
NM_000

75-175

835-935
1225-

AAGTAACAGTCCCATGAAACAAAGATGCAGTCGGGCACTCACTGGAGAGTTC
TGGGCCTCTGCCTCTTATCAGTTGGCGTTTGGGGGCAAGATGGTAATG
AGACATCGTGGTGCTAGCTTTCCAGAAGGCCTCCAGCATAGTCTATAAGAAA
GAGGGGGAACAGGTGGAGTTCTCCTTCCCACTCGCCTTTACAGTTGAA
GCATTTGATTTATCAGTGAAGATGCAGAAGGGAAATGGGGAGCCTCAGCTCA

074.2

1325

CATTCAGTTATGGTTGACTCTGGGTTCCTATGGCCTTGTTGGAGGGGG

NM_000

2460-

GTGGGCAGAAGAAAAAGCTAGTGATCAACAGTGGCAATGGAGCTGTGGAGG

610.3

2560

ACAGAAAGCCAAGTGGACTCAACGGAGAGGCCAGCAAGTCTCAGGAAAT

NM_001
779.2
NM_001
780.4
NM_001
781.1

478-578

350-450

460-560

GTGCTTGAGTCTCTTCCATCTCCCACACTAACTTGTGCATTGACTAATGGAAG
CATTGAAGTCCAATGCATGATACCAGAGCATTACAACAGCCATCGAG
GTCATCATCGCAGTGGGTGTCTTCCTCTTCCTGGTGGCTTTTGTGGGCTGCTGC
GGGGCCTGCAAGGAGAACTATTGTCTTATGATCACGTTTGCCATCT
AGGACATGAACTTTCTAAAACGATACGCAGGTAGAGAGGAACACTGGGTTGG
ACTGAAAAAGGAACCTGGTCACCCATGGAAGTGGTCAAATGGCAAAGA

NM_005

1288-

AAAGATCTGAAGGTCCCACCTCCATTTGCAATTGACCTCTTCTGGGAACTTCC

191.3

1388

TCAGATGGACAAGATTACCCCACCTTGCCCTTTACGTATCTGCTCTT

NM_006
889.3

146-246

TATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGGTGCTGC
TCCTCTGAAGATTCAAGCTTATTTCAATGAGACTGCAGACCTGCCA

NM_001

1320-

GCTCAGGGCTCTTTCCTCCACACCATTCAGGTCTTTCTTTCCGAGGCCCCTGTC

768.5

1420

TCAGGGTGAGGTGCTTGAGTCTCCAACGGCAAGGGAACAAGTACTT

NM_004

1230-

CGATAATCCTCCGATCTTCAATCCCACCACGTACAAGGGTCAGGTGCCTGAGA

360.2

1330

ACGAGGCTAACGTCGTAATCACCACACTGAAAGTGACTGATGCTGAT

NM_001
798.2

220-320

TCGCTGGCGCTTCATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGC
ACGTACGGAGTTGTGTACAAAGCCAGAAACAAGTTGACGGGAGAGGTG

NM_000

1055-

ACTTTTAACCCACACAAGCGAATCTCTGCCTTTCGAGCTCTGCAGCACTCTTA

075.2

1155

TCTACATAAGGATGAAGGTAATCCGGAGTGAGCAATGGAGTGGCTGC

NM_000

1975-

CATGTGTCCTGGTTCCCGTTTCTCCACCTAGACTGTAAACCTCTCGAGGGCAG

389.2

2075

GGACCACACCCTGTACTGTTCTGTGTCTTTCACAGCTCCTCCCACAA

NM_004
064.2

365-465

GCTTCCGAGAGGGGTTCGGGCCGCGTAGGGGCGCTTTGTTTTGTTCGGTTTTG
TTTTTTTGAGAGTGCGAGAGAGGCGGTCGTGCAGACCCGGGAGAAAG

NM_001

1295-

ATAATGTAAACGTCAATGCACAAAATGGATTTGGAAGGACTGCGCTGCAGGT

262.2

1395

TATGAAACTTGGAAATCCCGAGATTGCCAGGAGACTGCTACTTAGAGG

NM_004

1320-

GAGCTGGGAGCCCGGCAACTCTAGTATTTAGGATAACCTTGTGCCTTGGAAAT

364.2

1420

GCAAACTCACCGCTCCAATGCCTACTGAGTAGGGGGAGCAAATCGTG

NM_003
879.3
NM_000
246.3

445-545

470-570

CAAGACCCTTGTGAGCTTCCCTAGTCTAAGAGTAGGATGTCTGCTGAAGTCAT
CCATCAGGTTGAAGAAGCACTTGATACAGATGAGAAGGAGATGCTGC
GCCTGAGCAAGGACATTTTCAAGCACATAGGACCAGATGAAGTGATCGGTGA
GAGTATGGAGATGCCAGCAGAAGTTGGGCAGAAAAGTCAGAAAAGACC

NM_006

965-

AGGAGCTGCCCGAACTCTGGCTGGGGCAAAACGAGTTTGATTTTATGACGGA

079.3

1065

CTTCGTGTGCAAACAGCAGCCCAGCAGAGTGAGCTGTTGACTCGATCG

NM_003

2297-

CATGGGCTGTTAGGTTGACTTCAGTTTTGCCTCTTGGACAACAGGGGGTCTTG

006.3

2397

TACATCCTTGGGTGACCAGGAAAAGTTCAGGCTATGGGGGGCCAAAG

NM_001
288.4
NM_007
261.2

310-410

0-100

GTGATGGGGCCAAGATTGGGAACTGCCCATTCTCCCAGAGACTGTTCATGGT
ACTGTGGCTCAAGGGAGTCACCTTCAATGTTACCACCGTTGACACCAA
CGGGGAAGTGAGAGTCGGGGATCAGTCCTGCAAGCTACGGAGTCACTACAGG
GAGAGGTCTCATCACTAGAAATAGCCGAAGAACCTGCAGCCTCAACCA
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CREB1

CRIP1

CSAD

CSF2

CSNK2A1

CTGF

CTLA4

CTNNA1

CTNNB1

CTNNBL1

CX3C1

CX3CR1

CXCCR1

CXCL10

CXCL12

CXCL9

CXCR3

CXCR4

CYORF14

DAP10

DAP12

DEC1

DNAM-1

NM_004

4855-

379.3

4955

NM_001
311.4
NM_015
989.4
NM_000
758.2

269-369

205-305

475-575

TTTGATGGTAGGTCAGCAGCAGTGCTAGTCTCTGAAAGCACAATACCAGTCA
GGCAGCCTATCCCATCAGATGTCATCTGGCTGAAGTTTATCTCTGTCT
CAACCACCCCTGCTACGCAGCCATGTTTGGGCCTAAAGGCTTTGGGCGGGGC
GGAGCCGAGAGCCACACTTTCAAGTAAACCAGGTGGTGGAGACCCCAT
TCAAATTCTTCTGCCTAGCCTTAGCCATTAGAGAGAGGTCCTGCTAAAGATGG
ACTGCAAATGCGCTTGATGGAAGGAGATGTCAATTCCACTGAAGTCC
AGATGAGGCTGGCCAAGCCGGGGAGCTGCTCTCTCATGAAACAAGAGCTAGA
AACTCAGGATGGTCATCTTGGAGGGACCAAGGGGTGGGCCACAGCCAT

NM_177

1930-

CCATTCCCACCATTGTTCCTCCACCGTCCCACACTTTAGGGGGTTGGTATCTCG

559.2

2030

TGCTCTTCTCCAGAGATTACAAAAATGTAGCTTCTCAGGGGAGGCA

NM_001

1100-

ACCACCCTGCCGGTGGAGTTCAAGTGCCCTGACGGCGAGGTCATGAAGAAGA

901.2

1200

ACATGATGTTCATCAAGACCTGTGCCTGCCATTACAACTGTCCCGGAG

NM_005
214.3
NM_001
903.2

405-505

75-175

AGTCTGTGCGGCAACCTACATGATGGGGAATGAGTTGACCTTCCTAGATGATT
CCATCTGCACGGGCACCTCCAGTGGAAATCAAGTGAACCTCACTATC
TCGCCCAGCTAGCCGCAGAAATGACTGCTGTCCATGCAGGCAACATAAACTT
CAAGTGGGATCCTAAAAGTCTAGAGATCAGGACTCTGGCAGTTGAGAG

NM_001

1815-

TCTTGCCCTTTGTCCCGCAAATCATGCACCTTTGCGTGAGCAGGGTGCCATTC

098210.1

1915

CACGACTAGTTCAGTTGCTTGTTCGTGCACATCAGGATACCCAGCGC

NM_030
877.3
NM_002
996.3

855-955

140-240

TGATGCCAACAAACTGTATTGCAGTGAAGTGCTGGCCATATTGCTCCAGGAC
AATGATGAAAACAGGGAATTGCTTGGGGAGCTGGATGGAATCGATGTG
AGCACCACGGTGTGACGAAATGCAACATCACGTGCAGCAAGATGACATCAAA
GATACCTGTAGCTTTGCTCATCCACTATCAACAGAACCAGGCATCATG

NM_001

1040-

GGGCGCTCAGTCCACGTTGATTTCTCCTCATCTGAATCACAAAGGAGCAGGCA

337.3

1140

TGGAAGTGTTCTGAGCAGCAATTTTACTTACCACACGAGTGATGGAG

NM_000

1950-

GCAGCCACCAGTCCATTGGGCAGGCAGATGTTCCTAATAAAGCTTCTGTTCCG

634.2

2050

TGCTTGTCCCTGTGGAAGTATCTTGGTTGTGACAGAGTCAAGGGTGT

NM_001
565.1
NM_199
168.2

40-140

505-605

GCAGAGGAACCTCCAGTCTCAGCACCATGAATCAAACTGCGATTCTGATTTGC
TGCCTTATCTTTCTGACTCTAAGTGGCATTCAAGGAGTACCTCTCTC
GGGCCTGAGGTTTGCCAGCATTTAGACCCTGCATTTATAGCATACGGTATGAT
ATTGCAGCTTATATTCATCCATGCCCTGTACCTGTGCACGTTGGAAC

NM_002

1975-

CACCATCTCCCATGAAGAAAGGGAACGGTGAAGTACTAAGCGCTAGAGGAA

416.1

2075

GCAGCCAAGTCGGTTAGTGGAAGCATGATTGGTGCCCAGTTAGCCTCTG

NM_001
504.1
NM_001
008540.1
NR_001
544.2
NM_001
007469.1
NM_003
332.2
NM_017
418.2
NM_006
566.2

80-180

135-235

143-243

132-232

457-557

190-290

163-263

GTGAGTGACCACCAAGTGCTAAATGACGCCGAGGTTGCCGCCCTCCTGGAGA
ACTTCAGCTCTTCCTATGACTATGGAGAAAACGAGAGTGACTCGTGCT
GTCACTATGGGAAAAGATGGGGAGGAGAGTTGTAGGATTCTACATTAATTCT
CTTGTGCCCTTAGCCCACTACTTCAGAATTTCCTGAAGAAAGCAAGCC
GAGGCTGTCTGCCAACATCTTTCATCACTCTGCCTGCAACTATGAAAAATTTA
GTTCTAAAAAATGCAACCTTGCTAAATTGAGTACTAATAGGATTGGT
ATCCTCTTCCTGCTTTTGCTCCCAGTGGCTGCAGCTCAGACGACTCCAGGAGA
GAGATCATCACTCCCTGCCTTTTACCCTGGCACTTCAGGCTCTTGTT
CTGCACCTCATTCCAACTCCTACCGCGATACAGACCCACAGAGTGCCATCCCT
GAGAGACCAGACCGCTCCCCAATACTCTCCTAAAATAAACATGAAGC
AGGCCTTACTTTCCAGATCCAGATCCTTGTGCATACAACTGACTTGTGTGGGT
GAGGCTTGCAGAAAAAATCAGCTAGAACAGCCTTGGGGGTAGTGGCA
TAAACAGGATACGATAAAAGTCCTTAACCAAGACGCAGATGGGAAGAAGCG
TTAGAGCGAGCAGCACTCACATCTCAAGAACCAGCCTTTCAAACAGTTT
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DPP4

EGLN1

EGLN3

EIF1

ELF4

ENTPD1

Eomes

EPHA4

ETV6

FADD

FANCC

FAS

FASLG

FLT1

FLT3LG

FOS

FOXP3

FYN

FZD1

GAL3ST4

GARNL4

GAS2

GATA2

NM_001

2700-

CAGCAGTCAGCTCAGATCTCCAAAGCCCTGGTCGATGTTGGAGTGGATTTCCA

935.3

2800

GGCAATGTGGTATACTGATGAAGACCATGGAATAGCTAGCAGCACAG

NM_022

3975-

AGCAGCATGGACGACCTGATACGCCACTGTAACGGGAAGCTGGGCAGCTACA

051.1

4075

NM_022
073.3
NM_005
801.3
NM_001
421.3
NM_001
776.4

800-900

869-969

335-435

225-325

AAATCAATGGCCGGACGAAAGCCATGGT
AAGCTACATGGTGGGATCCTGCGGATATTTCCAGAGGGGAAATCATTCATAG
CAGATGTGGAGCCCATTTTTGACAGACTCCTGTTCTTCTGGTCAGATC
CCTGAACAGTCCTCGGTGAATCTGAGAGGAGAGGATGGGGTAAGGCAGAAG
CACCAGCTGTACTACTAGAAGGGAGCTTTTGGTGGTAGATCCCCTGGTG
AGCTCTGGAGGGCTCTGATAATCCCGTTGTCAGCTCTCTGAAAAGACAGCATG
GCTATTACCCTACAGCCCAGTGACCTGATCTTTGAGTTCGCAAGCAA
TTCGAGTAACTTTAGGAAAATGAGCTGCTGGACTCCTCAGTCAATCTGTCCTT
TCTAGTCAATGAAAAAGACAGGGTTTGAGGTTCCTTCCGAAACGGGG

NM_005

1670-

ATCCCATGCCCTGGGGTATTACCCAGACCCAACCTTTCCTGCAATGGCAGGGT

442.2

1770

GGGGAGGTCGAGGTTCTTACCAGAGGAAGATGGCAGCTGGACTACCA

NM_004
438.3

20-120

GCAGCGTTGGCACCGGCGAACCATGGCTGGGATTTTCTATTTCGCCCTATTTT
CGTGTCTCTTCGGGATTTGCGACGCTGTCACAGGTTCCAGGGTATAC

NM_001

3840-

GTATGAATATGAAATCAGAGACCAGGGCATGATGTTGCTAGGATTAGAGCCT

987.4

3940

CTCAGTCTGGCCTCTTCACCCAAGTGCAAGAACTCAGTCTCTTACTGT

NM_003

1560-

TGAGACTGCTAAGTAGGGGCAGTGATGGTTGCCAGGACGAATTGAGATAATA

824.2

1660

TCTGTGAGGTGCTGATGAGTGATTGACACACAGCACTCTCTAAATCTT

NM_000

2130-

GACTCAGTCAGACATGTTCACTAATGACTCAAGTGAGCCTTCGGTACTCCTGG

136.2

2230

TGCCCGCCCGGCCAGACCGTCAGCTTGATAATTACTAAAGCAAAGGC

NM_000
043.3
NM_000
639.1

90-190

625-725

CACCGGGGCTTTTCGTGAGCTCGTCTCTGATCTCGCGCAAGAGTGACACACAG
GTGTTCAAAGACGCTTCTGGGGAGTGAGGGAAGCGGTTTACGAGTGA
TCCATGCCTCTGGAATGGGAAGACACCTATGGAATTGTCCTGCTTTCTGGAGT
GAAGTATAAGAAGGGTGGCCTTGTGATCAATGAAACTGGGCTGTACT

NM_002

5615-

TTCAACTGCTTTGAAACTTGCCTGGGGTCTGAGCATGATGGGAATAGGGAGA

019.2

5715

CAGGGTAGGAAAGGGCGCCTACTCTTCAGGGTCTAAAGATCAAGTGGG

NM_001

927-

CCTCCCCAGAATGGAGGCAACGCCAGAATCCAGCACCGGCCCCATTTACCCA

459.2

1027

ACTCTGTACAAAGCCCTTGTCCCCATGAAATTGTATATAAATCATCCT

NM_005

1475-

ACTCAAGTCCTTACCTCTTCCGGAGATGTAGCAAAACGCATGGAGTGTGTATT

252.2

1575

GTTCCCAGTGACACTTCAGAGAGCTGGTAGTTAGTAGCATGTTGAGC

NM_014

1230-

GGGCCATCCTGGAGGCTCCAGAGAAGCAGCGGACACTCAATGAGATCTACCA

009.3

1330

CTGGTTCACACGCATGTTTGCCTTCTTCAGAAACCATCCTGCCACCTG

NM_002
037.3

765-865

GTCTTTGGAGGTGTGAACTCTTCGTCTCATACGGGGACCTTGCGTACGAGAGG
AGGAACAGGAGTGACACTCTTTGTGGCCCTTTATGACTATGAAGCAC

NM_003

2430-

GTGCCAATCCTGACATCTCGAGGTTTCCTCACTAGACAACTCTCTTTCGCAGG

505.1

2530

CTCCTTTGAACAACTCAGCTCCTGCAAAAGCTTCCGTCCCTGAGGCA

NM_024

1140-

CGAGCCCAAACCCTCAATCCCAATGCCCTCATCCATCCTGTTTCCACTGTTAC

637.4

1240

TGATCATCGCAGCCAGATATCAAGCCCTGCCTCTTTCGATTTGGGGT

NM_015

4140-

CCCACGGCTGGAAAGAGGCCTGTACGTTCTGGACGCGTTTTGTTGGCTGGGCT

085.4

4240

TCTGGAGGCACTGGCAAGGTCAAACTGCATTTCTTTAAGAACAGTTG

NM_005

915-

GATCTCCCGTGTGGATGGCAAAACATCCCCTATCCAAAGCAAATCTCCAACTC

256.3

1015

TAAAGGACATGAATCCAGATAACTACTTGGTGGTCTCTGCCAGTTAT

NM_032

1495-

GAAGAAGGAAGGGATCCAGACTCGGAACCGGAAGATGTCCAACAAGTCCAA

638.3

1595

GAAGAGCAAGAAAGGGGCGGAGTGCTTCGAGGAGCTGTCAAAGTGCATG
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GATA3

Gfi1

GILZ

GLIPR1

GLO1

GSK3B

GZMA

GZMB

GzmH

HDAC1

HDAC2

HES1

HLA-A

HOXA10

HOXA9

HOXB3

HOXB4

HPRT1

HRH1

HRH2

IAP

ICOS

ICOSLG

NM_001

2835-

AAGAGTCCGGCGGCATCTGTCTTGTCCCTATTCCTGCAGCCTGTGCTGAGGGT

002295.1

2935

AGCAGTGTATGAGCTACCAGCGTGCATGTCAGCGACCCTGGCCCGAC

NM_005

2235-

TCATCACTGGAGGTAAAAGCACAAGCAATGCCTGTGGACAAGATGTCATTCA

263.2

2335

TTCACTCAGCAAATGTTCATGGATCACCGGCTACCAAGGTACCAGGCA

NM_198

1400-

TTAAGCAGAGGCAACCTCTCTCTTCTCCTCTGTTTCGTGAAGGCAGGGGACAC

057.2

1500

NM_006
851.2

255-355

AGATGGGAGAGATTGAGCCAAGTCAGCCTTCTGTTGGTTAATATGGT
CTGCGTTCGAATCCATAACAAGTTCCGATCAGAGGTGAAACCAACAGCCAGT
GATATGCTATACATGACTTGGGACCCAGCACTAGCCCAAATTGCAAAA

NM_006

1240-

GGAAATGATATGGTACCCAGACACTGGGCTAGGCTGCAACTTTATCTCATTTA

708.1

1340

ATACTCCCAGCTGTCATGTGAGAAAGAAAGCAGGCTAGGCATGTGAA

NM_002

925-

ACTGATTATACCTCTAGTATAGATGTATGGTCTGCTGGCTGTGTGTTGGCTGA

093.2

1025

GCTGTTACTAGGACAACCAATATTTCCAGGGGATAGTGGTGTGGATC

NM_006
144.2
NM_004
131.3
NM_033
423.3
NM_004
964.2

155-255

540-640

705-805

785-885

AGACCCTACATGGTCCTACTTAGTCTTGACAGAAAAACCATCTGTGCTGGGGC
TTTGATTGCAAAAGACTGGGTGTTGACTGCAGCTCACTGTAACTTGA
ACACTACAAGAGGTGAAGATGACAGTGCAGGAAGATCGAAAGTGCGAATCT
GACTTACGCCATTATTACGACAGTACCATTGAGTTGTGCGTGGGGGACC
AAAAAAGGGACACCTCCAGGAGTCTACATCAAGGTCTCACACTTCCTGCCCT
GGATAAAGAGAACAATGAAGCGCCTCTAACAGCAGGCATGAGACTAAC
CAAGCCGGTCATGTCCAAAGTAATGGAGATGTTCCAGCCTAGTGCGGTGGTC
TTACAGTGTGGCTCAGACTCCCTATCTGGGGATCGGTTAGGTTGCTTC

NM_001

930-

AAGCCTATTATCTCAAAGGTGATGGAGATGTATCAACCTAGTGCTGTGGTATT

527.1

1030

ACAGTGTGGTGCAGACTCATTATCTGGTGATAGACTGGGTTGTTTCA

NM_004

1340-

TTGAGTTAATCAGCGTAAGGGGATTTCTAAAGCAGGCAATCCCTGTAGCCGC

649.5

1440

AGAGAATAAACGCCTTCCCAAAATGGCAACTTCCCACAGCCACATTTC

NM_002

1000-

GGAAGAGCTCAGATAGAAAAGGAGGGAGTTACACTCAGGCTGCAAGCAGTG

116.5

1100

ACAGTGCCCAGGGCTCTGATGTGTCCCTCACAGCTTGTAAAGTGTGAGA

NM_018

1503-

TTCTATAGAGATAGATATTGTCCTAAGTGTCAAGTCCTGACTGGGCTGGGTTT

951.3

1603

GCTGTCTTGGGGTCCCACTGCTCGAAATGGCCCCTGTCTTCGGCCGA

NM_152

1015-

GGCTCTAAACCTCAGGCCACATCTTTTCCAAGGCAAACCCTGTTCAGGCTGGC

739.3

1115

TCGTAGGCCTGCCGCTTTGATGGAGGAGGTATTGTAAGCTTTCCATT

NM_002
146.4

60-160

TGTCCGTTTAAATGCTGCTGGGAGACTCGTAAAAAAATCATCGTGGACCTGG
AGGATGAGAGGGGCGAGCTTTATTTCGGTCGGATTGCGGTGTGGTGGT

NM_024

1340-

CCTTTCTTTGTCCCCCACTCCCGATACCCAGCGAAAGCACCCTCTGACTGCCA

015.4

1440

GATAGTGCAGTGTTTTGGTCACGGTAACACACACACACTCTCCCTCA

NM_000
194.1

240-340

TGTGATGAAGGAGATGGGAGGCCATCACATTGTAGCCCTCTGTGTGCTCAAG
GGGGGCTATAAATTCTTTGCTGACCTGCTGGATTACATCAAAGCACTG

NM_000

3055-

GTGGCAGCTCAAAATGATATGTTTGAGTAGACGAACAGCTGACATGGAGTTC

861.2

3155

CCGTGCACCTACGGAAGGGGACGCTTTGAAGGAACCAAGTGCATTTTT

NM_022
304.1
NM_001
777.3
NM_012
092.2

600-700

897-997

640-740

GCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCGT
GGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGT
GCCATATTGGTTATTCAGGTGATAGCCTATATCCTCGCTGTGGTTGGACTGAG
TCTCTGTATTGCGGCGTGTATACCAATGCATGGCCCTCTTCTGATTT
AACTCTGGCACCCAGGCATGAAGCACGTTGGCCAGTTTTCCTCAACTTGAAGT
GCAAGATTCTCTTATTTCCGGGACCACGGAGAGTCTGACTTAACTAC

NM_015

1190-

CTGCTGGCGTTGGCTGTGATCCTGGAATGAGGCCCTTTCAAAAGCGTCATCCA

259.4

1290

CACCAAAGGCAAATGTCCCCAAGTGAGTGGGCTCCCCGCTGTCACTG
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ID2

IFNa1

IFNG

IFNGR1

IGF1R

IKZF1

IL10

IL10RA

IL12A

IL12RB1

IL12RB2

IL13

IL15

IL15Ra

IL17A

IL17F

IL17RA

IL18

IL18R1

IL18RAP

IL2

IL21R

IL22

NM_002
166.4
NM_024
013.1
NM_000

505-605

585-685
970-

CGGATATCAGCATCCTGTCCTTGCAGGCTTCTGAATTCCCTTCTGAGTTAATGT
CAAATGACAGCAAAGCACTGTGTGGCTGAATAAGCGGTGTTCATGA
ATCCCTCTCTTTATCAACAAACTTGCAAGAAAGATTAAGGAGGAAGGAATAA
CATCTGGTCCAACATGAAAACAATTCTTATTGACTCATACACCAGGTC
ATACTATCCAGTTACTGCCGGTTTGAAAATATGCCTGCAATCTGAGCCAGTGC

619.2

1070

TTTAATGGCATGTCAGACAGAACTTGAATGTGTCAGGTGACCCTGAT

NM_000

1140-

CCCGGGCAGCCATCTGACTCCAATAGAGAGAGAGAGTTCTTCACCTTTAAGT

416.1

1240

AGTAACCAGTCTGAACCTGGCAGCATCGCTTTAAACTCGTATCACTCC

NM_000
875.2

455-555

TCGGGGGGCCATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTG
TGGACTGGTCCCTGATCCTGGATGCGGTGTCCAATAACTACATTGTG

NM_006

4485-

CCGCTGTGTACTACTGTGTGCCTAGATTCCATGCACTCTCGTTGTGTTTGAAGT

060.3

4585

AAATATTGGAGACCGGAGGGTAACAGGTTGGCCTGTTGATTACAGC

NM_000
572.2
NM_001
558.2
NM_000
882.2

230-330

150-250

775-875

AAGGATCAGCTGGACAACTTGTTGTTAAAGGAGTCCTTGCTGGAGGACTTTA
AGGGTTACCTGGGTTGCCAAGCCTTGTCTGAGATGATCCAGTTTTACC
TGCCCAGCCCTCCGTCTGTGTGGTTTGAAGCAGAATTTTTCCACCACATCCTC
CACTGGACACCCATCCCAAATCAGTCTGAAAGTACCTGCTATGAAGT
CTTTCTAGATCAAAACATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGA
ATTTCAACAGTGAGACTGTGCCACAAAAATCCTCCCTTGAAGAACCG

NM_005

1292-

AGGAAAAGTGTTACTACATTACCATCTTTGCCTCTGCGCACCCCGAGAAGCTC

535.1

1392

ACCTTGTGGTCTACGGTCCTGTCCACCTACCACTTTGGGGGCAATGC

NM_001

1315-

CCTCCGTGGGACATTAGAATCAAATTTCAAAAGGCTTCTGTGAGCAGATGTAC

559.2

1415

CCTTTATTGGAGAGATGAGGGACTGGTACTGCTTAATCGACTCAGAT

NM_002
188.2

516-616

TTTCTTTCTGATGTCAAAAATGTCTTGGGTAGGCGGGAAGGAGGGTTAGGGA
GGGGTAAAATTCCTTAGCTTAGACCTCAGCCTGTGCTGCCCGTCTTCA

NM_172

1685-

AGGGTGATAGTCAAATTATGTATTGGTGGGGCTGGGTACCAATGCTGCAGGT

174.1

1785

CAACAGCTATGCTGGTAGGCTCCTGCCAGTGTGGAACCACTGACTACT

NM_002
189.2
NM_002
190.2
NM_052
872.3

39-139

240-340

210-310

CGCTCGCCCGGGGAGTCCAGCGGTGTCCTGTGGAGCTGCCGCCATGGCCCCG
CGGCGGGCGCGCGGCTGCCGGACCCTCGGTCTCCCGGCGCTGCTACTG
TACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGA
GAGATATCCCTCTGTGATCTGGGAGGCAAAGTGCCGCCACTTGGGCT
GCCCGCCTGTGCCAGGAGGTAGTATGAAGCTTGACATTGGCATCATCAATGA
AAACCAGCGCGTTTCCATGTCACGTAACATCGAGAGCCGCTCCACCTC

NM_014

3020-

CTACTATGTGGCGGGCATTTGGGATACCAAGATAAATTGCATGCGGCATGGC

339.4

3120

CCCAGCCATGAAGGAACTTAACCGCTAGTGCCGAGGACACGTTAAACG

NM_001
562.2

48-148

GACAGTCAGCAAGGAATTGTCTCCCAGTGCATTTTGCCCTCCTGGCTGCCAAC
TCTGGCTGCTAAAGCGGCTGCCACCTGCTGCAGTCTACACAGCTTCG

NM_003

2025-

GAATGAGGGGATTTTAAGTGTCTGAAGAGGCATTTTCTAGGGACCAGTGGGT

855.2

2125

GACTGAGTAACTGAAATGCTGCTTTCACTCCCTAACACCATGGATCTG

NM_003

2412-

GCTTGATGGACAATGGAGTGGGATTGAGACTGTGGTTTAGAGCCTTTGATTTC

853.2

2512

CTGGACTGGACTGACGGCGAGTGAATTCTCTAGACCTTGGGTACTTT

NM_000
586.2

300-400

AGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACAAACAG
TGCACCTACTTCAAGTTCTACAAAGAAAACACAGCTACAACTGGAGC

NM_021

2080-

CGTGTTTGTGGTCAACAGATGACAACAGCCGTCCTCCCTCCTAGGGTCTTGTG

798.2

2180

TTGCAAGTTGGTCCACAGCATCTCCGGGGCTTTGTGGGATCAGGGCA

NM_020
525.4

319-419

CTATCTGATGAAGCAGGTGCTGAACTTCACCCTTGAAGAAGTGCTGTTCCCTC
AATCTGATAGGTTCCAGCCTTATATGCAGGAGGTGGTGCCCTTCCTG
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IL23R

IL2RA

IL2RB

IL2RG

IL4

IL4R

IL5

IL6

IL6R

IL7R

IL9

INDO

IRF1

IRF2

IRF4

ITGA1

ITGA4

ITGA5

ITGAL

ITGB1

ITK

JAK1

JAK2

NM_144
701.2
NM_000

710-810
1000-

AACTGCAAATTCACCTGGATGATATAGTGATACCTTCTGCAGCCGTCATTTCC
AGGGCTGAGACTATAAATGCTACAGTGCCCAAGACCATAATTTATTG
CTTGGTAAGAAGCCGGGAACAGACAACAGAAGTCATGAAGCCCAAGTGAAA

417.1

1100

TCAAAGGTGCTAAATGGTCGCCCAGGAGACATCCGTTGTGCTTGCCTGC

NM_000

1980-

GTCCTGCTGCCCGAGCCAGGAACTGTGTGTGTTGCAGGGGGGCAGTAACTCC

878.2

2080

NM_000
206.1
NM_000
589.2
NM_000
418.2
NM_000
879.2
NM_000
600.1

595-695

625-725

705-805

105-205

220-320

CCAACTCCCTCGTTAATCACAGGATCCCACGAATTTAGGCTCAGAAGC
CCACAGCTGGACTGAACAATCAGTGGATTATAGACATAAGTTCTCCTTGCCTA
GTGTGGATGGGCAGAAACGCTACACGTTTCGTGTTCGGAGCCGCTTT
GACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCACAAGCAGC
TGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGG
ATCATCTCACCTATGCAGTCAACATTTGGAGTGAAAACGACCCGGCAGATTTC
AGAATCTATAACGTGACCTACCTAGAACCCTCCCTCCGCATCGCAGC
CCACAGAAATTCCCACAAGTGCATTGGTGAAAGAGACCTTGGCACTGCTTTCT
ACTCATCGAACTCTGCTGATAGCCAATGAGACTCTGAGGATTCCTGT
TGACAAACAAATTCGGTACATCCTCGACGGCATCTCAGCCCTGAGAAAGGAG
ACATGTAACAAGAGTAACATGTGTGAAAGCAGCAAAGAGGCACTGGCA

NM_000

993-

CTTTCTACATAGTGTCCATGTGCGTCGCCAGTAGTGTCGGGAGCAAGTTCAGC

565.2

1093

AAAACTCAAACCTTTCAGGGTTGTGGAATCTTGCAGCCTGATCCGCC

NM_002

1610-

TTGCTTTGACCACTCTTCCTGAGTTCAGTGGCACTCAACATGAGTCAAGAGCA

185.2

1710

TCCTGCTTCTACCATGTGGATTTGGTCACAAGGTTTAAGGTGACCCA

NM_000
590.1
NM_002
164.3
NM_002
198.1

300-400

50-150

510-610

AAGTACTAAAGAACAACAAGTGTCCATATTTTTCCTGTGAACAGCCATGCAA
CCAAACCACGGCAGGCAACGCGCTGACATTTCTGAAGAGTCTTCTGGA
CTATTATAAGATGCTCTGAAAACTCTTCAGACACTGAGGGGCACCAGAGGAG
CAGACTACAAGAATGGCACACGCTATGGAAAACTCCTGGACAATCAGT
CTGTGCGAGTGTACCGGATGCTTCCACCTCTCACCAAGAACCAGAGAAAAGA
AAGAAAGTCGAAGTCCAGCCGAGATGCTAAGAGCAAGGCCAAGAGGAA

NM_002

1375-

CAGTACCTGGAGCTTCTCTTTAACTCAGGACTCCAGCCCATTGGTAGACGTGT

199.2

1475

GTTTCTAGAGCCTGCTGGATCTCCCAGGGCTACTCACTCAAGTTCAA

NM_002
460.1

325-425

GGGCACTGTTTAAAGGAAAGTTCCGAGAAGGCATCGACAAGCCGGACCCTCC
CACCTGGAAGACGCGCCTGCGGTGCGCTTTGAACAAGAGCAATGACTT

NM_181

1875-

AAGTGGCAAGACTATAAGGAAAGAGTATGCACAACGTATTCCATCAGGTGGG

501.1

1975

GATGGTAAGACACTGAAATTTTTTGGCCAGTCTATCCACGGAGAAATG

NM_000

975-

GCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCCGGGGCGATTT

885.4

1075

ACAGATGCAGGATCGGAAAGAATCCCGGCCAGACGTGCGAACAGCTC

NM_002

925-

AGAAGACTTTGTTGCTGGTGTGCCCAAAGGGAACCTCACTTACGGCTATGTCA

205.2

1025

CCATCCTTAATGGCTCAGACATTCGATCCCTCTACAACTTCTCAGGG

NM_002

3905-

GTGAGGGCTTGTCATTACCAGACGGTTCACCAGCCTCTCTTGGTTTCCTTCCTT

209.2

4005

GGAAGAGAATGTCTGATCTAAATGTGGAGAAACTGTAGTCTCAGGA

NM_033

2000-

TTTTAACATTACCAAGGTAGAAAGTCGGGACAAATTACCCCAGCCGGTCCAA

666.2

2100

CCTGATCCTGTGTCCCATTGTAAGGAGAAGGATGTTGACGACTGTTGG

NM_005

3430-

GCCAGTAAAGAAGTCAGTATAGAACCACTAGCGAATAGTGTTGCTCTGGCAC

546.3

3530

AGACCACTGTGGTTGATGGCATGGCCCTCCAACTTGGAATAGGATTTT

NM_002
227.1
NM_004
972.2

285-385

455-555

GAGAACACCAAGCTCTGGTATGCTCCAAATCGCACCATCACCGTTGATGACA
AGATGTCCCTCCGGCTCCACTACCGGATGAGGTTCTATTTCACCAATT
CTCCTCCCGCGACGGCAAATGTTCTGAAAAAGACTCTGCATGGGAATGGCCT
GCCTTACGATGACAGAAATGGAGGGAACATCCACCTCTTCTATATATC
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JAK3

JunB
KIR2DL1
(NKAT1)/C
D158a
KIR2DL2
(NKAT6)/C
D158b
KIR2DL3
(NKAT2)/C
D158b

NM_000
215.2

1815

TGGAAGCAGCGAGCTTGATGAGCCAAGTGTCGTACCGGCATCTCGTGC

1155-

GCGCGCCTGGAGGACAAGGTGAAGACGCTCAAGGCCGAGAACGCGGGGCTG

229.2

1255

TCGAGTACCGCCGGCCTCCTCCGGGAGCAGGTGGCCCAGCTCAAACAGA

NM_014
218.2

NM_014
219.2

NM_015
868.2
NM_002

49 CD158d)

255.5

KIR2DS1
KIR2DS2
(NKAT5)/C
D158b
KIR2DS3

881-981

814-914

741-841

15-115

TCATCATCCTCTTCATCCTCCTCCTCTTCTTTCTCCTTCATCGCTGG
GCGTCCTGGCAGCAGAAGCTGCACCATGTCCATGTCACCCACGGTCATCATCC
TGGCATGTCTTGGGTTCTTCTTGGACCAGAGTGTGTGGGCACACGTG

TCCAGCCTTCTGTCAGTCAGCAGTGAAACTTATAAAATTTTTTGTG

NM_014
512.1
NM_012
312.2
NM_012

698-798

856-956

693-793

1527

(NKAT8)

314.3

KIR2DS5

NM_014

(NKAT9)

513.2

204-304

CTTCACCCACTGAACCAAGCTCCGAAACCGGTAACCCCAGACACCTACATGT
TCTGATTGGGACCTCAGTGGTCAAAATCCCTTTCACCATCCTCCTCTT
CAAGAGCCTGCAGGGAACAGAACAGTGAACAGCGAGGATTCTGATGAACAA
GACCATCAGGAGGTGTCATACGCATAATTGGATCACTGTGTTTTCACAC
GGCCTTCACCCACTGAACCAAGCTCCAAAACCGGTAACCCCAGACACCTACA
CGTTCTGATTGGGACCTCAGTGGTCAAACTCCCTTTCACCATCCTCCT
ACATACAAGAGGCTGCCTCTTAACACAGCACTTAGACACGTGCTGTTCCACCT
CCCTTCAGACTATCTTTCAGCCTTCTGCCAGCAGTAAAACTTATAAA
CTTCCTTCTGCACAGAGAGGGGACGTTTAACCACACTTTGCGCCTCATTGGAG
AGCACATTGATGGGGTCTCCAAGGGCAACTTCTCCATCGGTCGCATG

NM_013

1054-

CCAAATCTGGTAACCCCAGACACCTGCACATTCTGATTGGGACCTCAGTGGTC

289.2

1154

ATCATCCTCTTCATCCTCCTCCTCTTCTTTCTCCTTCATCTCTGGTG

KIR3DL2 (

NM_006

NKAT4)

737.2

CD158z)

CTCCGAAACCGGTAACCCCAGACACCTGCATGTTCTGATTGGGACCTCAGTGG

GACACGTGCTGTTCCACCTTCCCTCATGCTGTTTCACCTTTCCTCAGACTATTT

1427-

(KIRC1

GAGTCTGCAGGGAACAGAACAGCGAATAGCGAGGACTCTGATGAACAA

1551

313.1

KIR3DL3

TCTCCTTCATCGCTGGTGCTCCAACAAAAAAAATGCTGCGGTAATGGACCAA

1451-

NM_012

B1)

GAGGTGACATACACACAGTTGAATCACTGCGTTTTCACACAGAGAAAAA

535.3

(NKAT7)

KIR3DL1

GCAGGAAACAGAACAGCGAATAGCGAGGACTCTGATGAACAAGACCCTCAG

NM_020

KIR2DS4

(NKAT3/NK

GTGCTGCTGAAGGTCATGGATGCCAAGCACAAGAACTGCATGGAGTCATTCC

NM_002

KIR2DL4 (p

KIR2DL5A

1715-

NM_153
443.3

884-984

508-608

TGCCACCCACGGAGGGACCTACAGATGCTTCGGCTCTTTCCGTGCCCTGCCCT
GCGTGTGGTCAAACTCAAGTGACCCACTGCTTGTTTCTGTCACAGGA
CCTTGCGCCTCGTTGGACAGCTCCACGATGCGGGTTCCCAGGTCAACTATTCC
ATGGGTCCCATGACACCTGCCCTTGCAGGGACCTACAGATGCTTTGG

KIR3DS1 (

NM_001

1000-

CTCCAAATCTGGTAACCTCAGACACCTGCACATTCTGATTGGGACCTCAGTGG

NKAT10)

083539.1

1100

TCAAAATCCCTTTCACCATCCTCCTCTTCTTTCTCCTTCATCGCTGG

KIT

KLF10

Klf2

KLF4

NM_000
222.1
NM_005
655.1

5-105

570-670

CATCGCAGCTACCGCGATGAGAGGCGCTCGCGGCGCCTGGGATTTTCTCTGCG
TTCTGCTCCTACTGCTTCGCGTCCAGACAGGCTCTTCTCAACCATCT
GCTCAGGCAACAAGTGTGATTCGTCATACAGCTGATGCCCAGCTATGTAACC
ACCAGACCTGCCCAATGAAAGCAGCCAGCATCCTCAACTATCAGAACA

NM_016

1015-

GGAAGTTTGCGCGCTCAGACGAGCTCACGCGCCACTACCGAAAGCACACGGG

270.2

1115

CCACCGGCCATTCCAGTGCCATCTGTGCGATCGTGCCTTCTCGCGCTC

NM_004

1980-

CGAGCATTTTCCAGGTCGGACCACCTCGCCTTACACATGAAGAGGCATTTTTA

235.4

2080

AATCCCAGACAGTGGATATGACCCACACTGCCAGAAGAGAATTCAGT
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KLF6

KLRB1

KLRC1

NM_001

1165-

008490.1

1265

NM_002
258.2
NM_002
259.3

KLRD1

NM_002

(CD94)

262.3

KLRG1

LAIR1

LCK

LDHA

Lef1

LGALS3

LNK

LOC282997

LRP5

LRP6

LRRC32

MAD1L1

MAP2K1

MAPK14

MAPK3

MAPK8

MCL1

MIF

MMP14

NM_005
810.3

85-185

335-435

542-642

45-145

GGGATGCGTGTTCCAGCCAAAGCATGCCGTTCTGCACCCTACCCAGTTGCCTC
CAGGGCCTCTCCTTGGAAGGTCTTTTGAGGGCTAAAAAGGTCCTGTA
TGAGTTAAACTTACCCACAGACTCAGGCCCAGAAAGTTCTTCACCTTCATCTC
TTCCTCGGGATGTCTGTCAGGGTTCACCTTGGCATCAATTTGCCCTG
ACCTATCACTGCAAAGATTTACCATCAGCTCCAGAGAAGCTCATTGTTGGGAT
CCTGGGAATTATCTGTCTTATCTTAATGGCCTCTGTGGTAACGATAG
AGCCTGCTTCAGCTTCAAAACACAGATGAACTGGATTTTATGAGCTCCAGTCA
ACAATTTTACTGGATTGGACTCTCTTACAGTGAGGAGCACACCGCCT
TGCCTACGGCAACCCAAGCCCAGAATGACTATGGACCACAGCAAAAATCTTC
CTCTTCCAGGCCTTCTTGTTCTTGCCTTGTGGCAATAGCTTTGGGGCT

NM_002

1195-

GCACCTGAGGGTAGAAAGTCACTCTAGGAAAAGCCTGAAGCAGCCATTTGGA

287.3

1295

AGGCTTCCTGTTGGATTCCTCTTCATCTAGAAAGCCAGCCAGGCAGCT

NM_005

1260-

ATTAAGTGGACAGCGCCAGAAGCCATTAACTACGGGACATTCACCATCAAGT

356.2

1360

CAGATGTGTGGTCTTTTGGGATCCTGCTGACGGAAATTGTCACCCACG

NM_005

985-

CAGAATGGAATCTCAGACCTTGTGAAGGTGACTCTGACTTCTGAGGAAGAGG

566.1

1085

CCCGTTTGAAGAAGAGTGCAGATACACTTTGGGGGATCCAAAAGGAGC

NM_016

1165-

CCGTCACACATCCCATCAGATGTCAACTCCAAACAAGGCATGTCCAGACATC

269.3

1265

CTCCAGCTCCTGATATCCCTACTTTTTATCCCTTGTCTCCGGGTGGTG

NM_002
306.2

120-220

CAGCCGTCCGGAGCCAGCCAACGAGCGGAAAATGGCAGACAATTTTTCGCTC
CATGATGCGTTATCTGGGTCTGGAAACCCAAACCCTCAAGGATGGCCT

NM_005

4285-

CCTCCAGCCAGAAGTTAAACATCTGGGATATGACGTCTTCATGCCAGGGGCA

475.2

4385

CTCATTTCTTAGCAGCCTCTCTACATACATCTCTCAGGTGGTGCCAAG

NR_026
932.1

665-765

TGATCACATTCTACCTGGCATTATTTCATCTGAGTCCCTGTCCTAGCCCTTCTG
CCCATTAGACTGTAACCTTGTTTAGGGAAAGACCTGTGTCTTACTC

NM_002

2515-

TGGACACCAACATGATCGAGTCGTCCAACATGCTGGGTCAGGAGCGGGTCGT

335.1

2615

GATTGCCGACGATCTCCCGCACCCGTTCGGTCTGACGCAGTACAGCGA

NM_002

2185-

CTTAGATTATCCAGAAGGCATGGCAGTAGACTGGCTTGGGAAGAACTTGTAC

336.1

2285

TGGGCAGACACAGGAACGAATCGAATTGAGGTGTCAAAGTTGGATGGG

NM_005

3470-

CACCCTGGTGTGGGTTCTCCTGTTCTCTCTGTGCTCTTGCATTCTCTCATTCCCT

512.2

3570

TTTCCTCTATTGAGCAGAGCCTGGAGTTTGAGACTATGGAATCCA

NM_003
550.2

306-406

GAAGACCTGGGGGAAAACACCATGGTTTTATCCACCCTGAGATCTTTGAACA
ACTTCATCTCTCAGCGTGTGGAGGGAGGCTCTGGACTGGATATTTCTA

NM_002

970-

ACGGAATGGACAGCCGACCTCCCATGGCAATTTTTGAGTTGTTGGATTACATA

755.2

1070

GTCAACGAGCCTCCTCCAAAACTGCCCAGTGGAGTGTTCAGTCTGGA

NM_001
315.1
NM_002
746.2

450-550

580-680

TGGGCTCTGGCGCCTATGGCTCTGTGTGTGCTGCTTTTGACACAAAAACGGGG
TTACGTGTGGCAGTGAAGAAGCTCTCCAGACCATTTCAGTCCATCAT
AACGTGCTCCACCGAGATCTAAAGCCCTCCAACCTGCTCATCAACACCACCTG
CGACCTTAAGATTTGTGATTTCGGCCTGGCCCGGATTGCCGATCCTG

NM_139

945-

TCTCTGTAGATGAAGCTCTCCAACACCCGTACATCAATGTCTGGTATGATCCT

049.1

1045

TCTGAAGCAGAAGCTCCACCACCAAAGATCCCTGACAAGCAGTTAGA

NM_021

1260-

GCTGTAACTTCCTAGAGTTGCACCCTAGCAACCTAGCCAGAAAAGCAAGTGG

960.3

1360

CAAGAGGATTATGGCTAACAAGAATAAATACATGGGAAGAGTGCTCCC

NM_002
415.1

319-419

TCCTACAGCAAGCTGCTGTGCGGCCTGCTGGCCGAGCGCCTGCGCATCAGCC
CGGACAGGGTCTACATCAACTATTACGACATGAACGCGGCCAATGTGG

NM_004

1470-

GACAAGATTGATGCTGCTCTCTTCTGGATGCCCAATGGAAAGACCTACTTCTT

995.2

1570

CCGTGGAAACAAGTACTACCGTTTCAACGAAGAGCTCAGGGCAGTGG
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MPL

MYB

Myc

MYO6

NBEA

NCAM1

NCL

NFAT5

NFATC1

NFATC2

NFATC3

NKG2C

NKG2D

NKG2E

NKG2F

NM_005
373.2
NM_005

3245

ATAGCCAGTCACTGCCTTAAGAACATTTGATGCAAGATGGCCAGCACT

1610-

TCGGACACCGAGGAGAATGTCAAGAGGCGAACACACAACGTCTTGGAGCGCC

467.3

1710

AGAGGAGGAACGAGCTAAAACGGAGCTTTTTTGCCCTGCGTGACCAGA

NM_004

6655-

AAGTTGGGGAGATGGCACCTTCTCAGAGGATTGTGAAAATATGAGGAAGAAA

999.3

6755

CAAAACAGTGCATGTAGGAGCACAGGGCCACACAAAGGCATTCTATTG

NM_015

8645-

CTGAGAGCCCTTGAAGGACCAGAAAACTGCTTATTCCCACGCTTGATATCTGT

678.3

8745

CTCCAGCGAAGGCCACTGTATCATATACTATGAACGAGGGCGATTCA

NM_000

1620-

GGTATTTGCCTATCCCAGTGCCACGATCTCATGGTTTCGGGATGGCCAGCTGC

615.5

1720

TGCCAAGCTCCAATTACAGCAATATCAAGATCTACAACACCCCCTCT

NM_005

1492-

GAACAGAGATCGATGGGCGATCTATTTCCCTGTACTATACTGGAGAGAAAGG

381.2

1592

TCAAAATCAAGACTATAGAGGTGGAAAGAATAGCACTTGGAGTGGTGA

NM_173

3290-

CCCTGACAACTATTCAAACCCAGGACATCTCACAGCCTGGTACTTTTCCAGCA

214.1

3390

GTTTCTGCTTCTAGTCAGCTGCCCAACAGCGATGCACTATTGCAGCA

NM_172

2510-

CCAGTACCAGCGTTTCACCTACCTTCCCGCCAACGGTAACGCCATCTTTCTAA

390.1

2610

CCGTAAGCCGTGAACATGAGCGCGTGGGGTGCTTTTTCTAAAGACGC

NM_012

1815-

GACGGACATTGGAAGAAAGAACACGCGGGTGAGACTGGTTTTCCGAGTTCAC

340.3

1915

ATCCCAGAGTCCAGTGGCAGAATCGTCTCTTTACAGACTGCATCTAAC

NM_004

2190-

GTCCTTGAAGTTCCTCCATATCATAACCCAGCAGTTACAGCTGCAGTGCAGGT

555.2

2290

GCACTTTTATCTTTGCAATGGCAAGAGGAAAAAAAGCCAGTCTCAAC

NM_002

942-

TATGTGAGTCAGCTTATAGGAAGTACCAAGAACAGTCAAACCCATGGAGACA

260.3

1042

GAAAGTAGAATAGTGGTTGCCAATGTCTCAGGGAGGTTGAAATAGGAG

NM_007
360.1
NM_002
261.2
NM_013
431.2
NM_147
130.1

NKp44

NM_004

(CD336)

828.3

NKp46

NM_001

(CD335)

145457.1

Notch1

NR3C1

NR4A1

CAATGGCAGCAACAGGACCATGCTAGCTCCCAAGGCTTCTTCTACCA
AACTGTTGCATGGATCCTGTGTTTGCAACTGGGGAGACAGAAACTGTGGTTG

375.2

NKp30

NOS2

3145-

CAGTGGCACTTGGACTGCAATGCTTTACCTTGGACCTGAAGAATGTTACCTGT

NM_002

(CD337)

NKp80

895-995

NM_016
523.1
NM_000
625.4
NM_017
617.3

760-860

760-860

29-129

50-150

798-898

145-245

275-375

605-705

735-835

GGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTA
CACATTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTC
ACTCCTGAGCTCAAGAAATCAACACATCTTGGCCTCCCAAGTTGCTGGGATTA
CTGACACAAGCCACCGCCCCTGAGTGCTCATGTACCATTTAGCTTGT
TTATATTGGTCAACAGCAAAATGAACATTACTACTCAGCCTCCAACACATGCA
GTTTGCCTATACCAGGGATCCTGTCAAAATATACACCACTTATAGCT
GCATCTGTCCTCTCTCCTCAGGGAGGCAAGCATTTGATGCTCGAGGTCCCTGG
CAGTTGTGGTCCTTGGCAAGTGATGTGTGAGTCCCGTGTGTCATAGG
CTTCAACAGGTCACGGACCTTCCCTGGACCTCAGTTTCCTCACCTGTAGAGAG
AGAAATATTATATCACACTGTTGCAAGGACTAAGATAAGCGATGATG
TTTCATGGTTCCAAAGGAAAAGCAAGTGACCATCTGTTGCCAGGGAAATTAT
GGGGCTGTTGAATACCAGCTGCACTTTGAAGGAAGCCTTTTTGCCGTG
AAAAAGGAAGTTGTTCAAATGCCACTCAGTATGAGGACACTGGAGATCTAAA
AGTGAATAATGGCACAAGAAGAAATATAAGTAATAAGGACCTTTGTGC
TTGCCTGGGGTCCATTATGACTCCCAAAAGTTTGACCAGAGGACCCAGGGAC
AAGCCTACCCCTCCAGATGAGCTTCTACCTCAAGCTATCGAATTTGTC
CTGCCAGGCTTCACCGGCCAGAACTGTGAGGAAAATATCGACGATTGTCCAG
GAAACAACTGCAAGAACGGGGGTGCCTGTGTGGACGGCGTGAACACCT

NM_001

1665-

GCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAACTCGA

018077.1

1765

ATGAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATT

NM_002
135.3

155-255

CGGCCGGGTAGGGTGCAGCCTGAGGCTTGTTCAGCAGAACAGGTGCAAGCCA
CATTGTTGCCAAGACCTGCCTGAAGCCGGATTCTCCCCACTGCCTCCT
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NRIP1

NT5E

OPTN

P2RX7

p38

Pax5

PDCD1

PDCD1LG2

PDE3

PDE4

PDE7

PDK1

PECAM1

PHACTR2

PHC1

POP5

PPARA

PPP2R1A

PRDM1

PRF1

PROM1

PTGER2

PTK2

NM_003
489.2

335-435

NM_002

1214-

526.2

1314

NM_001
008211.1
NM_002
562.4
NM_006
303.3

625-725

340-440

507-607

TGACTCATGGAGAAGAGCTTGGCTCTGATGTGCACCAGGATTCTATTGTTTTA
ACTTACCTAGAAGGATTACTAATGCATCAGGCAGCAGGGGGATCAGG
ATTCGGGTTTTGAAATGGATAAACTCATCGCTCAGAAAGTGAGGGGTGTGGA
CGTCGTGGTGGGAGGACACTCCAACACATTTCTTTACACAGGCAATCC
TGAAGCTAAATAATCAAGCCATGAAAGGGAGATTTGAGGAGCTTTCGGCCTG
GACAGAGAAACAGAAGGAAGAACGCCAGTTTTTTGAGATACAGAGCAA
AGTTGGTGCACAGTGTCTTTGACACCGCAGACTACACCTTCCCTTTGCAGGGG
AACTCTTTCTTCGTGATGACAAACTTTCTCAAAACAGAAGGCCAAGA
CCCTCTCCCTGCTTGTGCTGCACAGGCTGCTCTGTGAGCACTTCAGGGTCCTG
TCCACGGTGCACACGCACTCCTCGGTCAAGAGCGTGCCTGAAAACCT

NM_016

2288-

CTCCAAGAGGAGCACACTTTGGGGAGATGTCCTGGTTTCCTGCCTCCATTTCT

734.1

2388

CTGGGACCGATGCAGTATCAGCAGCTCTTTTCCAGATCAAAGAACTC

NM_005
018.1
NM_025
239.3

175-275

235-335

CTTCTTCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCT
GCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGC
TGTGGAGCTGTGGCAAGTCCTCATATCAAATACAGAACATGATCTTCCTCCTG
CTAATGTTGAGCCTGGAATTGCAGCTTCACCAGATAGCAGCTTTATT

NM_000

3010-

CTGGCCAACCTTCAGGAATCCTTCATCTCTCACATTGTGGGGCCTCTGTGCAA

921.3

3110

CTCCTATGATTCAGCAGGACTAATGCCTGGAAAATGGGTGGAAGACA

NM_001

3855-

AATAATGGTGTATACCCTCATTCTCATTCCTGGGCAGCCCTTCCTTCCACCCTG

111307.1

3955

GCACCAAAATAATTTCTCCTCCATCCGTACCTTGCCTAGCCTCTCC

NM_002

2210-

GTAGCTCAACAAGGAATAGAGGGAGGAGTGTAATTTTGGTAGCTGGTGTTGA

604.2

2310

ATAGGGCCTTTGAGAATCAGACTGAACACAGTGAAATATGTGCCCAAA

NM_002

1170-

TGGATTGCCCATATCACGTCTTTACGCACAATACTTCCAAGGAGACCTGAAGC

610.3

1270

TGTATTCCCTAGAGGGTTACGGGACAGATGCAGTTATCTACATTAAG

NM_000

1365-

ATCTGCACTGCAGGTATTGACAAAGTGGTCAAGAAAAGCAACACAGTCCAGA

442.3

1465

TAGTCGTATGTGAAATGCTCTCCCAGCCCAGGATTTCTTATGATGCCC

NM_001

8350-

GGCAGAATGCCACTCTACCCTCAGGTCAATTTTATGGTATATGAAAATGCCAG

100164.1

8450

TAATATTTGTGCCACTTGCCAACTCGGGGGAGGAGGGGCTTTTCCCT

NM_004

2905-

ATACAGCTCCACCTACACCGGAATTACATGGCATCAACCCTGTGTTCCTGTCC

426.2

3005

AGTAATCCCAGCCGTTGGAGTGTAGAGGAGGTGTACGAGTTTATTGC

NM_015
918.3

560-660

GCTTCAGGCCCACTTGTTGAACAGAACAATCTGGGTAGCAACAGCATCTTCCA
CAGTTTTCCAAACTGGATAGCTGCCAACCAGCAGACATTACCCACTT

NM_001

5220-

GGGTGTGTTTGCTATACGAACATAATGGACGTGAAGTGGGGCAGAAACCCAG

001928.2

5320

AACTCAGCATTCAAGGATGCCCAGGAGAGCTGTCCCTGTTTTAAAGAG

NM_014

1440-

AACTTAACTCCTTGTGCATGGCCTGGCTTGTGGATCATGTATATGCCATCCGC

225.3

1540

GAGGCAGCCACCAGCAACCTGAAGAAGCTAGTGGAAAAGTTTGGGAA

NM_182
907.1

310-410

CATCCCTGCCAACCAGGAACTTCTTGTGTGGTATTGTCGGGACTTTGCAGAAA
GGCTTCACTACCCTTATCCCGGAGAGCTGACAATGATGAATCTCACA

NM_005

2120-

ACTGTTTTTCAGGGAGGTGGCTGGGTTTACACGCTAATCCCGATTCACCCTGT

041.3

2220

CCAAACTGCCTAAGCCCTCCGCCATTCTCAAGCCCTGCAGTCACAGC

NM_006

925-

AGCCTGCGGTCATCTCTCAATGACCCTCTGTGCTTGGTGCATCCATCAAGTGA

017.1

1025

AACCTGCAACAGCATCAGATTGTCTCTAAGCCAGCTGAATAGCAACC

NM_000

1410-

GTCAGAAGGAGCTACAAAACCTACCCTCAGTGAGCATGGTACTTGGCCTTTG

956.2

1510

GAGGAACAATCGGCTGCATTGAAGATCCAGCTGCCTATTGATTTAAGC

NM_005

1005-

GGTTCAAGCTGGATTATTTCAGTGGAACTGGCAATCGGCCCAGAAGAAGGAA

607.3

1105

TCAGTTACCTAACGGACAAGGGCTGCAATCCCACACATCTTGCTGACT
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PTPRK

RAC1

RAC2

RAP46

RARA

RHOA

RORA

RORC

RUNX1

RUNX2

S100A4

SATB1

SCAP2

SCML1

SCML2

SEL1L

SELL

SERPINE2

SHP-1

SIT1

SLA2

SLAMF1

SLAMF7

NM_001

4315-

GTGATCAACCGGATTTTTAGGATATGCAATCTAACAAGACCACAGGAAGGTT

135648.1

4415

ATCTGATGGTGCAACAGTTTCAGTACCTAGGATGGGCTTCTCATCGAG

NM_198

1250-

AAAGACCTTCGTCTTTGAGAAGACGGTAGCTTCTGCAGTTAGGAGGTGCAGA

829.1

1350

CACTTGCTCTCCTATGTAGTTCTCAGATGCGTAAAGCAGAACAGCCTC

NM_002

1069-

GCTGCCACAACTTGTGTACCTTCAGGGATGGGGCTCTTACTCCCTCCTGAGGC

872.3

1169

CAGCTGCTCTAATATCGATGGTCCTGCTTGCCAGAGAGTTCCTCTAC

NM_004

1490-

CTCTTGTGATCGTGTAGTCCCATAGCTGTAAAACCAGAATCACCAGGAGGTTG

323.3

1590

CACCTAGTCAGGAATATTGGGAATGGCCTAGAACAAGGTGTTTGGCA

NM_000
964.2

115-215

AGCCACCTAGCTGGGGCCCATCTAGGAGTGGCATCTTTTTTGGTGCCCTGAAG
GCCAGCTCTGGACCTTCCCAGGAAAAGTGCCAGCTCACAGAACTGCT

NM_001

1230-

GGTACTCTGGTGAGTCACCACTTCAGGGCTTTACTCCGTAACAGATTTTGTTG

664.2

1330

GCATAGCTCTGGGGTGGGCAGTTTTTTGAAAATGGGCTCAACCAGAA

NM_134

1715-

AAAATTAACCGAGACACTTTATATGGCCCTGCACAGACCTGGAGCGCCACAC

261.2

1815

ACTGCACATCTTTTGGTGATCGGGGTCAGGCAAAGGAGGGGAAACAAT

NM_001

1350-

CTCATCAATGCCCATCGGCCAGGGCTCCAAGAGAAAAGGAAAGTAGAACAGC

001523.1

1450

TGCAGTACAATCTGGAGCTGGCCTTTCATCATCATCTCTGCAAGACTC

NM_001
754.4

635-735

CAGCCATGAAGAACCAGGTTGCAAGATTTAATGACCTCAGGTTTGTCGGTCG
AAGTGGAAGAGGGAAAAGCTTCACTCTGACCATCACTGTCTTCACAAA

NM_004

1850-

GAAGCCACAGCAGTTCCCCAACTGTTTTGAATTCTAGTGGCAGAATGGATGA

348.3

1950

ATCTGTTTGGCGACCATATTGAAATTCCTCAGCAGTGGCCCAGTGGTA

NM_002
961.2

263-363

CAGGGACAACGAGGTGGACTTCCAAGAGTACTGTGTCTTCCTGTCCTGCATCG
CCATGATGTGTAACGAATTCTTTGAAGGCTTCCCAGATAAGCAGCCC

NM_001

1335-

TTCCGAAATCTACCAGTGGGTACGCGATGAACTGAAACGAGCAGGAATCTCC

131010.1

1435

CAGGCGGTATTTGCACGTGTGGCTTTTAACAGAACTCAGGGCTTGCTT

NM_003

3374-

TTTTACAGTTAATCCAGGAGAGGGAGTCCTTTGCCAACTGATGACCAACAGTT

930.3

3474

CCAAGCCAGATAGTCTCGTGAACAGTGACAATACAGAAATAAGGTGT

NM_001

925-

GCAACGTATGGTTCTTCTTCAGGGCTCTGCCTTGGCAACCCTCGGGCTGACAG

037540.1

1025

CATCCACAACACTTACTCAACTGACCATGCTTCTGCAGCACCACCTT

NM_006
089.2

360-460

ATTGGAAGCCCGTGACCCTCGCAATGCCACTTCAGTATGTATTGCTACGGTTA
TTGGAATTACTGGGGCCAGGTTACGGTTACGACTGGATGGTAGTGAC

NM_005

980-

GGGCAATCTAATAGCCCACATGGTTTTGGGTTACAGATACTGGGCTGGCATCG

065.4

1080

GCGTCCTCCAGAGTTGTGAATCTGCCCTGACTCACTATCGTCTTGTT

NM_000
655.3
NM_006
216.2

110-210

240-340

CTCCCTTTGGGCAAGGACCTGAGACCCTTGTGCTAAGTCAAGAGGCTCAATG
GGCTGCAGAAGAACTAGAGAAGGACCAAGCAAAGCCATGATATTTCCA
CGCTGCCTTCCATCTGCTCCCACTTCAATCCTCTGTCTCTCGAGGAACTAGGCT
CCAACACGGGGATCCAGGTTTTCAATCAGATTGTGAAGTCGAGGCC

NM_002

1734-

TGGTGCAGACGGAGGCGCAGTACAAGTTCATCTACGTGGCCATCGCCCAGTT

831.5

1834

CATTGAAACCACTAAGAAGAAGCTGGAGGTCCTGCAGTCGCAGAAGGG

NM_014
450.2

720-820

GCCCCAGCCCCCCGTAGCAGGGGCATGACTGTTTCCCAACCAGCACCCAAAG
ACGGGCGCCATTGCCAAGTCACAGGATGTGATCTACCCCGGACTTCCT

NM_032

1640-

AAAGGAAAGCTGAGATGATGTCTTACCGTAGCAGCAGATCTTGGATGGTCCA

214.2

1740

GGCTCTATGTGACCTCCAGAGCAAAGAGAAAGACTTCGGACAGTCTAG

NM_003
037.2
NM_021
181.3

580-680

215-315

GTGTCTCTTGATCCATCCGAAGCAGGCCCTCCACGTTATCTAGGAGATCGCTA
CAAGTTTTATCTGGAGAATCTCACCCTGGGGATACGGGAAAGCAGGA
GGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCA
GATGGAGGCTACTCCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCA
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SLC2A1

SMAD3

SNAI1

SOD1

SPI1

STAT1

STAT3

STAT4

STAT5A

STAT5B

Stat6

STMN1

TBX21

TBXA2R

Tcf7

TDGF1

TDO2

TEK

TERT

TF

TFRC

TGFA

TGFB1

NM_006

2500-

AGGCTCCATTAGGATTTGCCCCTTCCCATCTCTTCCTACCCAACCACTCAAATT

516.2

2600

AATCTTTCTTTACCTGAGACCAGTTGGGAGCACTGGAGTGCAGGGA

NM_005

4220-

TTAAAGGACAGTTGAAAAGGGCAAGAGGAAACCAGGGCAGTTCTAGAGGAG

902.3

4320

NM_005
985.2
NM_000
454.4
NM_003
120.1
NM_007
315.2

63-163

35-135

730-830

205-305

TGCTGGTGACTGGATAGCAGTTTTAAGTGGCGTTCACCTAGTCAACACG
GACCACTATGCCGCGCTCTTTCCTCGTCAGGAAGCCCTCCGACCCCAATCGGA
AGCCTAACTACAGCGAGCTGCAGGACTCTAATCCAGAGTTTACCTTC
GCCTATAAAGTAGTCGCGGAGACGGGGTGCTGGTTTGCGTCGTAGTCTCCTGC
AGCGTCTGGGGTTTCCGTTGCAGTCCTCGGAACCAGGACCTCGGCGT
CTCCGCAGCGGCGACATGAAGGACAGCATCTGGTGGGTGGACAAGGACAAG
GGCACCTTCCAGTTCTCGTCCAAGCACAAGGAGGCGCTGGCGCACCGCT
TTTGCTGTATGCCATCCTCGAGAGCTGTCTAGGTTAACGTTCGCACTCTGTGT
ATATAACCTCGACAGTCTTGGCACCTAACGTGCTGTGCGTAGCTGCT

NM_139

4535-

AGACTTGGGCTTACCATTGGGTTTAAATCATAGGGACCTAGGGCGAGGGTTC

276.2

4635

AGGGCTTCTCTGGAGCAGATATTGTCAAGTTCATGGCCTTAGGTAGCA

NM_003
151.2

789-889

AGACAATGGATCAGAGTGACAAGAATAGTGCCATGGTGAATCAGGAAGTTTT
GACACTGCAGGAAATGCTTAACAGCCTCGATTTCAAGAGAAAGGAGGC

NM_003

3460-

GAGACAGAGAGAGAGAAAGAGAGAGTGTGTGGGTCTATGTAAATGCATCTGT

152.2

3560

CCTCATGTGTTGATGTAACCGATTCATCTCTCAGAAGGGAGGCTGGGG

NM_012
448.3

200-300

AAGGAGAAGCCCTTCATCAGATGCAAGCGTTATATGGCCAGCATTTTCCCATT
GAGGTGCGGCATTATTTATCCCAGTGGATTGAAAGCCAAGCATGGGA

NM_003

2030-

AGAACATCCAGCCATTCTCTGCCAAAGACCTGTCCATTCGCTCACTGGGGGAC

153.3

2130

CGAATCCGGGATCTTGCTCAGCTCAAAAATCTCTATCCCAAGAAGCC

NM_203
401.1
NM_013
351.1
NM_001
060.3

287-387

890-990

385-485

CGTGGGTGGCGGCAGGACTTTCCTTATCCCAGTTGATTGTGCAGAATACACTG
CCTGTCGCTTGTCTTCTATTCACCATGGCTTCTTCTGATATCCAGGT
ACACAGGAGCGCACTGGATGCGCCAGGAAGTTTCATTTGGGAAACTAAAGCT
CACAAACAACAAGGGGGCGTCCAACAATGTGACCCAGATGATTGTGCT
CACACGCGCTCCTCCTTCCTCACCTTCCTCTGCGGCCTCGTCCTCACCGACTTC
CTGGGGCTGCTGGTGACCGGTACCATCGTGGTGTCCCAGCACGCCG

NM_003

2420-

ATTCCATTTCCAGTTCATCTATGGCAGTCCAGCCAGCTCCTGGGCAGCTTGAG

202.2

2520

AGGGCAAACCCAAAACCTCATGACAGCCAGAGCCTGTCTTTCAGCAT

NM_003

1567-

AAGGAAAGAAAACATCTTTAAGGGGAGGAACCAGAGTGCTGAAGGAATGGA

212.2

1667

AGTCCATCTGCGTGTGTGCAGGGAGACTGGGTAGGAAAGAGGAAGCAAA

NM_005
651.1
NM_000
459.2

0-100

615-715

AAGGTCAATGATAGCATCTGCCTAGAGTCAAACCTCCGTGCTTCTCAGACAGT
GCCTTTTCACCATGAGTGGGTGCCCATTTTTAGGAAACAACTTTGGA
CGAGTTCGAGGAGAGGCAATCAGGATACGAACCATGAAGATGCGTCAACAA
GCTTCCTTCCTACCAGCTACTTTAACTATGACTGTGGACAAGGGAGATA

NM_198

2570-

GGCTTCAAGGCTGGGAGGAACATGCGTCGCAAACTCTTTGGGGTCTTGCGGC

253.1

2670

TGAAGTGTCACAGCCTGTTTCTGGATTTGCAGGTGAACAGCCTCCAGA

NM_001
063.2

640-740

CTGCTCCACCCTTAACCAATACTTCGGCTACTCGGGAGCCTTCAAGTGTCTGA
AGGATGGTGCTGGGGATGTGGCCTTTGTCAAGCACTCGACTATATTT

NM_003

1220-

CAGTTTCCACCATCTCGGTCATCAGGATTGCCTAATATACCTGTCCAGACAAT

234.1

1320

CTCCAGAGCTGCTGCAGAAAAGCTGTTTGGGAATATGGAAGGAGACT

NM_003
236.2

780-880

TGCCACAGACCTTCCTACTTGGCCTGTAATCACCTGTGCAGCCTTTTGTGGGC
CTTCAAAACTCTGTCAAGAACTCCGTCTGCTTGGGGTTATTCAGTGT

NM_000

1260-

TATATGTTCTTCAACACATCAGAGCTCCGAGAAGCGGTACCTGAACCCGTGTT

660.3

1360

GCTCTCCCGGGCAGAGCTGCGTCTGCTGAGGCTCAAGTTAAAAGTGG
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TGFB2

TGFBR1

TIE1

TLR2

TLR8

TNF

TNFRSF18

TNFRSF1B

TNFRSF4

TNFRSF7

TNFRSF9

TNFSF10

TNFSF14

TOX

TP53

TRAF1

TRAF2

TRAF3

TSLP

TYK2

VEGFA

WEE1

ZAP70

NM_003

1125-

AAGCCAGAGTGCCTGAACAACGGATTGAGCTATATCAGATTCTCAAGTCCAA

238.2

1225

AGATTTAACATCTCCAACCCAGCGCTACATCGACAGCAAAGTTGTGAA

NM_004

4280-

GGGGAAATACGACTTAGTGAGGCATAGACATCCCTGGTCCATCCTTTCTGTCT

612.2

4380

CCAGCTGTTTCTTGGAACCTGCTCTCCTGCTTGCTGGTCCCTGACGC

NM_005

2610-

CATCGGGGAGGGGAACTTCGGCCAGGTCATCCGGGCCATGATCAAGAAGGAC

424.2

2710

NM_003
264.3

180-280

GGGCTGAAGATGAACGCAGCCATCAAAATGCTGAAAGAGTATGCCTCT
CTGCTTTCAACTGGTAGTTGTGGGTTGAAGCACTGGACAATGCCACATACTTT
GTGGATGGTGTGGGTCTTGGGGGTCATCATCAGCCTCTCCAAGGAAG

NM_138

2795-

GACAAAAACGTTCTCCTTTGTCTAGAGGAGAGGGATTGGGATCCGGGATTGG

636.3

2895

CCATCATCGACAACCTCATGCAGAGCATCAACCAAAGCAAGAAAACAG

NM_000

1010-

AGCAACAAGACCACCACTTCGAAACCTGGGATTCAGGAATGTGTGGCCTGCA

594.2

1110

CAGTGAAGTGCTGGCAACCACTAAGAATTCAAACTGGGGCCTCCAGAA

NM_004
195.2
NM_001
066.2
NM_003
327.2
NM_001
242.4
NM_001
561.4
NM_003
810.2
NM_003
807.2

445-545

835-935

200-300

330-430

255-355

115-215

270-370

AGGGGAAATTCAGTTTTGGCTTCCAGTGTATCGACTGTGCCTCGGGGACCTTC
TCCGGGGGCCACGAAGGCCACTGCAAACCTTGGACAGACTGCACCCA
CCCAGCTGAAGGGAGCACTGGCGACTTCGCTCTTCCAGTTGGACTGATTGTGG
GTGTGACAGCCTTGGGTCTACTAATAATAGGAGTGGTGAACTGTGTC
CCGTGCGGGCCGGGCTTCTACAACGACGTGGTCAGCTCCAAGCCGTGCAAGC
CCTGCACGTGGTGTAACCTCAGAAGTGGGAGTGAGCGGAAGCAGCTGT
CCAGATGTGTGAGCCAGGAACATTCCTCGTGAAGGACTGTGACCAGCATAGA
AAGGCTGCTCAGTGTGATCCTTGCATACCGGGGGTCTCCTTCTCTCCT
AGATTTGCAGTCCCTGTCCTCCAAATAGTTTCTCCAGCGCAGGTGGACAAAGG
ACCTGTGACATATGCAGGCAGTGTAAAGGTGTTTTCAGGACCAGGAA
GGGGGGACCCAGCCTGGGACAGACCTGCGTGCTGATCGTGATCTTCACAGTG
CTCCTGCAGTCTCTCTGTGTGGCTGTAACTTACGTGTACTTTACCAAC
ATTTTCAGAAGCCTCTGGAAAGTCGTGCACAGCCCAGGAGTGTTGAGCAATTT
CGGTTTCCTCTGAGGTTGAAGGACCCAGGCGTGTCAGCCCTGCTCCA

NM_014

3950-

AATGAGCAGCTTTGACTTTGACAGGCGGTTTGTGCAGGAAAGCACAGTGCCG

729.2

4050

TGTTGTTTACAGCTTTTCTAGAGCAGCTGTGCGACCAGGGTAGAGAGT

NM_000

1330-

GGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACC

546.2

1430

TCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGAC

NM_005

3735-

CGAGTGATGGGTCTAGGCCCTGAAACTGATGTCCTAGCAATAACCTCTTGATC

658.3

3835

CCTACTCACCGAGTGTTGAGCCCAAGGGGGGATTTGTAGAACAAGCC

NM_021

1325-

GTGGCCCTTCAACCAGAAGGTGACCTTAATGCTGCTCGACCAGAATAACCGG

138.3

1425

GAGCACGTGATTGACGCCTTCAGGCCCGACGTGACTTCATCCTCTTTT

NM_145

1795-

ATATGATGCCCTGCTTCCTTGGCCGTTTAAGCAGAAAGTGACACTCATGCTGA

725.1

1895

TGGATCAGGGGTCCTCTCGACGTCATTTGGGAGATGCATTCAAGCCC

NM_033
035.3
NM_003
331.3

395-495

485-585

CCGTCTCTTGTAGCAATCGGCCACATTGCCTTACTGAAATCCAGAGCCTAACC
TTCAATCCCACCGCCGGCTGCGCGTCGCTCGCCAAAGAAATGTTCGC
TCATCGCTGACAGCTGAGGAAGTCTGCATCCACATTGCACATAAAGTTGGTAT
CACTCCTCCTTGCTTCAATCTCTTTGCCCTCTTCGATGCTCAGGCCC

NM_001

1325-

GAGTCCAACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGC

025366.1

1425

ACATAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGAATGCAGAC

NM_003
390.2

5-105

TGCGTTTGAGTTTGCCGCGAGCCGGGCCAATCGGTTTTGCCAACGCATGCCCA
CGTGCTGGCGAACAAATGTAAACACGGAGATCGTGTGCCGGGCACTT

NM_001

1175-

GGAGCTCAAGGACAAGAAGCTCTTCCTGAAGCGCGATAACCTCCTCATAGCT

079.3

1275

GACATTGAACTTGGCTGCGGCAACTTTGGCTCAGTGCGCCAGGGCGTG
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ZNF516

p16

SHP2

NM_014

4830-

GGTGGGGGACGGCTTCATATACCTCTTCCTCAGTAATGCAAATGCGAGTTTTT

643.2

4930

GTGGTGGGGGTTAAGGCCCATAACAAAGGATCTTAAACCATGCAGTG

NM_000

975-

AAGCGCACATTCATGTGGGCATTTCTTGCGAGCCTCGCAGCCTCCGGAAGCTG

077.3

1075

TCGACTTCATGACAAGCATTTTGTGAACTAGGGAAGCTCAGGGGGGT

NM_002

4650-

TAGTCCCTAGGTTGCTACGGCTTATCATGTGCTTGGTAAAAGGTGATCGCAGG

834.3

4750

CD57/B3GA

NM_018

T1

644.3

145-245

TTCTCAGACGAGTTTACTTTACATGAGATGGAATCAGGCAGAGAGGC
CTGGACAGCGACCCCTTCTCAGACTCCAGTTGGGCCGGACTCTCCAAACCTGC
TTCCGCAATGGGTGGGTTGTGAGTGCTGGTAATGAGGAGCCGTGGGT

CD85/LILR

NM_001

2332-

AGCTGAGAAAACTAAGTCAGAAAGTGCATTAAACTGAATCACAATGTAAATA

B1

081637.1

2432

TTACACATCAAGCGATGAAACTGGAAAACTACAAGCCACGAATGAATG

NM_024

1675-

TTAGCAGGAGGCTCTCCTTGCTTGCACTCACCCTTTCTTATTGTCTTGCCCTGC

608.2

1775

ATCTGGGGGTCTGAATTTTTGGGAGCAGGCAATATCTGAAGGTGCA

NM_145

2570-

GCCCGGTGGTGTGTAGAGAAAAGCTGCTTGTTTACTCCTTAAGTCAATGTATT

043.2

2670

GGTGACTGTTGATTTGTTGAACAATTCAGGAATCAAGGGCTGTGGAG

Neil1

Neil2

PNK

POLR2A

POLR1B

IL-1alpha

IL-1beta

IL-12p40

Raf-1

IL-23p19

NM_003
681.3

3775-

TTCCAAGAAGCCAAAGACTCCTTCGCTTACTGTCTTCCTGTTGGGCCAGTCCG

3875

CTCGAGATGCTGAGAGAGCCAAGGATATTCTGTGCCGTCTGGAGCAT

NM_019

3320-

GGAGAACTCGGCCTTAGAATACTTTGGTGAGATGTTAAAGGCTGCTGGCTAC

014.3

3420

AATTTCTATGGCACCGAGAGGTTATATAGTGGCATCAGTGGGCTAGAA

NM_000

1085-

ACTCCATGAAGGCTGCATGGATCAATCTGTGTCTCTGAGTATCTCTGAAACCT

575.3

1185

CTAAAACATCCAAGCTTACCTTCAAGGAGAGCATGGTGGTAGTAGCA

NM_000
576.2

GGGACCAAAGGCGGCCAGGATATAACTGACTTCACCATGCAATTTGTGTCTTC
CTAAAGAGAGCTGTACCCAGAGAGTCCTGTGCTGAATGTGGACTCAA

1435-

GCAAGGCTGCAAGTACATCAGTTTTATGACAATCAGGAAGAATGCAGTGTTC

187.2

1535

TGATACCAGTGCCATCATACACTTGTGATGGATGGGAACGCAAGAGAT

NM_002

1990-

CCTATGGCATCGTATTGTATGAACTGATGACGGGGGAGCTTCCTTATTCTCAC

880.2

2090

ATCAACAACCGAGATCAGATCATCTTCATGGTGGGCCGAGGATATGC

NM_016
584.2

1.1

CD20_scfv_r

SCFV00

utuximab

2.1
SCFV00
4.1
SCFV00
6.1

Thymidine_k

SCFV00

inase

7.1
SCFV00
8.1

Human_CD1

SCFV00

9R_scfv

9.1

DECTIN-1R

840-940

NM_002

SCFV00

CD56R_scfv

CATTATCACGCCCAACCAGTTTGAGGCCGAGTTACTGAGTGGCCGGAA

937.2

gBAD-

CD45R_scfv

TCCCGGAGGACCTCCTTCCCGTCTACAAAGAAAAAGTGGTGCCGCTTGCAGA

NM_000

1R_scfv

c-MET_scfv

580-680

SCFV01
0.1

411-511

1-101

8-108

138-238

222-322

100-200

197-297

215-315

270-370

CAGGGACAACAGTCAGTTCTGCTTGCAAAGGATCCACCAGGGTCTGATTTTTT
ATGAGAAGCTGCTAGGATCGGATATTTTCACAGGGGAGCCTTCTCTG
AGACAGACACCCTGCTCCTCTGGGTGTCCGGCACCTGTGGCGACATCGTGATG
AGCAGAAGCCCCAGCAGCCTGGCCGTGTCCGTGGGCGAGAAAGTGAC
GCTGTCCCAGAGCCCCGCCATCCTGAGCGCCAGCCCTGGCGAGAAGGTGACC
ATGACCTGCCGGGCCAGCAGCTCTGTGAGCTACATGCACTGGTATCAG
CTGATCTACGCCGCCAGCAGCCTGAAGAGCGGCGTGCCCAGCCGGTTTAGCG
GCTCTGGCTCTGGCGCCGACTTCACCCTGACCATCAGCAGCCTGCAGC
TTCACCCTGAACATCCACCCCGTGGAGGAAGAGGACGCCGCCACCTACTACT
GCCAGCACAGCAGAGAGCTGCCCTTCACCTTCGGCTCCGGCACCAAGC
TCTACGTACCCGAGCCGATGACTTACTGGCAGGTGCTGGGGGCTTCCGAGAC
AATCGCGAACATCTACACCACACAACACCGCCTCGACCAGGGTGAGAT
ATTCAGCGGCTCTGGCTCCGGCACCGACTTCACTCTGATGATCTCTCGGGTGG
AGGCCGAGGACCTGGGCGTGTACTACTGCTTTCAGGGCAGCCACGTG
CTTCACCATCAGCAGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCAG
CAGTACCAGAGCCTGCCCTACACCTTCGGCCAGGGCACCAAGCTGCAG
CTGAAGATCGACAGCAGCAACGAGCTGGGCTTCATCGTGAAGCAGGTGTCCA
GCCAGCCCGACAACTCCTTCTGGATCGGCCTGAGCAGGCCCCAGACCG
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HERVK_6H5_scfv
CD19R_scfv

HER2_scfv

SCFV01
2.1
SCFV01
3.1
SCFV01
4.1

EGFR_scfv_

SCFV01

NIMO_CAR

5.1

RPL27

OAZ1

GABPa

XBP-1

MBD2

Bcl6b

TSLP-R

BTLA

HVEM

LTbR

CD43

mTOR

AMPK

SIP1

EphA2

CD254

BCLxL

Xbp1

IL27

NM_000
988.3
NM_004
152.2

137-237

204-304

64-164

7-107

23-123

313-413

CGGCGGCACCAGCTACAACCAGAAGTTCAAGGACAAGGCCATCCTGACCGTG
GACAAGAGCAGCAGCACCGCCTACATGGAACTGCGGAGCCTGACCAGC
GGCACCGACTACAGCCTGACCATCTCCAACCTGGAGCAGGAGGACATCGCCA
CCTACTTTTGCCAGCAGGGCAACACACTGCCCTACACCTTTGGCGGCG
CCTGCAGCGCCAGCAGCAGCGTGTCCTACATGCACTGGTATCAGCAGAAGTC
CGGCACTAGCCCCAAGCGGTGGATCTACGACACCTACAAGCTCGCCAG
AGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGCGACAGAGTGA
CCATCACCTGCCGGTCCAGCCAGAACATCGTGCACAGCAACGGCAACAC
GGGCCGGGTGGTTGCTGCCGAAATGGGCAAGTTCATGAAACCTGGGAAGGTG
GTGCTTGTCCTGGCTGGACGCTACTCCGGACGCAAAGCTGTCATCGTG
GGTGGGCGAGGGAATAGTCAGAGGGATCACAATCTTTCAGCTAACTTATTCT
ACTCCGATGATCGGCTGAATGTAACAGAGGAACTAACGTCCAACGACA

NM_002

1160-

GACCAAGTCCTGCATTGGGTGGTTTGGGTAATGAAGGAATTCAGCATGACCG

040.3

1260

ATATAGACCTCACCACACTCAACATTTCGGGGAGAGAATTATGTAGTC

NM_005
080.2

440-540

GGAGTTAAGACAGCGCTTGGGGATGGATGCCCTGGTTGCTGAAGAGGAGGCG
GAAGCCAAGGGGAATGAAGTGAGGCCAGTGGCCGGGTCTGCTGAGTCC

NM_003

2015-

ATTTACATTCAACTCTGATCCCTGGGCCTTAGGTTTGACATGGAGGTGGAGGA

927.3

2115

AGATAGCGCATATATTTGCAGTATGAACTATTGCCTCTGGACGTTGT

NM_181

2135-

CTTTATTTGTTCTAGGGCAGCTCTGGGAACATGCGGGATTGTGGAATTGGGTC

844.3

2235

AGGAACCCTCTCTGGTATTCTGGATGTTGTAGGTTCTCTAGCAGTCT

NM_022

1420-

CAAGGCAGCACGTCCAAAATGCTGTAAAACCATCTTCCCACTCTGTGAGTCCC

148.2

1520

CAGTTCCGTCCATGTACCTGTTCCATAGCATTGGATTCTCGGAGGAT

NM_001
085357.1

890-990

GCACCAACAGAATATGCATCCATATGTGTGAGGAGTTAAGTCTGTTTCTGACT
CCAACAGGGACCATTGAATGATCAGCATGTTGACATCATTGTCTGGG

NM_003

916-

CTCAGGGAGCCTCGTCATCGTCATTGTTTGCTCCACAGTTGGCCTAATCATAT

820.2

1016

GTGTGAAAAGAAGAAAGCCAAGGGGTGATGTAGTCAAGGTGATCGTC

NM_002

1435-

CTAACAGGGGCCCAAGGAACCAATTTATCACCCATGACTGACGGAGTCTGAG

342.1

1535

AAAAGGCAGAAGAAGGGGGGCACAAGGGCACTTTCTCCCTTGAGGCTG

NM_001

2798-

AAGCCAGGCTTCATGGAAAGATCGTATGTGTGACCCAAATATGAGTTCTTCA

030288.1

2898

GCTCAGCCATGGTAATCCCTTCCTTGAAGTCTCCATTTCTGCAGTACA

NM_004

5095-

TTAGTGTTGCTCCTGGGAGTTGATCCGTCTCGGCAACTTGACCATCCTCTGCC

958.2

5195

AACAGTTCACCCTCAGGTGACCTATGCCTACATGAAAAACATGTGGA

NM_006

975-

ATAGTGGTGACCCTCAAGACCAGCTTGCAGTGGCTTATCATCTTATCATTGAC

252.2

1075

AATCGGAGAATAATGAACCAAGCCAGTGAGTTCTACCTCGCCTCTAG

NM_001
009182.1

537-637

ACAAGCAACAGTAACTAGTGTCTTGGAATATCTGAGTAATTGGTTTGGAGAA
AGAGACTTTACTCCAGAATTGGGAAGATGGCTTTATGCTTTATTGGCT

NM_004

1525-

GAGCCGAGTGTGGAAGTACGAGGTCACTTACCGCAAGAAGGGAGACTCCAAC

431.2

1625

AGCTACAATGTGCGCCGCACCGAGGGTTTCTCCGTGACCCTGGACGAC

NM_003
701.2
NM_001
191.2

490-590

260-360

TACCTGATTCATGTAGGAGAATTAAACAGGCCTTTCAAGGAGCTGTGCAAAA
GGAATTACAACATATCGTTGGATCACAGCACATCAGAGCAGAGAAAGC
ATCTTGGCTTTGGATCTTAGAAGAGAATCACTAACCAGAGACGAGACTCAGT
GAGTGAGCAGGTGTTTTGGACAATGGACTGGTTGAGCCCATCCCTATT

NM_001

935-

ATTCATTGTCTCAGTGAAGGAAGAACCTGTAGAAGATGACCTCGTTCCGGAG

079539.1

1035

CTGGGTATCTCAAATCTGCTTTCATCCAGCCACTGCCCAAAGCCATCT

NM_145
659.3

143-243

CAGGAGCTGCGGAGGGAGTTCACAGTCAGCCTGCATCTCGCCAGGAAGCTGC
TCTCCGAGGTTCGGGGCCAGGCCCACCGCTTTGCGGAATCTCACCTGC
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IKZF2

GNLY

NFkB

NM_001

945-

079526.1

1045

NM_006
433.2
NM_001

2305-

165412.1

2405

GADD45alp

NM_001

ha

924.2

GADD45bet

NM_015

a

675.2

ATF3

MAD

Crem

SOCS1

SOCS3

DUSP16

Rps13

TBP

G6PD

Rbpms

KLF7

Vax2

RUNX3

ERK

ITCH

CBLB

DGKA

LTA

305-405

NM_001
030287.2
NM_002
357.2
NM_001
881.2

865-965

365-465

600-700

880-980

260-360

CCATGTACCTCCTATGGAAGATTGTAAGGAACAAGAGCCTATTATGGACAAC
AATATTTCTCTGGTGCCTTTTGAGAGACCTGCTGTCATAGAGAAGCTC
CAGGAGCTGGGCCGTGACTACAGGACCTGTCTGACGATAGTCCAAAAACTGA
AGAAGATGGTGGATAAGCCCACCCAGAGAAGTGTTTCCAATGCTGCGA
CTTGGGTAACTCTGTTTTGCACCTAGCTGCCAAAGAAGGACATGATAAAGTTC
TCAGTATCTTACTCAAGCACAAAAAGGCAGCACTACTTCTTGACCAC
GTTACTCCCTACACTGATGCAAGGATTACAGAAACTGATGCCAAGGGGCTGA
GTGAGTTCAACTACATGTTCTGGGGGCCCGGAGATAGATGACTTTGCA
TGTGGACCCAGACAGCGTGGTCCTCTGCCTCTTGGCCATTGACGAGGAGGAG
GAGGATGACATCGCCCTGCAAATCCACTTCACGCTCATCCAGTCCTTC
GGCTCAGAATGGGAGGACTCCAGAAGATGAGAGAAACCTCTTTATCCAACAG
ATAAAAGAAGGAACATTGCAGAGCTAAGCAGTCGTGGTATGGGGGCGA
GAGAATAAAGCTGCAGGACAGTCACAAGGCGTGTCTTGGTCTCTAAGAGAGT
GGGCACTGCGGCTGTCTCCTTGAAGGTTCTCCCTGTTGGTTCTGATTA
CTCCACCTCCTCGCGTCCGTAATCAGTGACGAGGTCCGCTACGTAAATCCCTT
TGCGGCGGACAAATGACCATGGAAACAGTTGAATCCCAGCATGATGG

NM_003

1025-

TTAACTGTATCTGGAGCCAGGACCTGAACTCGCACCTCCTACCTCTTCATGTT

745.1

1125

TACATATACCCAGTATCTTTGCACAAACCAGGGGTTGGGGGAGGGTC

NM_003

1870-

GGAGGATGGAGGAGACGGGACATCTTTCACCTCAGGCTCCTGGTAGAGAAGA

955.3

1970

CAGGGGATTCTACTCTGTGCCTCCTGACTATGTCTGGCTAAGAGATTC

NM_030
640.2
NM_001
017.2
NM_003
194.3

615-715

331-431

25-125

ATGGGTTTAACTCTCCTTTTGCCAGTCACCACCAGCCTGACCTCATACACTTTT
AGTACAATGGAGTGGCTGAGCCTTTGAGCACACCACCATTACATCA
GCATCTTGAGAGGAACAGAAAGGATAAGGATGCTAAATTCCGTCTGATTCTA
ATAGAGAGCCGGATTCACCGTTTGGCTCGATATTATAAGACCAAGCGA
CGCCGGCTGTTTAACTTCGCTTCCGCTGGCCCATAGTGATCTTTGCAGTGACC
CAGCAGCATCACTGTTTCTTGGCGTGTGAAGATAACCCAAGGAATTG

NM_000

1155-

ACAACATCGCCTGCGTTATCCTCACCTTCAAGGAGCCCTTTGGCACTGAGGGT

402.2

1255

CGCGGGGGCTATTTCGATGAATTTGGGATCATCCGGGACGTGATGCA

NM_001
008710.1

842-942

AAACAGCCTGTAGGTTTTGTCAGTTTTGACAGTCGCTCAGAAGCAGAGGCTGC
AAAGAATGCTTTGAATGGCATCCGCTTCGATCCTGAAATTCCGCAAA

NM_001

1546-

GTACTATTGAGATCTTTCGCGTCGATCCCAACGGCCTTAGCGGCGGCAGACTG

270943.1

1646

GAATAACACCTTACACCTTTCTGGCCTGCATTTCTGTAGACTTCACT

NM_012
476.2

871-971

CAGCGCCAGCAGCTGCAAGAAAGCTAACACTTAAGACTCCCACCCTGTGACA
CTGAGTCCCGAGCACAGCACCTTCCCAGTCTCCTGTGCCCCAGCGGAC

NM_004

2085-

GTGGTCTCATAATTCCATTTGTGGAGAGAACAGGAGGGCCAGATAGATAGGT

350.1

2185

CCTAGCAGAAGGCATTGAGGTGAGGGATCATTTTGGGTCAGACATCAA

NM_017
449.2
NM_031
483.4

785-885

155-255

CAAAGCAGGCTTCGAGGCCGTTGAGAATGGCACCGTCTGCCGAGGTTGTCCA
TCTGGGACTTTCAAGGCCAACCAAGGGGATGAGGCCTGTACCCACTGT
ACTGTGAGAACTTCAGGTTTTCCAACCTATTGGTGGTATGTCTGACAGTGGAT
CACAACTTGGTTCAATGGGTAGCCTCACCATGAAATCACAGCTTCAG

NM_170

3195-

TAATGTCGAAGTTGCCCGGAGCATCCTCCGAGAATTTGCCTTCCCTCCTCCAG

662.3

3295

TATCCCCACGTCTAAATCTATAGCAGCCAGAACTGTAGACACCAAAA

NM_001

1375-

TTCCTAACACCCACCCACTTCTCGTCTTTGTCAATCCTAAGAGTGGCGGGAAG

345.4

1475

CAGGGGCAAAGGGTGCTCTGGAAGTTCCAGTATATATTAAACCCTCG

NM_000
595.2

885-985

CTGATCAAGTCACCGGAGCTTTCAAAGAAGGAATTCTAGGCATCCCAGGGGA
CCACACCTCCCTGAACCATCCCTGATGTCTGTCTGGCTGAGGATTTCA
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FoxP1
CD223
(LAG3)
CD118

Txk

NM_032

6758-

CCTGAAAATCAGATTTACAATGCTGAAGGCATTTCTTGGGCCCAGTGTAGCTC

682.5

6858

ACGCAATCTCTGCTACCCATAAGCCTTGATGAAGATGATACAGTCCG

NM_002

1735-

CTTTTGGTGACTGGAGCCTTTGGCTTTCACCTTTGGAGAAGACAGTGGCGACC

286.5

1835

AAGACGATTTTCTGCCTTAGAGCAAGGGATTCACCCTCCGCAGGCTC

NM_002

2995-

CCTATTGTCCACCCATCATTGAGGAAGAAATACCAAACCCAGCCGCAGATGA

310.3

3095

NM_003
328.1

800-900

AGCTGGAGGGACTGCACAGGTTATTTACATTGATGTTCAGTCGATGTA
ATGACTCGTCTCCGATATCCAGTTGGGCTGATGGGCAGTTGTTTACCAGCCAC
AGCTGGGTTTAGCTACGAAAAGTGGGAGATAGATCCATCTGAGTTGG

NM_006

1325-

GATGGACGATGATGTTGAGTGCACGATGGTAGAGAAGAGAGTTCTTTCCTTG

257.2

1425

GCCTGGGAGCATCCGTTTCTGACGCACATGTTTTGTACATTCCAGACC

STS2

NM_001

1970-

GAGATGCTGCTGTTTCCAGAGGCGTCTTAGTCTCACCCAATGTGATTTGTAGA

(Ubash3a)

001895.1

2070

AGCACGAGACGCACTTTTATATCCCGGAATATTTCCCTCCGGCTTTC

Prkcq

RNF125

Lat

Skap1

Dok2

Axin2

Sh2d2a

NM_017
831.3

1290-

TGTGTAATAGAATAAAGGCCTGCGTGTGTCTGTGTTGAGCGTGCGTCTGTGTG

1390

TGCCTGTGTGCGAGTCTGAGTCAGAGATTTGGAGATGTCTCTGTGTG

NM_003

1360-

AAGTGGGAAGAGGCACGTTCATCAAACCTGTTACTAAACCAGCCTAGTCATA

726.3

1460

GCTCATCCCCATCTCTAAATGTGTCCACACAACCACATCTGCCTTTTC

NM_003
974.2

Lat2

Clnk

Car2

Fgl2

cathepsinC

CathepsinD

GCCAGGGACCCAGCTGTACGACTGGCCCTACAGGTTTCTGCGGCGCTTTGGGC
GGGACAAGGTAACCTTTTCCTTTGAGGCAGGCCGTCGCTGCGTCTCT

1035-

CTTGTCCAGCAAAACTCTGAGGGCCACGGCGAGTGTGAGGTCCACGGAAACT

655.3

1135

GTTGACAGTGGATACAGGTCCTTCAAGAGGAGCGATCCTGTTAATCCT

NM_001
161443.1

045.1

Lyn

650-750

NM_004

NR_028

Syk

GGATCATTGTATTACTCATCACAGATCGGAACGGAGGCCTGTGTTCT

NM_001

Klra5

CD11c

GCAAGGTGTGTATGTCCCTTTTGTCAGAGGGAACTGTATGAAGACAGCTTGCT

014987.1

(Ly49E)
CD7

790-890

NM_006
137.6
NM_000
887.3

341-441

414-514

440-540

700-800

TGCTGGAGCCCAAGCCTCAGGGGTGCTACTTGGTGCGGTTCAGCGAGAGCGC
GGTGACCTTCGTGCTGACTTACAGGAGCCGGACTTGCTGCCGCCACTT
CCTTCAGAGTCACAGAATAGATTAAGGCCTGATGATACTCAAAGGCCTGGGA
AAACTGATGACAAAGAATTTTCAGTGCCCTGGCACCTCATTGCAGTGA
CCTACACCTGCCAGGCCATCACGGAGGTCAATGTCTACGGCTCCGGCACCCT
GGTCCTGGTGACAGAGGAACAGTCCCAAGGATGGCACAGATGCTCGGA
CCCCTCAGCCTGTTGGCTTCTGTTCACCAGCTGCAAGGGTTTACATACACGGC
CACCGCCATCCAAAATGTCGTGCACCGATTGTTCCATGCCTCATATG

NM_003

1685-

CGGACTCTCCAAAGCACTGCGTGCTGATGAAAACTACTACAAGGCCCAGACC

177.3

1785

CATGGAAAGTGGCCTGTCAAGTGGTACGCTCCGGAATGCATCAACTAC

NM_002

1285-

TCCTGAAGAGCGATGAAGGTGGCAAAGTGCTGCTTCCAAAGCTCATTGACTTT

350.1

1385

TCTGCTCAGATTGCAGAGGGAATGGCATACATCGAGCGGAAGAACTA

NM_014

1863-

TGCAGAGCTGATTAAACAGTGTTGTGACTGTCTCATGGGAAGAGCTGGGGCC

146.3

1963

CAGAGGGACCTTGAGTCAGAAATGTTGCCAGAAAAAGTATCTCCTCCA

NM_052

1108-

GAAGGAGAACAAGGATGGTAGTTTCTTGGTCCGAGATTGTTCCACAAAATCC

964.2

1208

AAGGAAGAGCCCTATGTTTTGGCTGTGTTTTATGAGAACAAAGTCTAC

NM_000
067.2
NM_006
682.2
NM_001
114173.1

575-675

250-350

260-360

AGCTGTGCAGCAACCTGATGGACTGGCCGTTCTAGGTATTTTTTTGAAGGTTG
GCAGCGCTAAACCGGGCCTTCAGAAAGTTGTTGATGTGCTGGATTCC
CAATTCAGCAGGATCGAGGAGGTGTTCAAAGAAGTCCAAAACCTCAAGGAAA
TCGTAAATAGTCTAAAGAAATCTTGCCAAGACTGCAAGCTGCAGGCTG
TGCTCGGTTATGGGACCACAAGAAAAAAAAGTAGTGGTGTACCTTCAGAAGC
TGGATACAGCATATGATGACCTTGGCAATTCTGGCCATTTCACCATCA

NM_001

1495-

GAAGCCGGCGGCCCAAGCCCGACTTGCTGTTTTGTTCTGTGGTTTTCCCCTCC

909.3

1595

CTGGGTTCAGAAATGCTGCCTGCCTGTCTGTCTCTCCATCTGTTTGG
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Rab31

Spry2

S100A6

Lgals1

Hmgb2

HopX

Dock5

Ptpn4

PLZF

Foxo1

Foxo3

ID3

ZEB2

SMAD4

YAP

E2A

Nanog

OCT4

Sox2

TAL1

ELF1

SOX13

Nrp1

NM_006

3800-

868.3

3900

NM_005
842.2
NM_014
624.3
NM_002
305.3
NM_001
130688.1

85-185

539-639

60-160

125-225

TTTTGTAAAGAGCTTCCATCTGGGCTGGACCCAGTTCTTGCACATACAAGACA
CCGCTGCAGTCAGCTAGGACCTTTCCGCCATGTATTCTATTCTGTAG
AAAGAGGAAATACTCCGCGTGCGCTTGTAGAAGGGGAGTCGTCTCCAGCTCC
GAACCCCGGAGTGTTCATCAGCGGGGAATCTGGCTCCGAATTCTCTTT
TTCCTGGGGGCCTTGGCTTTGATCTACAATGAAGCCCTCAAGGGCTGAAAATA
AATAGGGAAGATGGAGACACCCTCTGGGGGTCCTCTCTGAGTCAAAT
GGTGCGCCTGCCCGGGAACATCCTCCTGGACTCAATCATGGCTTGTGGTCTGG
TCGCCAGCAACCTGAATCTCAAACCTGGAGAGTGCCTTCGAGTGCGA
CTGTCAACATGGGTAAAGGAGACCCCAACAAGCCGCGGGGCAAAATGTCCTC
GTACGCCTTCTTCGTGCAGACCTGCCGGGAAGAGCACAAGAAGAAACA

NM_001

1117-

AACAATAGGAAGCTATGTGTATCTTCTGTGTAAAGCAGTGGCTTCACTGGAA

145460.1

1217

AAATGGTGTGGCTAGCATTTCCCTTTGAGTCATGATGACAGATGGTGT

NM_024
940.6
NM_002
830.2

630-730

705-805

TGCGAGATGACAATGGGAACATCCTAGACCCTGACGAAACCAGCACCATTGC
CCTCTTCAAGGCCCATGAGGTGGCCTCCAAAAGGATTGAGGAAAAGAT
TCGAGGCTTTTTTTCTCCAGCCGAGAGGACGCGGCTGTGATATACGAAGACTT
TGTGTGGACAGTAATGACCTCACGTTTCCGATTGCCTGCTGGCAGAA

NM_006

1585-

TCCTGGATAGTTTGCGGCTGAGAATGCACTTACTGGCTCATTCAGCGGGTGCC

006.4

1685

AAAGCCTTTGTCTGTGATCAGTGCGGTGCACAGTTTTCGAAGGAGGA

NM_002

1526-

TCTCATCACCAACATCATTAACTGTTTCGACCCAGTCCTCACCTGGCACCATG

015.3

1626

ATGCAGCAGACGCCGTGCTACTCGTTTGCGCCACCAAACACCAGTTT

NM_001

1860-

CCGGAACGTGATGCTTCGCAATGATCCGATGATGTCCTTTGCTGCCCAGCCTA

455.2

1960

ACCAGGGAAGTTTGGTCAATCAGAACTTGCTCCACCACCAGCACCAA

NM_002
167.3
NM_014
795.2

195-295

20-120

AGGAAGCCTGTTTGCAATTTAAGCGGGCTGTGAACGCCCAGGGCCGGCGGGG
GCAGGGCCGAGGCGGGCCATTTTGAATAAAGAGGCGTGCCTTCCAGGC
TCCCAGAGAGAAACTTGGCGATCACGTTTTCACATGATGCTCACGCTCAGGGC
GCTTCAATTATCCCTCCCCACAAAGATAGGTGGCGCGTGTTTCAGGG

NM_005

1370-

AGGTTGCACATAGGCAAAGGTGTGCAGTTGGAATGTAAAGGTGAAGGTGATG

359.3

1470

TTTGGGTCAGGTGCCTTAGTGACCACGCGGTCTTTGTACAGAGTTACT

NM_139
118.2

755-855

ATGGGAGCTATGCAGCTGATTGAAGACTTCAGCACACATGTCAGCATTGACT
GCAGCCCTCATAAAACTGTCAAGAAGACTGCCAATGAATTTCCCTGTT

NM_003

4325-

ATACGTGTCAACACAGCTGGCTGGATGATTGGGACTTTAAAACGACCCTCTTT

200.2

4425

CAGGTGGATTCAGAGACCTGTCCTGTATATAACAGCACTGTAGCAAT

NM_024

1100-

CTACTCCATGAACATGCAACCTGAAGACGTGTGAAGATGAGTGAAACTGATA

865.2

1200

TTACTCAATTTCAGTCTGGACACTGGCTGAATCCTTCCTCTCCCCTCC

NM_002

1225-

AAGTTCTTCATTCACTAAGGAAGGAATTGGGAACACAAAGGGTGGGGGCAGG

701.4

1325

GGAGTTTGGGGCAACTGGTTGGAGGGAAGGTGAAGTTCAATGATGCTC

NM_003
106.2

151-251

CTTAAGCCTTTCCAAAAAATAATAATAACAATCATCGGCGGCGGCAGGATCG
GCCAGAGGAGGAGGGAAGCGCTTTTTTTGATCCTGATTCCAGTTTGCC

NM_003

4635-

ACAGCATCTGTAGTCAGCCGACAACTATTTCGGCCTTTTGGGGGTGGGTCTGG

189.2

4735

CCGTACTTGTGATTTCGATGGTACGTGACCCTCTGCTGAAGACTTGC

NM_032
377.3

125-225

AGACCCAGTTCACCTGCCCCTTCTGCAACCACGAGAAATCCTGTGATGTGAAA
ATGGACCGTGCCCGCAACACCGGAGTCATCTCTTGTACCGTGTGCCT

NM_005

3039-

ATTTATTGAGTGCCCACTACGTGCCAGGCACTGTTGCTGAGTTCCTGTGGGTG

686.2

3139

TGTCTCTCGATGCCACTCCTGCTTCTCTGGGGGCCTCTTTCTGTGCT

NM_003
873.5

370-470

GCCTCGCTGCTTTCTTTTCTCCAAGACGGGCTGAGGATTGTACAGCTCTAGGC
GGAGTTGGGGCTCTTCGGATCGCTTAGATTCTCCTCTTTGCTGCATT
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Blk

CCR10

ITGB7

Sox5

Bcl11b

SOX4

Tcf12

Dapl 1

Trf

Cpt1

Bim

C-flip

NM_001

990-

AGCTTCTTGCTCCAATCAACAAGGCCGGCTCCTTTCTTATCAGAGAGAGTGAA

715.2

1090

ACCAACAAAGGTGCCTTCTCCCTGTCTGTGAAGGATGTCACCACCCA

NM_001

1345-

GAACAGATGGGAACCAGCTCAATTGGGTGTCCACTCAAAGTGCTCTCTCCAG

296.3

1445

GGGCCTCAGTGACTGTGTTGCTAAACCCAGTGGTCAGTTCTCAGTTCT

NM_000

1278-

CAACGTGGTACAGCTCATCATGGATGCTTATAATAGCCTGTCTTCCACCGTGA

889.1

1378

CCCTTGAACACTCTTCACTCCCTCCTGGGGTCCACATTTCTTACGAA

NM_152

1885-

TAGCCATGCAATGATGGATTTCAATCTGAGTGGAGATTCTGATGGAAGTGCTG

989.2

1985

GAGTCTCAGAGTCAAGAATTTATAGGGAATCCCGAGGGCGTGGTAGC

NM_022

3420-

GAGATGTAGCACTCATGTCGTCCCGAGTCAAGCGGCCTTTTCTGTGTTGATTT

898.1

3520

CGGCTTTCATATTACATAAGGGAAACCTTGAGTGGTGGTGCTGGGGG

NM_003

3040-

GTTCACGGTCAAACTGAAATGGATTTGCACGTTGGGGAGCTGGCGGCGGCGG

107.2

3140

CTGCTGGGCCTCCGCCTTCTTTTCTACGTGAAATCAGTGAGGTGAGAC

NM_207

1105-

CACATGACCGCTTGAGTTATCCTCCACACTCAGTTTCACCAACAGACATAAAC

037.1

1205

ACGAGTCTTCCACCAATGTCCAGCTTTCATCGCGGCAGTACCAGCAG

NM_001
017920.2

190-290

CGAGAAAACAAGTGCCATTGCAAATGTTGCCAAAATACAGACACTGGATGCC
CTGAATGACGCACTGGAGAAGCTCAACTATAAATTTCCAGCAACAGTG

NM_003

1037-

CTGAAAGCAGAATACCTGTTTCAAAGAGTCAGCCGGTAACTCCTGAAAAACA

218.3

1137

TCGAGCTAGAAAAAGACAGGCATGGCTTTGGGAAGAAGACAAGAATTT

NM_020

1303-

GATATGGTGATATACTTTAGTGCTTTGTGCCTGCAAATTTCAAGACACCTTCA

244.2

1403

TCTAAATATATTCAAGACTGCATGTCATCAAGCACCTGAACAGGTTC

NM_138
621.4
NM_001
127183.1

257-357

653-753

CGGACTGAGAAACGCAAGAAAAAAAGACCAAATGGCAAAGCAACCTTCTGA
TGTAAGTTCTGAGTGTGACCGAGAAGGTAGACAATTGCAGCCTGCGGAG
TAGAGTGCTGATGGCAGAGATTGGTGAGGATTTGGATAAATCTGATGTGTCCT
CATTAATTTTCCTCATGAAGGATTACATGGGCCGAGGCAAGATAAGC
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Appendix B. Antibodies Used in Dissertation
Antibody specificity

Clone

Vendor

Fc*

H10104

Invitrogen

anti-CD19scFv mAb**

136.20.1

Cooper Lab

ROR1

4A5

Kipps, TJ Lab (UCSD)

CD3

SK7

BD Biosciences

CD4

RPA-T4

BD Biosciences

CD8

RPA-T8

BD Biosciences

CD19

HIB19

BD Biosciences

CD25

M-A251

BD Biosciences

CD27

M-T271

BD Biosciences

CD28

L293

BD Biosciences

CD32

FLI8.26 (2003)

BD Biosciences

CD38

HB7

BD Biosciences

CD45RA

HI100

BD Biosciences

CD45RO

UCHL1

BD Biosciences

CD56

B159

BD Biosciences

CD57

NK-1

BD Biosciences

CD62L

Dreg 56

BD Biosciences
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CD64

10.1

BD Biosciences

CD86

2331 FUN-1

BD Biosciences

CD95

DX2

BD Biosciences

CD122

TM-Beta 1

BD Biosciences

CD127

HIL-7R-M21

BD Biosciences

CD137

4B4-1

BD Biosciences

CD137L

C65-485

BD Biosciences

CCR7***

TG8

eBiosciences

CXCR4

12G5

BD Biosciences

CLA

HECA-452

BD Biosciences

CCR4

1G1

BD Biosciences

ICOS

ISA-3

eBiosciences

ICOS-L

MIH12

eBiosciences

OX40

ACT35

BD Biosciences

PD-1

MIH4

BD Biosciences

TCRαβ

WT31

BD Biosciences

TCRγδ

B1

BD Biosciences

TCRγδ

IMMU510

Thermo Fisher

TCRδ1

TS-1

Thermo/Pierce
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TCRδ2

B6

BD Biosciences

TCRγ9

B3

BD Biosciences

invariant NKT

6B11

BD Biosciences

NMS

015-000-120

Jackson ImmunoResearch

DNAM1

DX11

BD Biosciences

NKG2D

1D11

BD Biosciences

IL15

34559

R&D Systems

IFNγ

4S.B3

BD Biosciences

TNFα

MAb11

BD Biosciences

* To detect CAR expression
** To detect CD19-specific CAR expression
*** Used at 1:67 dilution
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